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Abstract 
The cubane core has been shown to be physically similar to benzene across the body diagonal, yet 
remains electronically and physically different in all other ways. It is proposed that this similarity 
may allow cubane to act as a bioisostere for benzene in pharmaceutical applications. As such, a 
number of novel synthetic approaches have been used to develop new routes to previously unknown 
cubane derivatives. The synthesis of several novel cubane based compounds is described herein. 
The synthetic routes contained within provide further insight into the potential functional group 
modifications for the cubane framework. These derivatives form key intermediates in the synthesis 
of a number of target analogues based in a variety of drug classes. These classes include anticancer 
chemotherapeutic drugs, novel Alzheimer’s disease compounds, antibacterial compounds, topical 
scabies medications as well as a well known antifungal compound. The overall study is designed to 
act as a base level investigation into the potential of cubane to act as a bioisostere for benzene in 
pharmaceutical analogues. Compounds were selected based upon the presence of a benzene ring, 
drug class as well as potential synthetic approach. The described compounds are thus designed to be 
analogous to current pharmaceutical drugs which are undergoing Phase I clinical trials, later testing, 
or are already available for purchase. Biological tests of these novel compounds have been 
subjected to, at least, base level comparison to the known drug analogue. Results of these studies 
have demonstrated that cubane analogues have similar biological activity to a number of benzene 
analogues in a variety of classes and thus merit further investigation into the use of cubane as a 
bioisostere for benzene. Further to this a P450 oxidation study has also been performed to help 
understand the metabolic processes that may be imparted upon the cubane core in a biological 
system. The results herein also demonstrate that cubane derived compounds hold great potential for 
their application in pharmaceutical compounds, yet underline the fact that cubane remains a 
diamond in the rough, for which many syntheses remain undiscovered. 
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Chapter 1 Cubane: As a Pharmaceutical Building Block 
1.1 Introduction 
The first published proposed structure of pentacyclo[4.2.0.02,5.03,8.04,7]octane (Cubane, 1.01) dates 
as far back as 1913, when Beesley and Thorpe identified it as a possible “caged” cube product in a 
series of caged carbon rings.1 The possible existence of such a compound was disputed later when it 
was calculated to be impossible due to the immense strain of the structure.2 However, it was later 
found that as no kinetically viable paths for the thermal rearrangement of cubane exist the structure 
is in fact relatively stable.3,4 This was first proven in 1964 by the complete synthesis of cubane 1,4-
dicarboxylic acid (1.02, Figure 1.1) by Eaton and Cole.5 
OH
O
HO
O
1.01 1.02  
Figure 1.1 – Cubane (1.01) and cubane 1, 4-dicarboxlyic acid (1.02). 
Initial speculative routes to synthesise the cubane core were primarily based on [2+2] 
photocyclisations of alkene rich compounds such as cyclooctatetraene.6 Further methods in which 
the cubane core became a focus have been summarised in a comprehensive review by Griffin.7 
 
Scheme 1.1 – Eaton’s early photodimerisation of cyclopentenone. 
After extensive consideration Eaton utilised a rather inspired synthetic route to develop the first 
synthesis of the cubane core (1.01).7 Prior to this breakthrough Eaton’s work had focussed primarily 
on the photodimerisation of cyclopentenone (1.03) and subsequent Wolff-Kishner reduction of the 
two dimerisation products (1.04 and 1.05) to give 1.06 (Scheme 1.1), as well as some work on the 
caged insecticidal compound, kepone (1.07, Figure 1.2).8-15 
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Cl Cl
Cl
ClCl
1.07 1.08  
Figure 1.2 – Kepone (1.07) and cyclooctatetraene (1.08). 
Of particular note is a latter article in which a strikingly similar polychlorinated caged halocarbon 
compound (1.10) was formed via cyclisation of 1.09 under ultraviolet irradiation (Scheme 1.2).15 
 
Scheme 1.2 – Diels-Alder cycloaddition under photochemical conditions. 
It is no surprise that Eaton’s initial synthetic strategy towards cubane began with cyclopentenone 
(1.03) and proceeded through two subsequent bromination reactions to give compounds 1.11 and 
1.12, dehalogenation to give the 2-bromocyclopenta-2,4-dienone (1.13) as a reactive intermediate 
(Scheme 1.3).5 
 
Scheme 1.3 – Initial steps in Eaton's first synthesis of cubane. 
This then undergoes a spontaneous Diels-Alder reaction to give the fused tricyclic compound 1.14, 
which then proceeds via photocyclisation to give the key intermediate caged compound 1.15 
(Scheme 1.4). 
 
Scheme 1.4 – Formation of the key intermediate. 
The final step to formation of the cubane core was via a quasi-Favorskii rearrangement of 1.15. In 
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this case 1.15 is primed to result in the semi-benzilic acid (1.16) transformation shown below 
(Scheme 1.5).16 The mechanism given in Scheme 1.5 highlights the importance of the halogen atom 
that remains in 1.13 as it directs the Favorskii-type ring contraction by offering a prime leaving 
group. 
 
Scheme 1.5 – Favorskii-type reaction mechanism. 
Finally, the resultant dicarboxylate 1.17 is esterified to give the more manageable dimethyl ester 
1.18 (Scheme 1.6). This final product, dimethyl cubane-1,4-dicarboxylate (1.18), has heightened 
importance in cubane chemistry as the additional ester functional groups provide vital protected 
handles for further modifications in extended synthetic strategies.17 
 
Scheme 1.6 – Eaton's synthesis of 1,4-methylcubane dicarboxylate. 
Later attempts at cubane synthesis included cycloeliminations, which sought to utilize compounds 
such as “diazabasketene” (1.19) to form the cubane core via an elimination of N2.7,18,19 Flash 
vacuum pyrolysis of diazabasketene was ultimately shown to give azocine (1.22) with the release of 
hydrocyanic acid under the proposed reaction given in Scheme 1.7. 
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Scheme 1.7 – Pyrolysis of diazabasketene.19 
In an alternative elimination reaction a pentavalent phosphonium salt (1.23) was treated with 
phenyllithium yielding 1.24 and subsequently heated or irradiated to yield cyclooctatetraene (1.26) 
via an intermediate tricyclic diene (1.25, Scheme 1.8).20 
 
Scheme 1.8 – Katz's attempted synthesis of cubane.20 
There have since been a number of alternate syntheses in which various modifications are made to 
both starting materials and reaction conditions. Currently, the best known method of synthesis, 
which follows closely that of the original by Eaton, is capable of producing multigram quantities 
quite readily through the use of specifically designed process equipment at the CSIRO capable of 
streamlining the reaction. 
In this synthesis Chapman utilised cyclopentanone (1.27), a more affordable starting material than 
1.05, which is subjected to ketal protection before being subjected to a similar reaction method to 
that described by Eaton.21 The procedure has subsequently been subtly modified numerous times to 
afford improved synthetic methods (Scheme 1.9).22-24 This method allows for a less difficult 
synthesis of 1.14 as the original method to this compound was noted by Eaton himself to be quite 
difficult.17 
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Scheme 1.9 – Improved synthesis of cubane.22 
It must also be noted that the complete synthesis of the hydrocarbon cubane core was initially 
completed via the photolytic removal of both t-butyl peresters formed via the dicarboxylic acid 
1.02.5 This was subsequently modified to utilise the Barton decarboxylation method, which utilises 
the formation of a reactive ester (1.30) which, when initiated undergoes a radical decomposition 
releasing carbon dioxide and yielding the desired cubane hydrocarbon (1.01, Scheme 1.10).25 
 
Scheme 1.10 – Barton decarboxylation of 1.02 to yield cubane (1.01). 
Over the last half century there have been a large number of transformations performed on the 
cubane moiety. However, as the compound is highly strained and not found in nature a large 
amount of focus has been placed on developing methods that are compatible with the cubane core.* 
It has been reported that a number of reaction conditions are capable of degrading the cubane core 
in several different ways.7,27 Unfortunately, these synthetic limitations often mean that cubane 
chemistry becomes costly and time consuming as failed reactions often result in loss of starting 
material and unwanted side-products through decomposition of the cubane core. 
                                                 
* Recently the synthesis of a novel octacyclopropylcubane in good yields (32% over two steps) was reported by de 
Meijer et al. The reaction proceeds via the catalytic conversion of cyclodicyclopropylethyne to give tricyclooctadiene 
which is the converted to the cubane system via light mediated [2+2] cycloaddition. The resultant highly stable 
product has an overall strain energy of >390 kcal mol-1.
26  
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Furthermore, cubane, in the absence of functionalised molecules, can rearrange in the presence of 
silver(I),28 rhodium(I),29 palladium(0/II),28,30 and carborate anions (Li+CB11Me12−).31 Cubane will 
also complex with Cp*(PMe3)IrH2 (Cp*=ƞ5-C5Me5) under photochemical conditions to give the 
cubyl hydride complex, but only in liquid xenon.32 For example, when allowed to stir over 10% 
palladium/carbon catalyst in methanol under an atmosphere of hydrogen at 20 ºC, cubane (1.01) 
was observed to decompose to afford tetracyclo[4.2.0.02,5.03,8]octane (secocubane, 1.31) within 2 
hours (Scheme 1.11).30 When allowed extended reaction time the ring system further rearranged to 
give tricyclo[4.2.0.03,8]octane (1.32) and subsequently bicyclo[2.2.2]octane (1.33). Alternatively, 
the rearrangement can also follow a via a rearrangement of secocubane to 1.35, which upon 
hydrogenation gives 1.36 which thus becomes a precursor to either 1.33 or 1.37.33 
 
Scheme 1.11 – Rearrangement and hydrogenation of cubane on Pd/C catalyst.30,33 
Direct halogenation of cubane under photoinitiated radical conditions also results in the degradation 
of the cubane core.34 In this case, alternate methods using phase-transfer catalysts have provided an 
alternative to these conditions.35 
Due to a large amount of reported investigation into transformations on the cubane core – in 
particular transformations of the para-dicarboxylate (1.02) – a number of compounds containing the 
cubane moiety have been developed. Although the primary utility of these compounds has been for 
extended research (i.e. investigations into physical properties, further functional group 
modifications as well as materials development), a number have been identified as biologically 
active.36-41 This lends weight to Eaton’s hypothesis that cubane type compounds may prove useful 
in medicine, particularly in cases of drug resistant and potentially unknown pathogens.17 These 
drug-type compounds will be further reviewed in Section 1.3. 
1.2 Physical Properties 
The large number of functional group transformations that have been performed on cubane has 
proven the framework to be both a stable and robust building block under a number of reaction 
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conditions.7,17,42 The cubane framework is also highly rigid, hence giving functional group 
substituents precise spatial relationships to each other.17,43 
Studies into the physical properties of cubane allowed for even further insight, showing that the 
distance across the cube (the body diagonal) is 2.72 Å, which is almost equivalent to the distance 
across the benzene ring, 2.79 Å.42 This similarity can be seen when cubane is viewed from one of 
its 8 apexes (Figure 1.3). However, whilst cubane’s physical appearance is similar to benzene, 
spectroscopically cubane has both proton and carbon resonances much further upfield (1H ~4 ppm 
13C ~50 ppm) highlighting significant electronic differences.27,44 
1.01 1.38  
Figure 1.3 – Cubane (apex view) and Benzene. 
A brief review of the physical properties of cubane is summarised in a comprehensive table (Table 
1.1). Of particular note are the bond distances in both the carbon-carbon bonds, which are longer 
than those in benzene; and the carbon-hydrogen bonds, which are shorter than those in benzene. 
Another interesting feature of the unsubstituted cubane core is that the vapour pressure of cubane is 
quite high, which results in pure cubane subliming at room temperature. 
Table 1.1 – Physical Properties of Cubane. 
C-C distance 1.562 Å 
C-H distance 1.097 Å 
Colour Transparent (White) 
Toxicity Non-toxic 
Stability Inert to light, water, air 
Decomposition Decomposes above 220ºC 
Density 1.29 g cm-3 
Vapor Pressure 1.1mm (298K) 
Melting Point 130-131ºC 
Solubility 18 wt% (hexene) 
Heat of Formation 144-166 kcal mol-1 
Strain Energy 166-181 kcal mol-1 
Crystal Structure for T < Tp R3 (a=72.7º) (Tp = 394 K) 
Crystal Structure for T > Tp R3 or R3m (α = 103.3º) 
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Lattice Modes Librons: 80-120 cm-1, phonons: 0-120 cm-1 
Vibrational Spectrum 18-modes (3 infrared, 8-raman active) between 
617-300 cm-1 
Electronic Spectrum HOMO (t2g ~ -9.4 eV), LUMO (t2u ~ -5 eV), band 
insulator 
ΔHacid  404±3 kcal mol-1  
pKa 40.8 (calc) 
Point Group (Oh)  E 8C3 6C2 6C4 3C2i 6S4 8S6 3σh 
N.B.: A more detailed table of the physical properties of cubane can be found in Yildrim’s review on solid cubane.42 
1.3 Cubane as a Potential Pharmaceutical Building Block 
Interestingly, Eaton observed that a number of other similarities exist between benzene and 
cubanes. For example, the enhanced s orbital character of the C-H bond as well as the fundamental 
necessity for ortho substituents on the cubane core to be coplanar.17 Of particular interest was the 
fact that substitution above and below the “benzene plane” were also made possible by ortho 
substitution of cubane.45,46 Figure 1.4 highlights the spatial differences between these two moieties 
when viewed along the benzene plane. In this case cubane actually has six positions that lie above 
and below the benzene plane. 
 
Figure 1.4 – Cubane (left) allows for variation in substitution when compared to benzene (right). 
Most cubanes have been documented to be relatively non-toxic, making them particularly 
interesting in biological applications.17 In fact, the work of Mahkam has shown that cubanes can be 
used as cross-linking polymers capable of controlled release of other drug molecules in vitro.41,47 It 
is thus unsurprising that Eaton first postulated the use of this carbon framework as a potential novel 
pharmaceutical starting material; alluding to the structural similarities between cubylamines 1.41 
and 1.42 and important drugs such as Symmetrel® (1.39) and Rimantadine® (1.40, Figure 1.5).17 
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NH2H3C
NH2
CH3
NH2
1.39 1.40
1.41 1.42  
Figure 1.5 – Antivirals, Symmetrel® and Rimantadine® with proposed cubyl analogues. 
A number of these biologically active compounds, such as 1.44, can be found in the literature in 
both patents and journal articles (Figure 1.6).36,37,39-41 Compound 1.43, for example, was one of a 
large library of nucleoside based compounds which sought to utilise uracil’s inhibition of cell 
division and broad-spectrum anti-pathogenicity. Other compounds in the series incorporated 
adenine for its potential to induce neuroprotective properties in biological systems.39,48,49 The results 
of these tests on HIV-1 reverse transcriptase, Hepatitis B and C, as well as CEM lymphomas 
showed highly promising results with certain compounds exhibiting high levels of activity.39 
N
HO
H
NO O
NO2
N
H
O
NC
t-Bu
t-Bu
t-Bu
O
1.43 1.44
t-Bu
O
 
Figure 1.6 – Some biologically active cubane compounds. 
In an unrelated study Pellicciari showed that the cubane moiety may provide a novel indicator for 
discriminating between mGluR1 and mGluR5 glutamate receptors.37 This line of research was taken 
even further by Curry in a patent describing a vast range of these types of compound for use in 
treating diseases of the central nervous system related to the glutamate receptor system.50 
NO2O
H
N
O
N
1.45
N
H
O
O
NO2Br
1.46  
Figure 1.7 – Angina drug Nicorandil (1.45) and a cubyl analogue (1.46). 
In an attempt to develop further functional group changes on the cubane framework, Eremenko 
reported the synthesis of a number of analogous compounds, including the most successful, 
1.46.40,51-57 When compared to the angina drug Nicorandil (1.45) the cubanyl compound 1.46 was 
observed to have a tenfold increase in activity with a decreased toxicity in mouse models. Whilst 
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this discovery may have come as a side-product of the investigation into nitroxyalkyl-substituted 
cubane-1,4-dicarboxamides and 4-bromocubanecarboxamides, this example demonstrated the 
potential for further investigation into the use of cubane in place of aromatic rings in current drug 
compounds.40,51 
O
N
H O
N
O
N
1.48
NH2HO
O
1.47  
Figure 1.8 – Some early examples of a cubanyl pharmaceutical. 
Cubane molecules have also been shown to be active as antifibrinolytic compounds (1.47), aiding in 
the prevention of blood clots, as well as potential inhibitors for ulcers (1.48, Figure 1.8).58,59 
However, these compounds are highly focussed; poly-substituted (e.g. 1.44) and show limited scope 
in terms of variation of functional groups and side chains. The literature also reveals a focus on the 
generation of simple cubane systems with known biologically active functional groups (NO2, CN, 
NCO, NH2), and although simplicity in drug type molecules is often best, future drug development 
and ultimately drug resistance in targeted afflictions will require further substituted and more highly 
selective cubane compounds to be synthesised.50,60 
1.4 Scope 
We aimed to develop a variety of different cubane based analogues of current market 
pharmaceuticals to investigate the effects of cubane in place of aryl moieties. This will serve as a 
proof of concept based upon Eaton’s original allusion to the possibility that cubane may serve as a 
bioisostere for benzene in pharmaceutical compounds. In order to gather information founded upon 
using cubane in a biologically active compound, it was proposed that the use of cubane to generate 
direct analogues of known pharmaceutical compounds would provide further information on its 
activity in known biological systems. That is to say that determining whether cubane – when used 
in place of a benzene ring in a pharmaceutical compound – showed any activity in a mode similar to 
that observed in the original drug. 
Since mono-substituted and para-substituted cubane starting materials are more readily available 
than those with ortho-substitutions, initial investigation into transformations on these groups 
provided a rational starting point. It was anticipated that the inherently lower toxicity of cubane 
combined with the structural similarities to the benzene ring may allow for potentially beneficial 
changes in the activity of the pharmaceutical compound. The low toxicity of cubane may result in 
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less healthy cell damage as drug metabolism occurs. The use of known pharmaceuticals also allows 
for a direct comparison to the aryl analogue allowing for more rapid testing and reducing the need 
to develop numerous screens to analyse drug efficacy. 
A survey of current market pharmaceuticals revealed a large number of mono- and para-substituted 
phenyl group compounds for which the cubane analogues would be both synthetically viable and 
allow for a comparative analysis of the biological activity. Since some transformations of the 
cubane skeleton proceed quite similarly to that of the benzene based analogues the methods for 
synthesis of the desired compounds could possibly be employed directly to facilitate synthesis. 
However, in some cases, the cubane core may be sensitive to the reaction conditions used for the 
original pharmaceutical and modifications or alternatives to these methods must be found. 
Regardless of the biological results arising for these investigations, the results may spark insights 
into the mode of action of particular biological systems, inspire creative drug design and garner 
further interest into developing improved synthetic techniques for cubane systems. 
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Chapter 2 A Cubane Analogue of Vorinostat 
2.1 Introduction 
Of the many afflictions of mankind today, cancer remains the most prevalent, the most infamous 
and one of the most difficult to treat. These aspects are due to, in part, the generic title of cancer and 
the implied diversity inherent to the disease. The diversity in the disease has led to a diversity in 
treatment, the most pertinent to the field of organic chemistry being chemotherapy; the use of 
chemical compounds in order to cause a deleterious effect on cancerous cells. Under ideal 
circumstances deleterious effects would remain isolated to cancerous cells with no harm being 
caused to any healthy cells within the biological system. Therefore, as an initial foray into the 
development of cubanyl analogues of current pharmaceuticals the selection of a current anticancer 
compound provided an excellent challenge for synthesis. 
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Figure 2.1 – Vorinostat (SAHA) and its cubyl analogue. 
Recently, the identification of a novel therapeutic target, Vorinostat (SAHA, 2.01), has shown 
promising results in the treatment of a number of cancers.1,2 It can be observed that 2.01 contains a 
mono-substituted phenyl moiety. As such it was proposed that a cubanyl analogue (2.02) be 
synthesised in order to gauge the potential for cubane, as a functional moiety in a biological 
application, wherein it is applied as a bioisostere for benzene. 
2.1.1 A Brief Pharmaceutical History of Vorinostat 
Vorinostat (2.01, Figure 2.1) was first identified as a potential drug candidate by Breslow and co-
workers who patented the synthesis of the compound in 1993.3 Breslow et al. identified that 70% of 
murine erythroleukemia cells were imparted with renewed viability at a concentration of only 2.5 
µM. Further to this Vorinostat, then known as “Compound 3”, was able to treat human 
promyelocytic leukaemia (HL-60) cells at concentrations of 1 µM.4 In 1995, Stowell was able to 
synthesise the compound now known as suberoylanilide hydroxamic acid (SAHA) with a slightly 
improved yield.5 
Further to this Stowell investigated the compound’s ability to treat prostate cancer cells, showing 
that it was quite viable in in vitro tests. From these developments the drug was then studied 
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extensively, eventually being approved by the Food and Drug Administration (FDA) for the 
treatment of cutaneous T-cell lymphoma (CTCL) in 2006. Currently, Vorinostat is the only Histone 
Deacetylase inhibitor (HDACi) approved by the FDA for treatment of CTCL, making it the first to 
be approved of its kind.2 
In order to fully understand the efficacy of Vorinostat as an anticancer chemotherapy the basic 
mode of action must first be understood. In a healthy body, the mechanism of cellular growth and 
protein expression is tightly regulated in a number of different ways. One mode is to regulate the 
transcription of DNA by controlling the binding of the transcription enzymes that begin the process 
of gene expression.2,6 
Within the cell, chromatin is responsible for the way in which DNA is ordered within the cell 
nucleus. Chromatin contains the nucleosome, comprised of a DNA double helix encompassing an 
octameric core of eight histone proteins.7 The histone proteins contain a tail of lysine residues, 
which are positively charged in a normal static cell, allowing the octamers to bind tightly with the 
negatively charged DNA backbone.7 When a cell is proliferating, enzymes known as histone acetyl 
transferases acetylate the lysine residue, subsequently neutralising the charge, releasing the 
octamers and thus allowing DNA transcription enzymes to bind with the DNA backbone.6 In this 
state the chromatin is said to be expanded and transcription is thus activated.8 
To regulate the transcription of DNA a competing enzyme, histone deacetylase (HDAC), removes 
the acetyl functional groups from the lysine residues resulting in a tightened chromatin structure and 
repressed DNA transcription.9,10 The HDACs are divided between two families, the classical family 
and the sirtuin family, consisting of a total of four classes.11,12 These classes are differentiated by 
their structure and biological activity.11,13 
A number of malignancies can occur if the correct regulation of genes fails to moderate the 
expression of tumour suppressor and/or cell cycle regulatory proteins.7,14 The result is limited 
growth arrest in cells as well as unregulated proliferation, cell differentiation and apoptosis, which 
can ultimately result in the aforementioned malignancies.9,10 Should HDAC be overexpressed cells 
ultimately over-proliferate, thus becoming cancerous.14 Therefore, a regulated balance is required 
within the cell cycle system. 
In the case of excessive HDAC activity, a HDAC inhibitor (HDACi) can be administered as a 
chemotherapeutic treatment to help regulate HDAC activity.13 A large variety of HDACi’s have 
been developed; the primary target of HDACi’s being the classical family.11 Of these, the most 
successful is Vorinostat, an hydroxamate type inhibitor.2 Vorinostat has been found to have activity 
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in managing a number of malignancies, both solid and hematologic.2 Studies have shown that 
greater efficacy has been apparent in hematologic malignancies.15 
 
Figure 2.2 – Vorinostat in the binding pocket of HDAC. 
Although still not fully understood, the mode of action of Vorinostat as a HDACi has been 
investigated.2 It is believed to bind selectively in the binding pocket of the HDAC enzyme (Figure 
2.2).1 In one prime example, Vorinostat was shown to induce the activation of the p21WAF1 gene, 
which is an inhibitor of cell proliferation.14 Whilst this is particularly beneficial in the treatment of 
cancer, Vorinostat is also reportedly responsible for the repression of other genes.14 
Although the primary use of Vorinostat is the targeting of cutaneous T-cell lymphoma (CTCL), 
evidence has shown it to be effective in combinatorial treatment of other cancers with other 
anticancer compounds such as Taxol and Carboplatin.2,14 It does, however, also show some toxicity 
in patients due to limited target specificity.2 As such, it may be postulated that improved biological 
activity or lowered levels of deleterious effect could potentially be achieved via structural 
modifications. 
2.1.2 The Synthesis of Vorinostat 
Vorinostat has been synthesised in a number of ways since its discovery in the early 1990s. As 
such, these methods will be briefly reviewed below in an attempt to identify a method that is most 
appropriate for an analogous cubane based synthesis. 
In 1993 the first synthesis of Vorinostat was reported by Breslow, whose original procedure gave 
the desired product in a single step using suberoyl dichloride in a basic solution of aniline (2.04), 
aqueous potassium hydroxide and hydroxylamine (Scheme 2.1). Under these conditions the desired 
product (2.01) was synthesised in low yields (15-30%) making it quite inefficient for industrial 
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scale-up. 
 
Scheme 2.1 – Breslow's first reported synthesis of Vorinostat. 
In this case, the reaction also yielded a partially insoluble dianilide, N1,N8-diphenyloctanediamide 
(2.05), which caused purification problems as it was quite difficult to separate from the desired 
product (Figure 2.3).3 
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Figure 2.3 – N1,N8-diphenyloctanediamideside-product. 
In an attempt to improve yields a second synthesis was developed by Stowell and co-workers 
utilising a similar procedure to the first (Scheme 2.2).  
 
Scheme 2.2 – Stowell's synthesis of Vorinostat. 
In this instance suberic acid (2.06) was first reacted with aniline (2.04) to form 2.05 and submitted 
to a half hydrolysis in aqueous potassium hydroxide to give a mixture of the unwanted dianilide 
(2.05), in lowered amounts, and the suberanilic acid (2.07). Esterification of 2.07 then allowed for 
separation of 2.05 via chromatography and thus an improved yield on the final hydroxamic acid 
formation (2.01), which was performed in methanol under anhydrous conditions with sodium metal.  
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The result was an overall yield of 35% and elimination of troublesome side-products (2.05), which 
proved Stowell’s method to be a more effective synthesis than the original synthesis of Breslow. 
The limiting reaction in this procedure was the formation of the suberanilic acid (2.07), which was 
formed in 41.7% and allowed for chromatographic separation from 2.05.5 
A third synthetic method by Mai et al. sought to limit the formation of 2.05 by first cyclising 
suberic acid (2.06) in acetic anhydride to generate 2.09. This was then coupled with aniline (2.04) to 
give an improved yield of the suberanilic acid (2.07, 94% yield). Subsequent conversion to the ethyl 
anhydride (2.10) which was finally reacted with hydroxylamine in methanol to give the desired 
product in 64% yield and therefore an overall yield of 58.7% (Scheme 2.3).16 It may be stated that 
the selection of anhydride functionality (2.10) may have been a poor choice as methyl ester 
conversion to the hydroxamic acid was shown previously to give higher yields. 
 
Scheme 2.3 – Mai's synthesis of Vorinostat. 
The most efficient method, which was reported by Gediya et al. provides a straightforward and high 
yielding approach which takes place in only two steps with preferable reaction conditions for large 
scale synthesis (Scheme 2.4).17 
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Scheme 2.4 – Gediya’s synthesis of Vorinostat. 
Gediya’s method begins with the monomethyl ester of suberic acid (2.11) which was then coupled 
under peptide coupling conditions using dicyclohexyl carbodiimide (DCC, 2.13) and 1-
hydroxybenzotriazole (HOBt, 2.14) with aniline (2.04) to give the suberanilic acid methyl ester 
(2.08) in high yields (88.7%). The methyl ester (2.08) was then reacted at room temperature with 
freshly prepared hydroxylamine to give the desired product (2.01) in 90% yield.17 
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Figure 2.4 – The standard peptide coupling reagents; DIC, DCC and HOBt respectively. 
Synthetically, there are clearly a number of viable options, all of which are based simply around the 
coupling of a suberoyl side chain to aniline (2.04). As such, an analogous synthesis in the cubane 
system should therefore be quite similar. 
2.1.3 A Cubane Analogue of Vorinostat 
 
To investigate the hypothesis of the use of cubane as a potential analogue for drug type molecules, 
it was observed that the binding pocket of the target HDAC relied not on the phenyl constituent of 
Vorinostat but rather on the suberoyl hydroxamic acid tail. It must also be noted that a number of 
factors which may affect the binding of a cubyl analogue have not been discussed. For example, 
problems in binding may arise due to the electronic differences between the two moieties. There 
may in fact be significant pi-stacking effects which take place within these systems that are able to 
confer enhanced activity of aromatic systems.  
Other examples include the significant out-of-plane steric bulk that the cubane ring has when 
compared to benzene. This may impart significant difficulties with respect to the ability of the 
analogue to gain access to the active site of the HDAC. It is thus our hope to uncover whether these 
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factors do indeed contribute to the activity of the desired analogue and thus help us to design further 
experiments based upon these results. In this case the use of cubane as a replacement for the phenyl 
group provided a relatively straightforward synthetic route and as such a good entry point into 
investigating the use of cubane in a drug type molecule. 
Optimally, the synthesis of a cubyl analogue (i.e. 2.02) would follow closely the synthesis of 
Vorinostat (2.01). Therefore, a straightforward synthetic procedure was proposed which employed 
analogous methodology reported in Gediya’s syntheses of Vorinostat (Section 2.1.2). This synthetic 
strategy would make use of an amino cubane moiety analogous to that of aniline (2.21) as shown in 
Scheme 2.5.  
 
Scheme 2.5 – Synthetic strategy towards the cubane analogue of Vorinostat. 
Following the method employed by Gediya the cubylamine (2.21) may then be coupled to a mono-
ethyl ester of suberic acid (2.22) using standard peptide coupling reagents, 
dicyclohexylcarbodiimide (DCC, 2.13) and 1-hydroxybenzotriazole (HOBt, 2.14) (Scheme 2.6). 
The use of peptide coupling reagents on a cubane moiety of this type has not been previously 
reported. 
 
Scheme 2.6 – Peptide coupling of the cubylamine to suberoyl side chain. 
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The synthesis of the cubylamine moiety is a particularly notable synthesis. In a review of cubane 
chemistry by Eaton it was proposed that cubylamine (1.39) may be a pharmaceutical analogue of 
the multi-functional drug Symmetrel™ (Amantadine, 1.37, Figure 2.5).18 
NH2
1.39
NH2
1.41  
Figure 2.5 – The drug Symmetrel™ and a possible cubyl analogue. 
Whilst the synthesis of cubylamine (1.41) has previously been described it has not been tested as 
the proposed antiviral analogue.19 Interestingly, 1.39 is administered as the hydrochloride salt both 
as an antiviral agent and as a treatment for Parkinson’s disease. In this way the synthesis and 
subsequent testing of cubylamine hydrochloride (2.21) may also be a potential drug candidate and 
shall be discussed below. 
2.2 Results and Discussion 
Synthesis of the cubane analogue of Vorinostat (2.02) began with half hydrolysis of the 1,4-diester 
(1.18) with one molar equivalent of sodium hydroxide. The resulting solid was then purified via 
acid-base extraction to give 2.15 in 94% yield.20 Spectroscopic analysis matched the literature and 
2.15 was easily distinguished from 1.18 via the integration of the 3H methyl resonance at δH 3.69 
ppm. 
 
Scheme 2.7 – Half hydrolysis of cubane diester. 
Barton decarboxylation was initially performed under standard conditions using 2-mercaptopyridine 
N-oxide sodium salt (2.17) and t-butyl thiol (2.27) in benzene (Scheme 2.8). Although this method 
is quite efficient and results in a product that is relatively pure, recent research within our group has 
led to an improved method for Barton decarboxylation that was subsequently used for this 
synthesis. This method uses chloroform as the solvent, the hydrogen atom source and the radical 
trap.21 
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Scheme 2.8 – Barton Decarboxylation mechanism. 
In either case the resultant mono-methyl ester (2.18) was hydrolysed with methanolic sodium 
hydroxide without further purification to give 2.19 in an average yield of around 80% over two 
steps (Scheme 2.8 and Scheme 2.9).22 Once again, spectroscopic analysis was concurrent with the 
literature and 2.19 was easily identified via the 1H-NMR which now shows an unsymmetrical 
splitting pattern around 4.0 ppm that is typical of the mono-substituted cubane core. This method is 
quite reproducible under all conditions and is a crucial modification in a number of synthetic 
transformations on the cubane core. 
 
Scheme 2.9 – Hydrolysis to cubane carboxylic acid. 
In order to progress in the synthesis the amino cubane core must first be formed. Previously, the 
application of a Curtius rearrangement on 2.19 has been shown to be a facile method, particularly 
by utilising diphenylphosphoryl azide (DPPA, 2.28) to generate the carbonyl azide intermediate 
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(2.30).19,23 The use of DPPA as the azide source allows for a reagent that is more easily purified and 
quantified for use in reactions. The rearrangement takes place under basic conditions in refluxing t-
butanol yielding a t-butyl carbamate (2.20), which is a stable protecting group for the newly formed 
cubyl amine moiety. This method was thus used to induce a one-pot Curtius rearrangement that 
proceeded smoothly in 67% yield (Scheme 2.10). Spectroscopically, 2.20 was identified by the 
presence of an indicative 9H singlet at δH 1.46 ppm, along with 13C-NMR spectrum and a Low 
Resolution Mass Spectroscopy (LRMS) signal that concurred with those given in the literature. 
 
Scheme 2.10 – Curtius rearrangement to form the Boc-protected amine. 
Subsequent acid catalysed deprotection of 2.20 gave the ammonium chloride salt 2.21 in 90% yield 
when purified via trituration in a solution of diethyl ether and acetone.24 2.21 was found to be stable 
under standard laboratory conditions and could be easily stored for an extended period with 
minimal degradation. The mono-substituted ammonium chloride salt was previously reported in the 
literature with little spectroscopic data.19 Upon 1H-NMR analysis of 2.21 it was noted that only the 
cubyl multiplets were observed between 4.00 and 4.30 ppm. Similarly in the 13C-NMR spectrum 
only four different resonances were observed. Furthermore, LRMS gave further evidence for the 
presence of the desired salt. 
 
Scheme 2.11 – Acid deprotection to the ammonium hydrochloride salt. 
The para-substituted diammonium chloride compound (2.33) had previously been thoroughly 
documented by Eaton and others.24-26 Interestingly, Eaton notes the instability of free base cubyl 
amines stating that they succumbed to decomposition upon standing overnight.24 
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Figure 2.6 – Para-substituted cubyl amines. 
To couple the suberoyl side chain to 2.18 a number of methods were investigated. Initially, diethyl 
suberate was converted to the half acid via half hydrolysis. In accordance with our synthetic 
strategy it was believed that the use of diisopropylcarbodiimide (2.12, DIC) or 
dicyclohexylcarbodiimide (2.13, DCC) would facilitate a peptide coupling reaction between 
substrates 2.18 and 2.22. In order to proceed, it was required that the ammonium chloride first be 
converted to the free cubylamine base (1.41) to facilitate coupling. 
Under these conditions, the reaction was allowed to proceed for several hours while being 
monitored by thin layer chromatography (TLC). It was noted that over this time a number of spots 
were observed via TLC with only a very minor intensity spot being identified as the product (2.23). 
 
Scheme 2.12 – Peptide coupling of suberoyl side-chain. 
Upon workup it was observed that the compound had undergone considerable decomposition. From 
TLC and gas chromatographic mass spectrometry (GCMS) it was determined that decomposition of 
the cubane framework had occurred. At room temperature and upon organic base mediated 
neutralisation of the stabilising hydrochloride salt the free electron pair on the nitrogen seemed to 
lead to rapid degradation of the cubane core. 
Further review of the literature led us to speculate that the free amine most likely promotes a similar 
decomposition pathway as that which was reported for the hydroxyl group in 2.34 (Scheme 2.13). 
This illustrates the propensity for the free electron pair to shift by means of homoketonisation to 
give the tricyclooctenone (2.35), and further to a vinylcyclobutenylketene (2.36, Scheme 2.13). This 
decomposition was noted to be extremely rapid and intermediates are impossible to isolate.18,27 
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Scheme 2.13 – Hormann’s proposed kinetic degradation of cubane via homoketonisation. 
Although some target product (2.23) was observed via this peptide coupling method the subsequent 
workup gave very poor yields (<5%), all of which were contaminated by urea which formed as a 
by-product of the coupling reaction. Therefore, a more rapid and easily purified coupling reaction 
was required for the reaction to proceed. Further to this the use of the cubylamine 1.41 and its 
hydrochloride salt 2.18 would be potentially too unstable to be utilised in a biological application as 
was alluded to earlier. 
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Figure 2.7 – Ureas formed as by-products of DIC and DCC respectively and EDC. 
To enhance the purity, and hopefully expedite the reaction, 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC, 2.39), another peptide coupling reagent known for its solubility in water, was 
also utilised. However, at room temperature the reaction time was once again observed to be 
excessive (>2 hours) and poor yields under these conditions were also observed. It was believed 
that the long reaction times at ambient temperatures required for these reactions could not 
outcompete the decomposition.  
To further underline the instability of the cubyl amine, Eaton and Hormann noted that when 1.41 
was obtained it was not stable to prolonged storage. It was also shown that the cubyl amine 1.41 
could be formed by “careful basification of cold aqueous solutions of their hydrochlorides with 
sodium hydroxide and quick extraction onto methylene chloride.”19 From here conversion to the 
azide (2.40) was used to illustrate the rearrangements which can occur upon treatment with acid 
(Scheme 2.14). In this way the use of cubylamine (1.41) as an analogous drug to Symmetrel (1.39, 
Figure 2.5) may not be possible as the decomposition of the cubyl core may occur in vivo. 
 
Scheme 2.14 – Formation of a cubyl azide via cubylamine and its induced rearrangement. 
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This instability issue dictated that a more facile reaction method be employed. The desired reaction 
was determined to require a number of conditions that would increase yield, purity and accelerate 
reaction times. First, the reaction must limit the rate of generation of the free base cubylamine; 
second, the reaction must promote a stable amide bond formation; third, the reaction must be 
readily purified under standard laboratory conditions; finally, the reaction must yield good 
quantities of product. As such, a number of amide forming reactions were considered.28-34 
Although a number of possible alternatives do exist, the reaction which fit the criteria best was a 
modified Schotten-Baumann reaction (Scheme 2.15).35,36 When performed under anhydrous 
conditions the reaction still requires the generation of the unstable free amine. However, the facile 
nature of the reaction allows for lowered temperatures and a controlled rate of addition of organic 
base allowed control of the formation of the free amine. Although this reaction is traditionally not 
anhydrous, the use of anhydrous conditions in this instance was preferable. 
 
Scheme 2.15 – Schotten-Baumann reaction mechanism. 
Thus, the acid chloride of the monoethyl suberate (2.38) was formed via the addition of oxalyl 
chloride to a stirred suspension of 2.19. Excess oxalyl chloride was removed in vacuo and the acid 
chloride was dissolved in anhydrous methylene chloride. A suspension of 2.18 was added and the 
reaction was cooled to -30 ºC. The reaction proceeded rapidly upon dropwise addition of 
triethylamine at -30ºC to give the desired product (2.20) in good yield (85%). The 1H-NMR 
spectrum of the desired product is easily assigned via the presence of the two signature cubyl 
multiplets around 4 ppm; the splitting consistent with the methylene groups of the suberoyl side 
chain as well as the doublet and triplet associated with the ethyl ester. Further spectroscopic 
analysis in both the 13C-NMR spectrum as well as high resolution mass spectroscopy (HRMS) gave 
strong evidence for the isolation of 2.20. 
 
Scheme 2.16 – Revised synthesis of 2.20 via Schotten-Baumann amide synthesis. 
Initially, triethylamine was used to couple the suberoyl side chain to the cubane moiety. In a revised 
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synthesis Hünig’s base (diisopropylethylamine, DIPEA) was found to improve the yield to 91%. It 
is believed that this is due to the increased steric hinderance observed in DIPEA leading to a 
decreased rate at which the free base cubylamine (1.41) is formed in situ, thus limiting the 
decomposition via homoketonisation. 
Final conversion to the cubanyl Vorinostat analogue (2.02) proceeded via hydroxylamine 
hydrochloride substitution of 2.20. This was achieved by following a similar reaction given by 
Gediya et al. in the synthesis of Vorinostat.17 As such, the reaction proceeded smoothly to afford the 
desired cubyl analogue of Vorinostat (2.02) in 62% yield. 
 
 
Scheme 2.17 – Synthesis of hydroxamic acid. 
Notably, cubane protons were observed at δ~4 ppm in the 1H-NMR spectrum and similar shifts 
were observed for all other resonances reported by Breslow for 2.01.3,5,17 In the 13C-NMR spectrum, 
the carbon resonances of cubane and also the carbonyl carbon of the amide groups appeared in the 
range 40-70 ppm and 165-170 ppm, respectively. The resonances related to the suberoyl 
hydroxamic acid chain are very similar to those reported for 2.01.17 HRMS results gave further 
evidence for the formation of the product and X-Ray crystallographic data gave confirmation of the 
desired structure (Figure 2.8, Appendix 2). 
 
Figure 2.8 – Crystal structure of 2.02. 
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The synthesis of the cubane analogue described above follows closely the method of Gediya’s 
synthesis of Vorinostat with some modifications to account for the highly energetic nature of the 
cubane core. 
2.3 Biological Studies 
In order to determine the efficacy of a cubyl analogue of Vorinostat in vitro assays were performed 
by the Drug Discovery Group of the Queensland Institute of Medical Research (QIMR) led by Prof. 
Peter Parsons. The Drug Discovery Group is a long time collaborator whose assistance in these 
studies was greatly beneficial to this project. 
2.3.1 Methods 
Vorinostat (2.01) was purchased from Sigma-Aldrich (Catalogue #10009929). 2.02 was synthesized 
as shown (Section 2.2). Both compounds were dissolved in dimethyl sulfoxide (DMSO). MM96L 
and MCF7 were human tumor cell lines derived from melanoma and breast cancer respectively. 
NFF were early passage neonatal fibroblasts. 
2.3.1.1 Sulforhodamine B assay for inhibition of growth of cells cultured as monolayers 
Cells were seeded at 5,000 per microtitre well (96-well plate) in 10% FCS-RPMI 1640 culture 
medium, treated, and allowed to grow until the controls were nearly confluent (5-6 days). Culture 
media was removed; the wells were then washed twice with phosphate buffered solution (PBS), 
fixed with ethanol for a minimum of 5 min. and washed with water. Sulforhodamine B (SRB) 
solution (50 µL of 0.4% in 1% acetic acid) was added and the mixture left at room temperature for a 
minimum of 15 min. The plate was washed rapidly with tap water and then twice with 0.1-1% 
acetic acid the liquid being removed by tapping each time.  After addition of 100 µL/well of 10 mM 
Tris base (unbuffered, pH > 9), plates were left for  a minimum of 5 min, then the absorbance was 
read at 564 nm on an ELISA reader with SOFTmax® PRO Version 3.1.2, with a 3 second prior 
shaking operation. Data were exported as text files and analysed via an Excel spreadsheet. After 
subtraction of a blank (i.e. wells with no cells, A564 typically ~0.04), growth inhibition was 
calculated as a percentage of the untreated control and plotted against dose.37 
2.3.1.2 Inhibition of the growth of human melanoma transplants in nude mice 
Human melanoma cells MM96L were injected subcutaneously (2 million cells/site in 50 µl culture 
medium) into 4 sites each on the flanks of 4 nude (nu/nu) mice (i.e. 16 tumor sites per treatment 
group). Treatment was commenced the following day with intraperitoneal injection of 1 mg of drug 
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in 50 µL of DMSO and was continued daily. The untreated mice were injected with DMSO alone. 
The tumors were measured with calipers and the volume calculated and plotted against time.  
2.3.2 Results and Discussion 
2.3.2.1 Inhibition of cell growth in culture  
Vorinostat (2.01) was observed to inhibit the growth of both tumour cell lines with an IC50 of 
approximately 0.03 µg/ml (Figure 2.9). The healthy cells (NFF) however, were observed to not be 
affected to the same extent. The novel compound 2.02 gave similar results (Figure 2.10). 
 
Figure 2.9 – Inhibition of cell growth by 2.01. 
 
Figure 2.10 – Inhibition of cell growth by 2.02. 
Both 2.01 and 2.02 killed cancer cells (MM96L, MCF7) at lower doses than normal neonatal foetal 
fibroblast (NFF) cells. This indicates that the cubane analogue is accepted into the cell and is 
capable of targeting a specific binding site and is capable of killing tumour cells. The half maximal 
inhibitory concentration (IC50) for both compounds was observed to be similar for each cell line, 
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indicating the potency of 2.02 is comparable to that of Vorinostat (2.01). This was a highly 
promising initial result as it showed the potential for the compound to bind in a similar manner with 
similar results to that reported for the original pharmaceutical compound. It should also be noted 
that 2.02 demonstrated a lower toxicity towards healthy NFF cells. This is a particularly interesting 
result as it demonstrated a benefit in the use of the cubane in analogous drug compounds. 
2.3.2.2 Inhibition of the growth of melanoma xenografts in nude mice 
A pilot experiment was carried out to determine the maximum tolerated dose of each drug when 
given intraperitoneally daily for an extended period. The same daily dose of 1 mg was selected for 
both drugs because of their similar activity in vitro. A much higher dose (6 mg), given twice only 
with a three-day interval, was observed to be overtly toxic. Injection of the drugs was commenced 
one day after implantation of the tumour cells to maximize opportunities for observing inhibition of 
tumour growth. The results (Figure 2.11) show that 2.01 had very little effect on growth of the 
tumours. However, treatment with 2.02 had to be discontinued after day 11 due to the observation 
of clinical toxicity in which the mice became very sluggish and were thus terminated; however no 
inhibition of tumour growth was observed during the treatment period.  
 
Figure 2.11 – Growth of MM96L Human Melanoma in Nude Mice. 
The anticancer activity of the cubyl analogue (2.02) resembled that of Vorinostat (2.01) in that it 
was selectively toxic to tumour normal when compared to cells in culture in vitro. However, this did 
not translate to an in vivo study in this mouse model. In this, neither compound showed significant 
activity against the MM96L human melanoma xenografts, and 2.02 appeared to generate some 
additional toxicity in the mouse.  It is possible that 2.02 targets some other cell type or function in 
the intact mouse. However, it must be noted that the in vivo results were not fully appropriate for 
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the biological testing of Vorinostat and were performed opportunistically as tumour cells were on 
hand at the time of the study. A more appropriate in vivo study is currently being performed at the 
CSIRO using a cutaneous T-cell lymphoma (CTCL) mouse model as Vorinostat is used in the 
treatment of CTCL. 
2.3.2.3 LogP studies into Vorinostat and the cubyl analogue 
LogP measurements were also attained to determine the influence of the cubane moiety on the 
pharmacokinetics of the compound (Table 2.1). These results show the cubyl analogue (2.02) to 
have a far higher LogP than that of Vorinostat (2.01). It can also be determined from Table 2.1 that 
calculations of LogP from within the Chemdraw program have not yet been designed to 
accommodate the strained, yet stable nature of the cubane core. The measured LogP value is 
understandable given the electronic nature of the cubane core when compared to that of the benzene 
ring. The cubane core is, in essence, a hydrocarbon. Its nature is therefore more hydrophobic than 
that of the electron rich benzene ring in 2.01. 
Table 2.1 – LogP Values of Vorinostat vs. Cubyl Analogue (2.02). 
 Measured Calculated in Chemdraw 
 LogPhplc LogP CLogP 
Vorinostat (2.01) 0.99 1.79 0.99 
Cubyl analogue (2.02) 1.52 -0.02 -1.32 
However, the increased LogP is suggestive of a potential benefit in terms of biological activity. 
Both central nervous system penetration and gastric absorption studies show a parabolic 
relationship with an optimum LogP value of around 2 ± 1. Since Vorinostat has a LogP of 0.99 and 
the cubane analogue has a LogP of 1.52 it may be reasonable to expect improved CNS penetration 
with the cubane analogue and increased bioavailability throughout further areas in the body.38,39 
2.4 Experimental 
4-Methoxycarbonylcubane carboxylic acid (2.15) 
OH
O
MeO
O  
1,4-Bis(methoxycarbonyl)cubane (1.18, 0.501 g, 2.27 mmol) was dissolved in anhydrous 
tetrahydrofuran (15 ml) under an argon atmosphere. To this solution was added methanolic NaOH 
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(0.93 ml, 2.45 M, 2.31 mmol) dropwise and the mixture allowed to stir overnight. The solvent was 
removed by rotary evaporator without heat. Water was added and the solution extracted with 
chloroform (3 x 10 ml) to remove any unreacted diester (5%). The aqueous layer was then acidified 
to pH 2 using concentrated aqueous hydrochloric acid and the solution was extracted once again 
with chloroform (1 x 16 ml, 2 x 10 ml). The solution was dried (MgSO4), filtered and evaporated to 
give 2.15 as a white solid (0.440 g, 94%). M.p. 181-182 ºC (Lit.22 182-183 ºC); FTIR/ATR (υ, cm-1) 
3003 (0.18), 2560(0.15), 1683 (0.70), 1619(0.50), 1440(0.50), 1368 (0.52), 1291 (0.79), 1233 
(0.95), 1207 (1.00),1094 (0.73), 1018 (0.33), 925 (0.48), 849 (0.68), 772 (0.43), 730 (0.40), 705 
(0.55), 612 (0.19); 1H-NMR (400 MHz, CDCl3) δ: 4.25 (s, 6H), 3.69 (s, 3H); 13C-NMR (100 MHz, 
CDCl3) δ: 176.90, 171.85, 55.82, 55.46,51.66, 47.05. 
Cubane carboxylic acid (2.19) 
OH
O
 
4-Methoxycarbonylcubane carboxylic acid (2.15, 2.01 g, 9.73 mmol) was added to anhydrous 
methylene chloride (30 ml) under an atmosphere of argon. Oxalyl chloride (3.77 g, 2.54 ml, 29.7 
mmol) was added along with a drop of N,N-dimethylformamide and the solution was allowed to stir 
for 30 min. until clear. The solution was evaporated under vacuum without heating and the resultant 
solid (2.16) placed under an inert atmosphere. The solid was then dissolved in benzene (10 ml). 
This solution was then added dropwise over a period of 30 min. to a solution of 2-mercaptopyridine 
N-oxide sodium salt (1.6 g, 11 mmol), t-butyl thiol (1.8 g, 2.25 ml, 20 mmol), and a catalytic 
amount of DMAP (23 mg) refluxing in a solution of benzene (30 ml)  simultaneously irradiated 
with a 250 Watt Tungsten lamp. The reaction was allowed to proceed for 1.5 h before being cooled.  
A solution of saturated Ca(OCl)2 (10 ml) was added in portions and the reaction mixture was 
transferred to a separatory funnel and diluted with diethyl ether (20 ml) and washed with water 
(3x25 ml). The aqueous wash was back extracted with diethyl ether (25 ml) and the combined 
organic extract was dried (MgSO4) and concentrated to approximately 15 ml on the rotary 
evaporator. Methanolic NaOH solution (20 ml, 1.25 M, 25 mmol) was added and the mixture was 
heated under reflux for 1 hour, cooled and then concentrated to near dryness under vacuum. 
Benzene (25 ml) was added and the solvent was again removed to near dryness.  
Water (25 ml) was added and the mixture extracted with methylene chloride (3x10 ml). The 
aqueous layer was separated and acidified slowly to pH 1-2 with concentrated aqueous hydrochloric 
acid; a solid formed and the mixture was extracted with methylene chloride (1x25 ml, 2x10 ml). 
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The combined organic extract was dried (MgSO4) and the solvent removed by rotary evaporation. 
The green/yellow solid was purified by column chromatography Ethyl acetate: Hexane (1:1) to give 
1.10 g (77%) of cubane carboxylic acid (2.19).M.p. 124-126 ºC (Lit.22 124-125 ºC); FTIR/ATR (υ, 
cm-1) 2986 (0.49), 2603 (0.23), 1668 (1.00), 1419 (0.64), 1318 (0.78), 1239 (0.65), 1217 (0.54), 
1194 (0.40), 1101 (0.30), 1064 (0.20), 949 (0.59), 910 (0.63), 886 (0.47), 839 (0.64), 701 (0.53), 
637 (0.18); 1H-NMR (300 MHz, CDCl3) δ: 4.30 (m, 3H), 4.04 (m, 4H); 13C-NMR (75 MHz, 
CDCl3) δ: 178.76, 55.43, 49.43, 47.84, 45.18.  
t-Butyl cubanylcarbamate (2.20) 
H
N O
O  
A solution of cubane carboxylic acid (2.19, 0.50 g, 3.37 mmol), triethylamine (0.34 g, 1 eq.), and 
freshly distilled diphenylphosphoryl azide (0.93 g, 1 eq.) in t-butyl alcohol (10 ml) was heated at 
reflux for 24 h. Following this the solvent was removed by rotary evaporation and the subsequent 
solid residue was purified by column chromatography EtOAc: Hexane (2:3) to give0.49 g (67%) of 
t-butyl cubanylcarbamate (2.20) as an off-white solid.M.p.150-152 ºC dec.; FTIR/ATR (υ, cm-1) 
3242 (0.17), 2978 (0.64), 1703 (0.81), 1361 (0.85), 1334 (1.00), 1258 (0.34), 1215 (0.31), 1161 
(0.76), 1089 (0.46), 1067 (0.56), 1048 (0.55), 1032 (0.47), 1015 (0.45), 839 (0.51), 776 (0.45), 734 
(0.36), 690 (0.32); 1H-NMR (400 MHz, CDCl3) δ: 5.04 (br, s, 1H), 4.06 (m, 3H), 3.95 (br, m, 1H), 
3.88 (br, s, 3H), 1.46 (s, 9H); 13C-NMR (75 MHz, CDCl3) δ: 66.3, 52.6, 48.1, 42.4, 28.4.; 
LRESIMS m/z (C13H17NO2 + Na) found: 242.13. 
Aminocubane hydrochloride (2.21) 
NH3 Cl
 
Acetyl chloride (1 ml, 14mmol) was added dropwise to a stirred solution of anhydrous methanol (2 
ml) at -30ºC and allowed to stir for 15 min. Solid t-Butyl cubanylcarbamate (2.20, 0.100 g, 0.456 
mmol) was added and the solution was allowed to stir for 1 hour, and then allowed to warm to room 
temperature. The reaction was monitored via TLC to determine the disappearance of 2.20. The 
solvent was removed via rotary evaporation to give a brown solid which was washed with a solution 
of diethyl ether and acetone (4:1) and filtered to give 2.21 as a white solid (0.06 g, 90%).M.p.>250 
ºC; FTIR/ATR (υ, cm-1) 3324 (0.18), 2983 (0.33), 1614 (0.79), 1540 (1.00), 1329 (0.34), 1255 
(0.59), 1213 (0.47), 992 (0.25), 835 (0.34), 636 (0.43), 590 (0.49); 1H-NMR (300 MHz, D2O) δ: 
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4.12 (m, 3H), 3.91 (m, 4H); 13C-NMR (100 MHz, D2O (dioxane reference)) δ: 64.95, 50.58, 48.91, 
43.40; LRESIMS m/z (C8H10ClN – Cl) found: 120.16.  
8-ethoxy-8-oxooctanoic acid (2.22) 
O
EtO
O
OH
 
To a solution of 1-Ethyl 8-methyloctanedioate (12.66 ml, 0.054 mol) in tetrahydrofuran (25 ml) was 
added 2.5M ethanolic KOH (21.5 ml, 0.054 mol) and the solution stirred at 0 °C for 18 h. The 
solution was then stirred for a further 6 h at room temperature. The solvent was removed by 
evaporation and water (200 ml) was added. The solution was extracted with diethyl ether (4x50 ml) 
before being acidified to pH 2-3 with concentrated aqueous hydrochloric acid. The acidified 
aqueous layer was extracted with methylene chloride (4x100 ml). The organic layer was dried 
(MgSO4), filtered and the solvent removed by evaporation to yield (8.6 g, 79%) of low melting 
solid. The solid was purified by Kugelrohr distillation to give (6 g, 55%) of pure 8-ethoxy-8-
oxooctanoic acid (2.22) as an amorphous white solid. M.p. 23-25 ºC; 1H-NMR (300 MHz, CDCl3) 
δ: 4.10 (q, J = 7.1 Hz, 2H), 2.30 (dt, J = 17.5, 7.5 Hz, 4H), 1.62 (m, 4H), 1.34 (m, 4H), 1.23 (t, J = 
7.1 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ: 179.22, 173.77, 60.22, 34.24, 33.80, 28.69, 28.64, 
24.71, 24.44, 14.23. 
Ethyl 8-(cubylamino)-8-oxooctanoate (2.20) 
H
N
OEt
O
O
 
8-Ethoxy-8-oxooctanoic acid (2.22, 1.50 g, 7.55 mmol) was dissolved in anhydrous methylene 
chloride (5 ml) under an atmosphere of argon. The solution was stirred and cooled to 0 ºC. Oxalyl 
chloride (0.75 ml, 8.26 mmol) was added slowly. A drop of DMF was added to increase the 
reaction rate and the solution was allowed to stir for 2 hours. Following this the solvent was 
removed under vacuum to give ethyl 8-chloro-8-oxooctanoate (2.38), 0.240g of which was 
dissolved in anhydrous methylene chloride (20 ml) to give a 0.054 M solution.  
Aminocubane hydrochloride (2.21, 0.031 g, 0.199 mmol) was suspended in anhydrous methylene 
chloride (20 ml) and the mixture cooled to -30 ºC. A solution of 2.38 (3.69 ml, 0.054 M) in 
methylene chloride was added and the solution was stirred for five min. Triethylamine (0.11 ml, 
0.80 mmol) was added dropwise and the solution was allowed to stir for 15 min. A precipitate 
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formed and the solution was allowed to warm to room temperature. The solvent was removed via 
rotary evaporator. Column chromatography was performed on the residue with 20% ethyl acetate in 
hexanes to give ethyl 8-(cubylamino)-8-oxooctanoate (2.20, 0.051 g, 85%) as a white solid. M.p. 
100-102 ºC; FTIR/ATR (υ, cm-1) 3243 (0.35), 2982 (0.50), 2925 (0.28), 1733 (0.88), 1632 (1.00), 
1538 (0.98) 1468 (0.39), 1416 (0.35), 1334 (0.74), 1247 (0.58), 1215 (0.52), 1171 (0.94), 1094 
(0.50), 1026 (0.65), 842 (0.34), 709 (0.45), 653 (0.41); 1H-NMR (400 MHz, CDCl3) δ: 5.93 (br, s, 
1H), 4.10 (m, 5H), 3.91 (m, 4H), 2.26 (t, J = 7.5 Hz, 2H), 2.15 (t, J = 7.5 Hz, 2H), 1.60 (m, 4H), 
1.32 (m, 4H), 1.23 (t, J = 7.1 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ: 173.79, 172.28, 66.61, 
60.19, 52.58, 47.81, 42.92, 52.58, 47.81, 42.92, 36.18, 34.25, 28.82, 28.78, 25.24, 24.75, 14.24; 
HRESIMS m/z calculated for (C18H25NO3 + Na): 326.1732; Found: 326.1729. 
N1-Cubyl-N8-hydroxyoctanediamide (2.02) 
H
N
N
HO
O
OH
 
A solution of KOH (0.26 g, 3.89 mmol) in methanol (2 ml) was added slowly to a stirred solution of 
hydroxylamine hydrochloride (0.138 g, 1.98 mmol) in methanol (2 ml) at 0 °C. The solution was 
stirred for 30 min. Ethyl 8-(cubylamino)-8-oxooctanoate (2.20, 0.06 g, 0.198 mmol) in methanol (3 
ml) was added dropwise at 0 °C and the solution was allowed to stir overnight. The solvent was 
removed and water (10 ml) was added followed by slow addition of acetic acid to pH 6-7. The 
resultant solid precipitate was filtered, dried and recrystallised from methanol to obtain N1-cubyl-
N8-hydroxyoctanediamide (2.02) (0.035 g, 62%) as a white solid. M.p. 165-167 ºC dec.; FTIR/ATR 
(υ, cm-1) 3243 (0.51), 2991 (0.39), 2929 (0.43), 2861 (0.20), 1741 (0.20), 1668 (0.61), 1650 (0.44), 
1608 (1.00), 1539 (0.98), 1468 (0.48), 1415 (0.60), 1386 (0.31), 1319 (0.67), 1252 (0.39), 1217 
(0.38), 992 (0.45), 969 (0.43), 878 (0.27), 842 (0.32), 758 (0.30), 723 (0.50) 632 (0.40) 563 (0.25); 
1H-NMR (300 MHz, DMSO-d6) δ: 10.30 (s, 1H), 8.63 (s, 1H), 8.40 (s, 1H), 4.00 (m, 3H), 3.86 (m, 
4H), 2.05 (t, J = 7.4 Hz, 2H), 1.91 (dd, J = 9.6, 5.1 Hz, 2H), 1.45 (m, 4H), 1.22 (m, 4H); 13C-NMR 
(101 MHz, DMSO-d6) δ: 171.38, 168.97, 65.92, 51.82, 46.69, 41.88, 34.96, 32.13, 28.23, 24.86; 
HRESIMS m/z calculated for (C16H22N2O3 + Na): 313.1528; Found: 313.1523;. Elemental analysis 
calculated for C16H22N2O3: C: 66.18%; H: 7.64%; Found: C: 66.17%; H: 7.76%. 
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Chapter 3 A Cubane Analogue of Leteprinim 
3.1 Introduction 
The next target was selected from a different class of pharmaceuticals. Vorinostat is designed to 
target primarily cutaneous cells; Leteprinim (AIT-082, Neotrofin, 3.01) is targeted towards neuronal 
cells and is specifically designed to pass through the blood brain barrier to stimulate the outgrowth 
of neuronal dendrimers. In this case, therefore, a cubane analogue will allow us to investigate not 
only the efficacy of such an analogous compound, but also the biological route a drug of this type 
will follow. This may further allow us to determine the possible side effects that cubane based 
analogues will have in various biological systems as they are taken up and subsequently 
metabolised by the biological systems for which they are designed. This may thus allow us to 
determine not only the positive effects the drug may possess but also identify any potential negative 
effects caused by implementing the cubane modification. 
 
Figure 3.1 – Leteprinim (AIT-082, 3.01) and its cubyl analogue. 
3.1.1 A Brief Pharmaceutical History of Leteprinim 
Alzheimer’s Disease (AD) has been linked to a number of factors within the brain.1 One of these 
factors is the decreased production of nerve growth factors (NGF).2 The decreased production of 
NGF may be due to defects in the immune or nerve cells of the brain.3 Working on this theory, 
Glasky sought to design a series of compounds capable of correcting these cellular defects.4 
Initially, the goal was to develop a compound which was able to impart two unique therapeutic 
effects. The compounds were designed with a bridging moiety that would first allow uptake into the 
target site and subsequently break upon metabolism of the drug, releasing the two active moieties. 
Those drugs that contained a purine moiety were expected to impart a strong neurological activity 
in a similar mode to adenosine.5,6 However, upon biological testing it was discovered that 
Leteprinim (which was at that time labelled AIT-082) was apparently not cleaved biologically and 
imparted significantly greater neurite outgrowth in rat pheochromocytoma cells (PC12) than the 
purine moiety alone.4 Leteprinim was then employed in further biological studies in order to 
determine the compound’s mode of action.7,8 
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Studies performed in vitro showed 3.01 to be capable of increasing the cellular production of NGF 
mRNA, fibroblast growth factor (FGF-2) mRNA as well as effect a long term limited increase in 
Neurotrophin (NT-3) mRNA production.7 These results gave reason to pursue a rodent model 
experiment which also proved highly successful, showing significant memory improvements in 
rats.9-14 The success from these investigations resulted in approval for progression into phase I trials 
in 1997.9 
The first Phase I study group was limited to eight healthy elderly volunteers who were administered 
escalating single doses of Leteprinim, with quite encouraging results.9 Following this, a number of 
other investigative studies were performed, each showing similar positive results that supported the 
case for Leteprinim as a treatment for neurodegenerative diseases.12-27 In perhaps the most elaborate 
reported study nineteen patients with mild to moderate dementia severity were treated; first with 
low doses of Leteprinim (150 mg) each day for one week and then with high doses (500 or 1000 
mg) each day for a second week.18 The subjects were tested by PET scanning before the test began, 
and again after both the low dose and the high dose periods. The results of these scans showed that 
some significant changes occurred in the metabolic activity of certain areas of the brain. These 
results were coupled with results from neurocognitive tests that showed that patients treated with 
high doses of the drug had significantly improved memory, attention and judgement following 
treatment.17 
Leteprinim has also been shown to have neuroprotective properties which may, as a result, provide 
a preventative measure for stroke as well as other neurodegenerative diseases.10 Strangely, 
following such positive test results further testing has not been performed since 2007. Spectrum 
Pharmaceuticals (formerly NeoTherapeutics) have been seeking a co-development partner for this 
drug since the commencement of clinical trials.17 
3.1.2 The Synthesis of Leteprinim 
The first reported synthesis was patented in 1991.4 The method, developed by Glasky, was one in a 
series he used to generate a number of other similar hypoxanthine derivatives. The synthesis 
followed a complex route which was designed to yield various analogues stemming from the 
adenine and hypoxanthine pharmacophores.  
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Scheme 3.1 – Glasky’s original synthesis of AIT-082 (Leteprinim). 
The first step was a Michael addition of ethyl acrylate (3.04) to the precursor adenine (3.03). 
Following this, diazotisation of the Michael addition product (3.05) via dropwise addition of 
saturated aqueous sodium nitrite to a solution of 3.05 in acetic acid gave the hypoxanthine core of 
3.06. Subsequent hydrolysis and para-nitro phenol functionalisation (using 3.08) of the side chain to 
give the activated ester (3.09), prepared the compound for substitution with 4-aminobenzoic acid 
ethyl ester (3.10). This substitution was performed by heating the reagents (3.09 and 3.10) in 
DMSO at ~40 ºC for 72 h to give 3.11 in 30% yield. Finally, hydrolysis of the remaining ethyl ester 
of 3.11 gave the desired compound 3.01. The final product, along with analogous compounds 3.11, 
3.09 and 3.07, were tested and all were observed to exhibit neurotropic activity; the latter three to a 
lesser extent than that of 3.01. 
In a later synthetic method Glasky reviewed his past procedure and determined that the synthesis 
could be improved by building the hypoxanthine moiety from the 4-amino benzoate (3.12) starting 
material.15 β-Alanine, as the acid chloride hydrochloride salt (3.13), was added under modified 
Schotten-Baumann conditions to 3.12. The ammonium chloride salt was then neutralised under 
basic conditions to give the intermediate 3.14 (Scheme 3.2). 
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Scheme 3.2 – Initial building block for Leteprinim synthesis. 
Following this, 2-amino-2-cyanoacetamide (3.15) was reacted at around 50 ºC with triethyl 
orthoformate (3.16) in order to generate a second reactive intermediate; the imidoester 3.17. This 
imidoester was observed to be more stable in acetonitrile than other solvents and as such was 
synthesised in solution without purification using a relative molar ratio of 1.08 equivalents of 3.16 
to 3.15. 
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EtO OEt
OEt
+ H2N
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OEtMeCN
3.15 3.16 3.17  
Scheme 3.3 – Synthesis of imidoester 3.17. 
 
Upon generation of the imidoester 3.17, a solution of 3.14 in methanol at 35 ºC was added to 
generate the cyclocondensation product 3.18 as a precipitate after 2 hours (Scheme 3.4). Glasky 
noted that should the reaction be performed at lowered temperatures a number of side reactions may 
occur. Glasky further noted that the product 3.18 can be washed with methanol to purify and 
subsequently dried at below 40 ºC to prevent generation of hydrogen cyanide via decomposition. 
 
Scheme 3.4 – Cyclocondensation to yield 3.18. 
Triethyl orthoformate (3.16) was once again employed in order to complete the cyclisation of the 
purine ring system. 3.18 was dissolved in glacial acetic acid, excess 3.16 was then added and the 
solution heated at reflux for 4.5 hours. Upon cooling 3.11 was found to be insoluble and was 
purified by washing with acetic acid followed by ethanol (Scheme 3.5). This product was then 
hydrolysed in aqueous base overnight to give the desired product 3.01 in a similar manner to that 
described in Scheme 3.1. 
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Scheme 3.5 – Cyclisation to the hypoxanthine derivative 3.11. 
A third synthesis of 3.01, patented by Lei et al. in 2004, provided an alternative synthetic route, 
which was a more viable method for the synthesis of the cubyl analogue 3.02 (Scheme 3.6).24 This 
is primarily due to the coupling of the aniline derivative (3.19) under Schotten-Baumann conditions 
to give the Michael acceptor 3.21. When compared to conditions such as those depicted in Scheme 
3.1 it is apparent that the free amine is, in this case, not subject to increased temperatures or 
extended reaction times. 
 
Scheme 3.6 – Lei’s synthesis of AIT-0082 Potassium Salt. 
In Lei’s synthesis it is clear that the method takes a quite different approach as the Michael acceptor 
(3.21) is now formed from ethyl aminobenzoate (3.19). Once coupled under Michael conditions, it 
removes the need for the coupling at later stages. This demonstrates that the acrylamide (3.21) is 
capable of being an adequate Michael acceptor for the addition of adenine (3.03). The Michael 
addition product (3.22) can then be diazotised to give the hypoxanthine derivative (3.11) which is 
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then hydrolysed to yield the desired compound, Leteprinim (3.01). The potassium salt of 
Leteprinim, 3.23 is also shown here as it provides a more soluble derivative for improved biological 
delivery. It is apparent in this synthetic route that the yields are quite good for the majority of steps. 
In fact, the Michael addition reaction is the lowest yielding step (65%) throughout the synthesis. 
This is quite notable when compared to the original synthesis in which the lowest yielding step was 
the amide bond formed between 3.09 and 3.10 which proceeds in only 30% yield (Scheme 3.1). 
3.1.3 A Cubane Analogue of Leteprinim 
To explore the hypothesis that the phenyl ring may be substituted for a cubane due to the similar 
spatial distances across the ring system, the proposed cubane analogue 3.02 was therefore chosen to 
be investigated. In keeping with the results observed in the cubyl Vorinostat analogue (2.02), the 
resultant product in this investigation is expected to have different physical properties to the original 
drug but maintain a similar level of biological activity. As a pharmaceutical analogue it is important 
to gauge a comparison of activity at least at a basic level.  
Leteprinim (3.01) was initially tested for activity against rat pheochromocytoma (PC12) cells.4 
Therefore analogous testing against these cells should at least show a primary comparison of 
activity between the two compounds. Insights from this testing will allow us to gain greater 
knowledge into the use of cubane as a potential bioisostere to the phenyl moiety in 
pharmaceutically active compounds. The use of a para-substituted cubane core provides an 
additional synthetic challenge and through this synthesis we can further determine how these 
compounds react under novel conditions, which will add to the library of modifications that may be 
applied in cubane chemistry. 
H
N
OH
O
O
N
N
HN N
O
3.02  
Figure 3.2 – The proposed cubane analogue of Leteprinim. 
The synthesis of a cubyl analogue of Leteprinim is unprecedented in the literature. As such, a novel 
method was required. It was determined that the use of Glasky’s synthetic route would be 
inappropriate for the cubane core as it would require the free cubyl amine to react with the p-nitro 
phenolic ester 3.09. Under the conditions reported by Glasky this reaction was performed at 35-40 
ºC. From prior experience in the preparation of a free-base cubylamine we anticipated that 
significant degradation of the cubane core would be observed under these conditions.  
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However, the method of Lei et al. utilised a Schotten-Baumann reaction similar to that employed in 
our synthesis of the Vorinostat analogue 2.02 (Chapter 2).24 As we had already established this 
method for the formation of cubyl amides, an attempt to synthesise the first reported cubyl 
acrylamide was thus proposed (Scheme 3.7). 
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Scheme 3.7 – Proposed retrosynthetic approach to a Leterinim analogue. 
As the reaction required an analogue of the p-amino benzoate compound (3.19), the synthesis of a 
corresponding cubyl analogue (3.28) may be achieved using a similar method to that used in the 
preceding chapter (2.18, 0). Following the preparation of an acrylamide intermediate (3.27) it was 
anticipated that a Michael addition could be performed to give the advanced intermediate 3.24. In 
Lei’s synthesis, adenine (3.03) was used in the Michael addition reaction and it may be that this is 
due to a more nucleophilic nature when compared to hypoxanthine (3.26). As such, it was believed 
that it would be best not to deviate from established chemistry. 
3.2 Results and Discussion 
Beginning with the half acid 2.12, diphenylphosphoryl azide (DPPA, was used to produce the Boc 
protected amine 3.29 via Curtius rearrangement (Scheme 3.8).† The use of t-butanol as the solvent 
resulted in a 66% yield. Analysis of the 1H-NMR spectrum showed a signature t-butyl singlet 
resonance at 1.43 ppm along with a methyl ester singlet at 3.68 ppm. Interestingly, the cubyl proton 
resonances appear as a single multiplet at 4.07 ppm, most likely due to the similar electronic effects 
imparted by both the amide and the ester moieties. In the 13C-NMR spectrum the carbonyl 
resonance of the carbamate moiety is not observed even with extended delay times, however, all 
                                                 
† The mechanism of the Curtius rearrangement is illustrated in Scheme 2.10. 
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other carbon resonances are observed in positions consistent with the structure of 3.29. The absence 
of the aforementioned carbonyl peak may be explained by the lack of adjacent protons through 
which a proton decoupling effect may be achieved. The amine of the carbamate is also likely to 
undergo hydrogen-deuterium exchange and thus further limiting the desired proton decoupling 
effect required to define the carbonyl carbon under these particular 13C-NMR conditions. 
 
Scheme 3.8 – Curtius rearrangement to give the t-Boc-protected amine. 
Removal of the t-Boc protecting group was once again performed with hydrochloric acid in 
methanol to give the ammonium chloride 3.30 in good yield (82%).‡ Spectroscopic analysis 
revealed that the cubyl proton resonances had shifted to give a single 6H proton resonance at 4.14 
ppm along with a corresponding 3H methyl ester resonance at 3.64 ppm. 
 
Scheme 3.9 – Formation of the ammonium chloride intermediate. 
Reaction of the ammonium chloride salt (3.30) with acryloyl chloride (3.31) in a modified Schotten-
Baumann reaction, using triethylamine as the organic base, gave the desired acrylamide (3.27) in 
good yield (66%). The product was easily identified via 1H-NMR spectroscopy, which revealed the 
presence of a typical cubyl proton multiplet at 4.16 ppm along with two associated double doublets 
at 6.28 and 5.64 ppm attributed to the terminal protons of the double bond. A multiplet at 6.09 ppm 
was also attributed to the methine proton of the double bond. HRMS analysis also gave a molecular 
ion consistent with the product 3.27.  
It should be noted that the use of Hünig’s base in this reaction may also improve the yield. 
However, this avenue of investigation was not followed as yields were sufficient for progression in 
the synthetic route. 
                                                 
‡ The generation of HCl in situ via the careful addition of acetyl chloride to anhydrous methanol allows for a more 
facile preparation of a highly concentrated methanolic hydrochloric acid solution. The methyl acetate that is formed can 
be easily removed in vacuo upon workup. 
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Scheme 3.10 – Acrylamide formation under Schotten-Baumann conditions. 
Following the method of Lei, 3.27 would thus become the required Michael acceptor for the 
subsequent coupling to the adenine moiety (3.03). In the method of Lei, an equivalent amount of 
sodium metal was added to a stirred solution of adenine in methanol in a large scale (>5g) reaction. 
Lei reported that upon dissolving 3.03 the phenyl acrylamide (3.21) was added and the solution was 
heated at reflux. Under the same conditions, the cubyl analogue (3.27) was observed to 
preferentially form the intermediary methoxypropanamide (3.32) with only minor amounts of the 
desired product (3.25) formed. 
 
Scheme 3.11 – Formation of an undesired Michael product. 
In order to facilitate the desired reaction a number of alternative conditions were attempted 
including excess sodium  metal; excess adenine; lowered reaction time; catalytic sodium metal; 
utilising alternative organic bases such as lithium diisopropylamine (LDA) as well as potassium or 
sodium hydride; and the use of non-protic solvents such as tetrahydrofuran. Further investigations 
into phase-transfer catalysed reactions using zinc oxide under microwave conditions were also 
found to be unsuccessful.28 
We suspected that the excess amount of sodium methoxide due to the difficulties associated with 
accurately weighing out small amounts of sodium metal may have led to further synthetic 
difficulties.29 Therefore, an analytically prepared solution of sodium methoxide in methanol (25% 
w/v) was employed. The reaction proceeded more reliably, ultimately resulting in an increased yield 
of the desired product (3.25, 30%). Based on recovered starting material (60%) the reaction may 
indeed be said to be greatly improved. 
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Scheme 3.12 – Improved synthesis of correct Michael product. 
However, the most important development at this stage was the discovery of an adequate 
purification method. Lei’s method indicated that the desired product precipitates from solution upon 
cooling.24 In this case any methoxy propanamide side-product formed would most likely remain in 
solution and therefore be easily separated from the desired product. In the case of the cubane 
analogue the precipitate was found to contain not only the product (3.25) but also a large amount of 
unreacted adenine (3.03). The mother liquor contained both the starting material (3.27) and the 
methoxy propanamide side-product (3.32). Obviously, the purification of such a novel compound 
was not established. Therefore, development of a purification method was required.  
Initially, purification of large amounts of the precipitate were performed using high pressure liquid 
chromatography (HPLC), which required the crude mixture to be transported to our collaborators at 
the CSIRO in Melbourne for HPLC purification. The purified product was thus returned as a 
meagre percentage of the material originally sent down due to the high amounts of adenine within 
the sample. The purified product was also found to retain some traces of trifluoroacetic acid (used 
in the mobile phase), which caused degradation of the product over time. However, thorough 
investigations into chromatographic solvent systems resulted in the discovery of an adequate, highly 
polar, solvent system for flash column chromatography. Using a system of 10% methanol in 
chloroform greatly increased the overall productivity of the reaction and removed the need for 
HPLC purification as well as the aforementioned complications. Furthermore, the reaction could 
now be conveniently monitored in order to identify the formation of the product. 
Upon isolation of a clean and pure sample of 3.25, a spectroscopic analysis of the novel compound 
could be more easily achieved. The 1H-NMR spectrum contained an indicative split cubyl multiplet 
of six protons at 3.95 ppm along with two distinct triplet signals that were easily associated to the 
methylene carbons within the newly formed bridge between the two major moieties. Further 
confirmation was gained via analysis of the 13C-NMR spectrum which clearly showed the presence 
of aromatic carbons as was expected in the purine moiety. Finally, high resolution mass 
spectrometry gave a molecular ion that was consistent with the molecular formula of the product 
3.25. 
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Scheme 3.13 – Diazotisation of the Michael addition product. 
In the following step, diazotisation of the amino function, on the adenine ring, was performed via 
addition of a saturated solution of sodium nitrite to a solution of 3.25 in acetic acid to produce the 
oxo-functionality in the desired product (3.24) in 52% yield (Scheme 3.13). 
Initially, the reaction was problematic as the reaction methods and purification methods on the 
novel cubane system resulted in some loss of product through degradation as well as difficulties in 
purification. This was initially due to difficulties in judging the progress of the reaction. However, 
3.24 could be purified using the same chromatographic solvent system of 10% methanol in 
chloroform utilised in the purification of 3.25. 
Finally, the synthesis of 3.02 was completed via basic hydrolysis of the ester functionality on the 
cubane core. The reaction was performed at room temperature to minimise the reverse Michael 
reaction occurring. Following an overnight hydrolysis the desired product (3.02) was confirmed via 
NMR analysis which showed indicative resonances similar to those seem in the Leteprinim (3.01) 
system although with a typical cubyl multiplet resonance at 3.96 ppm in place of the Leteprinim 
aromatic resonances. The loss of the methyl ester resonance which was present in 3.20 was no 
longer observed in either 1H-NMR or 13C-NMR spectrum leading to a positive identification of the 
desired product via NMR. HRMS analysis gave a molecular ion consistent with that of 3.02. 
 
Scheme 3.14 – Hydrolysis to the cubane analogue of Leteprinim (3.02). 
The acid 3.02 was then converted to the potassium salt, 3.27, by careful addition of an analytically 
accurate aqueous solution of potassium hydroxide. The solvent was removed and the salt, which 
was produced quantitatively, was then used for biological testing. The potassium salt simply 
allowed for better solubility in aqueous systems. This same method is employed in the aromatic 
analogue (3.01→3.23) to facilitate biological delivery. 
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Scheme 3.15 – Formation of the potassium salt of the cubane analogue of Leteprinim (3.27).30 
3.3 Biological Studies 
Biological studies for the cubyl analogue of Leteprinim were performed by Dr. Cathrin Nourse, a 
postdoctoral researcher in Prof. Helen Cooper’s Neuronal Migration Laboratory at the Queensland 
Brain Institute at The University of Queensland, St. Lucia.  
3.3.1 Methods 
Leteprinim, 3.01 was purchased from Toronto Research Chemicals Inc. (Cat.:#L329900). The cubyl 
analogue, 3.02, was synthesized as reported (Section 3.2). Both compounds were dissolved in 
dimethyl sulfoxide. PC12 cells were derived from rat adrenal medulla. 
3.3.1.1 Assay for the stimulation of growth of PC12  
PC12 cells were plated at a density of 0.5 x 105 cells/well on 0.0015% poly-L-ornithine (Sigma, 
USA) coated coverslips in 24-well plates and cultured in growth medium (RPMI; 10% normal 
horse serum, 5% foetal calf serum, penicillin (50 U/ml), streptomycin sulphate (50 mg/ml)). 
Twenty-four hours after plating, growth medium was replaced with differentiation medium 
(DMEM; 1.5% normal horse serum, 1.5% foetal calf serum, penicillin (50 U/ml), streptomycin 
sulphate (50 mg/ml)) containing test compounds and NGF (40ng/ml) (Millipore, USA). Compounds 
were dissolved in RPMI to a stock concentration of 10mM and diluted to a final concentration of 
10µM, 50µM and 100µM in culture medium. After a further 48h, spent medium was replaced with 
fresh differentiation medium containing test compounds and NGF at the above concentrations. At 
24h, 48h and 72h, cells were fixed in 4% paraformaldehyde and washed in phosphate buffered 
solution (PBS) several times and then mounted using Prolong Gold (Invitrogen, USA). Images were 
captured on an AxioImager (Zeiss, Germany) using DIC optics. Neuronal differentiation was 
assessed by the presence of processes on cells compared to control conditions (control conditions: 
cells cultured without compound and NGF, cells cultured with NGF only, cells cultured with 
compound only). 
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3.3.2 Results and Discussion 
It was initially observed that under control conditions (i.e. without compound) PC12 cells were able 
to develop neurite outgrowth to a minor extent when neuronal growth factor (NGF) was present. 
This is observed particularly well in cell cultures incubated for 72 hours. Those cells not treated 
with NGF were observed not to develop neurite outgrowth (Figure 3.3).§ 
 
Figure 3.3 – Neurite outgrowth of PC12 Cells under control conditions. 
In order to gauge comparative efficacy, solutions of the Leteprinim salt (3.23) and the cubyl 
analogue 3.27 were administered to PC12 cells in increasing doses. Cells were observed every 24 
hours in order to judge the extent of neurite outgrowth. It was observed that in both cases no neurite 
outgrowth is present at any timescale or concentration (Figure 3.4 and 0). 
 
Figure 3.4 – Comparison of neurite outgrowth in the absence of NGF. 
Finally, PC12 cells were treated with solutions of 3.23 and 3.27 in varying concentrations in 
combination with NGF. The cells were once again monitored at intervals of 24 hours to determine 
the presence and of extent neurite outgrowth.  
                                                 
§The results shown in Figure 3.3, Figure 3.4, and Figure 3.5 are elaborated further in 0 
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Figure 3.5 – Comparison of neurite outgrowth in the presence of NGF. 
Both compounds, Leteprinim (3.23) and the cubyl analogue (3.27), exhibit neuritogenic activity on 
PC12 cells with cells growing longer neurites compared to the control cultures containing NGF 
only. This neuritogenic activity appears to be dose dependent with higher concentrations inducing 
longer neurite outgrowth. As neither of the compounds are observed to be capable of inducing 
neurite outgrowth in the absence of NGF this suggests a synergistic effect between the compounds 
and NGF. 
It can be stated that the cubanyl analogue is potentially acting as a bioisostere in this circumstance. 
The results illustrate the potential for cubane containing compounds to impart a biological effect 
similar to that of the benzyl analogue. Furthermore, if studies are taken further into live model 
studies it may be anticipated that the results are improved due to potentially increased CNS 
penetration as was discussed in Chapter 2. These studies are extensive and will be performed in due 
course. 
3.4 Experimental 
1-Methyl-4-(t-butoxycarbonylamino)cubylcarboxylate (3.29) 
H
N O
O
O
O  
4-Methoxycarbonylcubane carboxylic acid (2.12) (3.0g, 9.7 mmol) was dissolved in anhydrous t-
butanol (40 ml) and stirred under an argon atmosphere. Triethylamine (1.34 ml, 1 eq.) was added 
and the solution was allowed to stir until clear. Freshly distilled DPPA (2.1 ml, 1 eq.) was then 
added and the solution was heated to reflux for 2 days. On cooling the solvent was removed in 
vacuo. The product was purified via column chromatography with 100% Ethyl acetate to give 1-
methyl-4-(t-butoxy-carbonylamino)cubylcarboxylate (3.29) (1.77 g, 66%) as a white solid. M.p. 
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166-168ºC; FTIR/ATR (ν, cm-1) 3397 (0.22), 2985 (0.20), 1724 (0.78), 1690 (1.00), 1502 (0.75), 
1435 (0.38), 1366 (0.29), 1317 (0.64), 1248 (0.55), 1203 (0.88), 1152 (0.60), 1088 (0.91), 1019 
(0.46), 965 (0.28), 843 (0.30), 779 (0.29); 1H-NMR (300 MHz, CDCl3) δ: 4.07 (m, 6H), 3.68 (s, 
3H), 1.43 (s, 9H).; 13C-NMR (125 MHz, CDCl3) δ: 203.0, 172.6, 66.2, 55.9, 51.4, 50.2, 50.2, 44.5, 
28.2. 
4-(Methoxycarbonyl)cubaneammonium chloride (3.30) 
O
O
NH3Cl
 
Acetyl chloride (15 ml, 0.21mol) was added very slowly to anhydrous methanol (30ml) stirred 
vigorously at -30ºC under an argon atmosphere. After 15min.1-methyl-4-(t-butoxy-
carbonylamino)cubylcarboxylate (3.29) (1.5g, 5.4mmol) was added. The solution was stirred for 1 
hour then allowed to warm to room temperature. The solvent was removed by rotary evaporation to 
give a green/yellow solid which was washed with diethyl ether: acetone (4:1) and filtered to give 
3.30 (0.943 g, 82%) as an off-white solid. M.p. >250ºC; 1H-NMR (300 MHz, D2O) δ: 4.14 (s, 6H), 
3.64 (s, 3H); 13C-NMR (75 MHz, D2O) δ: 174.96, 64.17, 56.13, 52.28, 47.74, 44.93. 
Methyl 4-acrylamidocubanecarboxylate (3.27) 
O
O
H
N
O
 
4-(Methoxycarbonyl)cubaneammonium chloride (3.30, 1.5 g, 7.0 mmol) and acryloyl chloride 
(3.31, 0.70 g, 7.7 mmol) were stirred in anhydrous methylene chloride (40 ml) at -30 °C under an 
argon atmosphere. Triethylamine (3.87 ml, 4 eq.) in anhydrous methylene chloride (11 ml) was 
added dropwise via syringe pump over 30 min. The solution was stirred for a further 20 min. before 
the solvent was removed by rotary evaporation. The product was purified by column 
chromatography (Ethyl acetate) to give methyl 4-acrylamidocubanecarboxylate (3.27, 1.07 g, 66%) 
as a white solid. M.p. 184-186ºC dec.; FTIR/ATR (ν, cm-1) 3246 (0.31), 3006 (0.20) 1725 (0.68), 
1650 (0.52), 1616 (0.57) 1527 (0.86), 1431 (0.34), 1405 (0.34), 1318 (0.95), 1239 (0.52), 1200 
(0.99), 1129 (0.31), 1091 (1.00), 997 (0.72), 906 (0.27), 843 (0.33), 812 (0.37), 686 (0.79), 629 
(0.52); 1H-NMR (300 MHz, CDCl3) δ: 6.30-6.26 (dd, J = 17.0, 1.3 Hz, 1H), 6.08 (m, 2H), 5.66-5.64 
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(dd, J = 10.1, 1.4 Hz, 1H), 4.16 (m, 6H), 3.69 (s, 3H); 13C-NMR (100MHz, CDCl3) δ: 172.65, 
164.74, 130.01, 127.00, 66.60, 55.76, 51.52, 50.23, 45.09; HRESIMS m/z calculated for 
(C13H13NO3 + Na): 254.0793, Found: 254.0795.  
Methyl 4-[3-(6-amino-9H-purin-9-yl)propanamido]cubanecarboxylate (3.25) 
O
O
N
H
ON N
H2N
N
N  
Adenine (3.03, 0.321 g, 2.4 mmol) was suspended in anhydrous methanol (40ml) and sodium 
methoxide in methanol (25% w/w, 0.32ml) was added with stirring. The solution was allowed to 
stir for 30 min. until all adenine had dissolved. Methyl 4-acrylamidocubanecarboxylate (3.27, 0.50 
g, 2.16 mmol) was added and the solution was heated at reflux overnight. The solvent was removed 
and the resultant precipitate was purified by column chromatography (10% methanol: chloroform) 
to give methyl 4-[3-(6-amino-9H-purin-9-yl)propanamido]cubanecarboxylate (3.25, 0.278 g, 35%). 
Starting material (60%) was also recovered and was able to be recycled for further reactions. 
M.p.>250ºC; 1H-NMR (500 MHz, methanol-d4) δ: 8.13 (s, 1H), 7.96 (s, 1H), 7.82 (s, 1H), 4.43 (t, J 
= 6.6 Hz, 2H), 3.98-3.91 (m, 6H), 3.60 (s, 3H), 2.71 (t, J = 6.6 Hz, 2H); 13C-NMR (75 MHz, 
DMSO-d6) δ: 171.68, 169.00, 155.90, 152.33, 149.36, 140.91, 118.68, 65.91, 54.94., 51.16, 49.42, 
44.15, 34.86, 30.68; HRESIMS m/z calculated for (C18H18N6O3 + Na): 389.1338, Found: 389.1346. 
Methyl 4-[3-(6-oxo-5H-purin-9(6H)-yl)propanamido]cubanecarboxylate (3.24) 
O
O
N
H
OHN N
O
N
N  
Methyl 4-[3-(6-amino-9H-purin-9-yl)propanamido]cubanecarboxylate (3.25, 0.168 g, 0.46 mmol) 
was dissolved in glacial acetic acid (1.5ml). The solution was stirred for 15 min. before a solution of 
sodium nitrite (0.970 g, 14.0 mmol) was added and the solution was heated at reflux overnight. The 
solution was monitored and upon completion the solvent was removed via rotary evaporation. The 
crude solid was purified by column chromatography (10% methanol : chloroform) to give 3.24 (87 
mg, 52%) as a white solid. 1H-NMR (300 MHz, DMSO-d6) δ: 12.26 (s, 1H), 8.71 (s, 1H), 8.03 (s, 
1H), 7.95 (s, 1H), 4.34 (t, J = 6.5 Hz, 2H), 3.98 (dd, J = 16.8, 4.3 Hz, 6H), 3.61 (s, 3H), 2.68 (t, J = 
6.5 Hz, 2H); 13C-NMR (100 MHz, methanol-d4) δ: 174.39, 172.99, 171.65, 146.58, 142.39, 65.9, 
55.0, 51.2, 49.4, 44.2, 35.1; HRESIMS m/z calculated for (+ H): 368.1359; Found: 368.1353; 
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Elemental analysis calculated C18H17N5O4: C:58.85%; N:19.06%; H:4.66%; Found:  C:58.53%; 
N:19.18%; H:4.78% 
4-{3-[6-oxo-1H-purin-9(6H)-yl]propanamido}cubanecarboxylic acid (3.02) 
OH
O
N
H
OHN N
O
N
N  
4-[3-(6-amino-9H-purin-9-yl)propanamido]cubanecarboxylic acid (3.24, 6 mg, 0.016mmol) was 
suspended in water (1ml). Sodium hydroxide (1 mg, 0.025mmol) was added and the solution was 
stirred overnight. Concentrated hydrochloric acid was added until pH 1 whereupon a precipitate was 
formed. The solvent was removed under reduced pressure and the solid was washed with water to 
give 4-[3-(6-amino-9H-purin-9-yl)propanamido]cubanecarboxylic acid (26) (5 mg, 90%) as a 
crystalline solid. 1H-NMR (400 MHz, DMSO-d6) δ: 8.06 (s,1H), 7.83 (s, 1H), 4.45 (t, J = 6.5 Hz, 
2H), 3.96 (m, 6H), 2.75 (t, J = 6.5 Hz, 2H); 13C-NMR (101 MHz, DMSO-d6) δ: 175.33, 168.80, 
164.44, 151.42, 149.21, 137.41, 124.15, 65.96, 59.44, 48.57, 44.45, 35.35; HRESIMS m/z 
calculated for (C17H15N5O4 + K): 392.0761; Found:392.0756. 
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Chapter 4 A Cubane Analogue of a Cephalosporin 
4.1 Introduction 
The biological results described in previous chapters (Chapter 2, Chapter 3) demonstrate that 
cubane may well be supplemented for a phenyl moiety in pharmaceutical analogues and retain 
activity, to a similar extent, to that of the original drug. In order to determine whether cubane is an 
applicable analogue in various pharmaceutical compounds another form of biologically active drug 
compound was considered. Cefaclor (4.01, Figure 4.1) is a second generation cephalosporin type 
antibiotic which remains a highly prescribed drug in the current market.1,2 Cefaclor has been 
thoroughly investigated since its patenting and as such, provides an excellent target for comparison 
of activity. 
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Figure 4.1 – Cefaclor (4.01), an antibacterial target for the cubane analogue (4.02). 
4.1.1 A Brief Pharmaceutical History of Cefaclor 
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Figure 4.2 – Cephalosporin C and Penicillin G. 
The cephalosporins are a bastion in anti-bacterial compounds. Their initial development as a 
treatment for penicillin resistant infection has resulted in a vast library of analogues that provide a 
strong treatment against a number of bacterial infections. The first cephalosporins (Cephalosporin 
C (4.03) and Cephalosporin N) were isolated in 1955 from a fungus – Cephalosporium acremonium 
– originally found growing in a sewerage outlet.3-5 Following its isolation and its characterisation in 
1960, it was reported that Cephalosporin C (4.03) bore a strong structural and pharmacological 
 66 | Chapter 4 
resemblance to the premier antibacterial family of the time, the Penicillins such as Penicillin G 
(4.04, Figure 4.2).6-8 
Due to the potential and interest in cephalosporins, an extensive library of analogues has been 
generated since the mid-1970s. In the process, a number of different routes have been used to 
synthesise the various analogues. Cefalexin (4.05), a first generation analogue, was first introduced 
to the domestic market in 1967 by Lilly Research Laboratories.9 
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Figure 4.3 – Cephalexin. 
As a modification of the original cephalosporin compounds, Cephalexin showed complete oral 
absorption, marginally reduced bacterial inhibition at comparable effective dose figures.9 Prior to 
this synthesis, the majority of cephalosporin antibiotics were administered intraperitoneally. The 
incorporation of a phenylglycine side chain at position 7 allowed for oral absorptivity, so long as no 
bulky side chain was present at the 3 position.1 As such, Cephalexin quickly became a benchmark 
antibacterial and remains one of the foremost prescribed medicines in the current market.2 
Cefaclor, a second-generation cephalosporin was developed in much the same manner.10,11 In this 
case the drug is analogous to Cephalexin with substitution of a chlorine atom for the methyl group 
at the 3-position. Cefaclor showed improved pharmacology in terms of an increased spectrum of 
inhibition of bacteria, both gram-positive and some gram-negative bacteria. In addition to this, 
further research into its biological activity showed that Cefaclor was systemic. It was found 
throughout the majority of the tissues and fluids in the body, and was rapidly excreted unchanged in 
the urine, making Cefaclor an excellent general purpose antibiotic.1 As such the cephalosporins, 
Cefaclor in particular, is an excellent choice for a cubyl analogue within the class of antibacterial 
drugs. 
4.1.2 The Synthesis of Cefaclor 
A synthetic procedure was not published in Chauvette’s initial pharmacological activity report, 
however, the method of cephalosporin synthesis, developed by Dane in 1964, would most likely 
have provided the most straightforward method at the time (Scheme 4.2).12 
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This method employs an amine protecting group in the form of ethyl acetoacetate being reacted 
with (R)-2-phenylglycine (4.06), which first formed an imine before tautomeric rearrangement gave 
the corresponding Dane salt (4.07). Pivaloyl chloride was then added at low temperatures to form 
the highly reactive mixed anhydride (4.08), which was not isolated. 
 
Scheme 4.1 – Synthesis of the Dane Salt and Dane Anhydride. 
The mixed anhydride (4.08) was then reacted immediately with the cephalosporin core (4.09R) to 
give 4.10 in which the amine remained protected.** Following this coupling the ethyl acetoacetate 
group on the side chain was then deprotected via an acidic workup (pH 1-2) and pH adjustment to 
approximately pH 4.5 precipitated the desired cephalosporin product (4.11) at low temperatures. 
This method was employed later by Chauvette to develop what has become the current industrial 
synthesis of Cefaclor.10,13,14  
 
Scheme 4.2 – Cephalexin synthesis via Dane Anhydride. 
Another method, published by Woodward in 1979, involved the acid chloride ammonium chloride 
salt of (R)-2-phenylglycine (4.06) undergoing nucleophilic attack by the cephalosporin core (4.13, 
Scheme 4.3).15 The addition of N,O-bis(trimethylsilyl)acetamide (BSA) increases the solubility of 
the cephalosporin core (4.12) and allowed the reaction to be performed in anhydrous methylene 
                                                 
** N.B.: The cephalosporin core was first solubilised by the addition of either a non-nucleophilic organic base (e.g. 
triethylamine) or a silylating reagent such as N,O-bis(trimethylsilyl)acetamide (BSA). 
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chloride (Scheme 4.3).  
 
Scheme 4.3 – Woodward’s cephalosporin synthesis. 
A number of recently published synthetic methods make use of a biologically assisted synthetic 
method. By making use of penicillin G acylase (PGA) from Escherichia coli as an enzymatic 
coupling agent the desired cephalosporin can be prepared in good yield (57%, Scheme 4.4).16-19 In 
this method the key issue lies in preventing hydrolysis of Cefaclor upon production. In one 
particular synthetic method the yield was increased to 80% with in situ product removal methods.20 
Similar publications report the use of an immobilized enzyme to assist in purification.16 These 
methods are technically the highest yielding to date, however industrial methods maintain a 
synthetic coupling approach.10,13,14 An industrial approach utilising PGA would first require 
increased productivity and a less labour-intensive fermentation process for an adequate scale of 
production of the enzyme.21 
 
Scheme 4.4 – Enzymatic production of Cefaclor. 
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Another method, utilising p-nitrophenol (4.17) in a more straightforward approach has also been 
reported (Scheme 4.5).22 In this method the formation of an activated intermediate, a para-nitro 
phenyl ester, provided a leaving group for nucleophilic attack by the cephalosporin core. In this 
method triethylamine was used to increase the solubility of the cephalosporin core, 7-Amino-3-
Chloro Cephalosporanic Acid (7-ACCA, 4.16) as well as to facilitate the reaction. 
 
Scheme 4.5 – Tao’s patented synthesis of Cefaclor. 
It is clear that these procedures all require a single enantiomer of 2-phenylglycine to be used to 
synthesise the correct final isomer. In an attempt to lower the costs associated with industrial 
production of cephalosporins, Kemperman et al. were able to develop a method that allowed for the 
use of racemic 2-phenylglycine (4.19) as a starting material.23 The coupling of the side chain to the 
cephalosporin core was performed in a modified method similar to that employed initially by Dane 
(Scheme 4.1 and Scheme 4.2).  
  
Scheme 4.6 – Kemperman’s stereoselective synthesis (Part A). 
 70 | Chapter 4 
 
Scheme 4.7 – Kemperman’s stereoselective synthesis (Part B). 
Pyridoxal hydrochloride (Vitamin B6, 4.21) was added to the coupled adduct to induce 
racemisation (Scheme 4.6). Simultaneous addition of a complexing agent [2,7-
dihydroxynaphthalene (CA1) or α-naphthol (CA2)] resulted in the formation of a selective clathrate 
with the desired stereoisomer, which may then be separated from the racemic product mixture to 
ultimately give a yield of 73% of 4.01 (Scheme 4.7).23,24 
4.1.3 A Cubane Analogue of Cefaclor 
The cephalosporin analogue target 4.02 was chosen to include an antibacterial compound in our 
analysis of cubane in drug analogues. It also provided a synthetic challenge to develop a preparation 
of cubyl amino acid, and to further determine the structure activity relationship differences between 
the phenyl moiety and the cubane structure. In the case of these particular cephalosporin 
compounds the activity of the drug is imparted by the cephalosporin core, the phenylglycine side-
chain is in place to improve the oral absorption of the drug.25 In keeping with the observed 
outcomes of the cubyl analogue of Vorinostat (Chapter 2), in which an increased LogP value in the 
cubane system was observed, it was speculated that this may translate to an increased penetration of 
the CNS and the gastric tract. Further investigation into these properties may be undertaken in the 
future following preliminary investigations into the antibacterial efficacy of 4.02R. 
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Scheme 4.8 – Proposed method of a cubane analogue of Cefaclor. 
Upon review of the literature, the most attractive method from which to proceed was via that of 
Dane, as modified by Chauvette (Scheme 4.8).12,14 The method was selected as it would provide a 
completely synthetic approach as well as following the well-established standard industry method. 
An added interest in this synthesis is the required development of an enantioselective synthesis of 
the cubane amino acid (2-amino-2-(cubanyl)acetic acid, 4.29). Recently, there has been some 
unpublished research into the synthesis of such an analogue with encouraging results.26 However, 
stereoselectivity in such a synthesis has not been achieved and as such provides a secondary, yet 
nonetheless important challenge within the overall context of this synthesis. 
 
Figure 4.4 – (R)-2-Phenylglycine (4.06) and the cubane analogue (4.29α). 
An analogue of the amino acid (R)-2-phenylglycine (4.06), (R)-2-amino-2-(cubanyl)acetic acid, 
(4.29α) would open further avenues of pharmaceutical and biochemical research as it would provide 
a novel unnatural amino acid from which many peptide based drugs may be developed. 
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4.2 Results and Discussion 
In order to synthesise an accurate cubanyl analogue to any cephalosporin, a key requirement would 
be to develop a stereoselective route to a cubane analogue of (R)-2-phenylglycine (4.06). In the 
proposed method (Scheme 4.8), the use of the Strecker amino acid synthesis is an integral step. This 
requires the formation of several electron-rich reactive intermediates (Scheme 4.9).27 The formation 
of an aldehyde attached directly to the cube may result in decomposition similar to that previously 
discussed (Scheme 2.13) and as such, we were cautious towards such an approach.28,29 However, 
the formation of stable imine salts have been reported to be possible via the cubane 
carboxaldehyde.30 
 
Scheme 4.9 – Strecker amino acid synthesis mechanism. 
The synthesis of a substituted cubane amino acid analogue has been reported. Pellicciari was able to 
utilise the methods of Chakraborty et al. to produce a stereoselective synthesis of (S)-2-(4’-
carboxycubyl)glycine (4.44), an mGluR1 antagonist, and potential treatment for neuronal damage 
and neurological disease (Scheme 4.10).31-33  
From this method Pellicciari reported the final amino acid (4.44) to have a 14% overall yield with 
47% enantiomeric excess. It is important to note that the two diastereomeric nitrile compounds 
(4.40 and 4.41) are separable by column chromatography, which constitutes an efficient process to 
resolve the chiral amino acid. 
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Scheme 4.10 – Pellicciari’s synthesis of a novel cubanemGluR1 receptor. 
The method employed a chiral auxiliary, (R)-2-amino-2-phenylethanol (4.45), to direct the 
formation of the major (S,R)-Strecker-type intermediate (4.40). Mechanistically, the imine 
formation between the aldehyde and 4.45 causes steric hindrance that prevents attack from the 
upper face and hence formation of the (S, R)-isomer is favoured. The end result, following an 
oxidative cleavage and hydrolysis, is the formation of the (S)-amino acid (e.g. 4.44).  
NH2
OH
NH2
OHSR
4.45 4.46  
Figure 4.5 – The two enantiomers of the chiral auxiliary 2-amino-2-phenylethanol. 
This can be rationalised as an antiperiplanar nucleophilic attack, wherein the phenyl group may be 
viewed perpendicular to the imine bond (Figure 4.6). Conversely, using the (S)-2-amino-2-
phenylethanolchiral auxiliary (4.46) the (R, S)-isomer (4.41) can be formed predominantly.32 
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Figure 4.6 – Diastereomeric control imparted by R-2-amino-2-phenylethanol (4.45). 
Cubane carboxaldehyde (4.27) was prepared from 1,4-cubanedicarboxylate (1.13) as outlined in 
Scheme 4.8. The reaction proceeded via hydrolysis and Barton decarboxylation methods as 
described in Chapter 2 to give 2.16. Following this, the cubane carboxylic acid (2.16) was reduced 
to the cubylcarbinol derivative (4.26) via the method of Priefer et al (Scheme 4.11).34 This method 
was selected as it makes use of borane dimethyl sulphide complex (BH3·SMe2) as the reducing 
agent, providing a safer and simpler alternative to LiAlH4 or AlH3.35,36 
 
Scheme 4.11 – Borane reduction of 2.16 to give the alcohol 4.26. 
Initially, oxidation of 4.26 to the cubane carboxaldehyde (4.27) was performed under standard 
Swern oxidation conditions. The Swern oxidation requires the initial formation of the 
dimethylchlorosulphonium ion (4.49) of dimethyl sulfoxide to which is then added the alcohol 
(4.26). This then forms the alkoxysulfonium ion which, upon addition of organic base results in the 
deprotonation of the alcohol via an intermediate sulphur ylide (4.26a). It is important to note that 
the final basification step must be performed at or below -78 °C to avoid unwanted side-products.37 
 
Scheme 4.12 – Swern oxidation of cubylcarbinol. 
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The resulting product, cubane carboxaldehyde (4.27), may then be worked up under aqueous 
conditions with dilute hydrochloric acid and extracted into methylene chloride. Published syntheses 
of 4.27 report high yields (~70%) on a variety of scales, however, in our hands the yields were 
greatly diminished (~20%). This may have been due to decomposition during purification of this 
unstable compound, or perhaps the volatility of the product led to the loss of product upon drying in 
vacuo. Further investigation of the possible decomposition phenomena is explored to a greater 
extent in Section 5.2. 
 
Scheme 4.13 – Difficulties were experienced in the Strecker reaction. 
The aldehyde, although produced in low yield, was used in the subsequent standard and modified 
Strecker reactions. In this case however, the reaction failed to yield any Strecker product. We 
speculated that under Swern conditions or during imine formation the carbon migration to give 
homocubane was able to occur.28 A number of methods were employed to facilitate the reaction, for 
example adding molecular sieves to drive the reaction by removing the water being formed 
(Scheme 4.9); Lewis acid catalysts such as Yb(OTf)3 were also employed in an effort to enhance the 
formation of the imine.38 The formation of the aldehyde via addition of MnO2 and subsequent 
addition of (R)-2-amino-2-phenylethanol (4.45) to form the imine was also attempted without 
success.39 
 
Scheme 4.14 – Rearrangement of 4.50 on silica. 
As stated earlier, the difficulty in completing the synthesis was believed to have been caused due to 
the volatility of 4.27 and purification of the aldehyde invariably lead to further decomposition. This 
may be explained with an analogous reaction shown by Eaton and Yip in the rearrangement of 1-
homocubylbromide (4.49) on silica gel.40 
Repeat attempts to perform this reaction under various conditions gave similar results and the 
Strecker product (4.28) was not formed. It was therefore decided that an alternative method be 
found to synthesise the mono-substituted amino acid. It is known that in the case of the para-
substituted cubane core the aldehyde forms quite readily.31,41 Therefore, following the synthesis of 
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the methyl 4-(hydroxymethyl)cubane-1-carboxylate a Swern oxidation was performed. Following 
chromatographic purification, the product was stable if stored below -4 ºC.30,42 The stability of this 
compound may be due to an electron stabilising effect through the cubane framework (as postulated 
in Chapter 3). 
In order to continue with this reaction scheme to yield the desired monosubstituted cubyl amino 
acid, decarboxylation of the cubane core would be required at a later stage. However, generation of 
the carboxylic acid on the cubane core would require hydrolysis of the methyl ester. This would 
most likely cause the hydrolysis of the nitrile group from the Strecker reaction resulting in a second 
carboxylic acid group (4.52). Barton decarboxylation of this compound may have produced a 
variety of products as well as the loss of stereocontrol within the compound (Scheme 4.15). 
Therefore, an alternative method, in which a stable aldehyde is generated, was desirable.  
 
Scheme 4.15 – Potential products resulting from decarboxylation of 4.52. 
It has been reported that an iodinated cubane carboxaldehyde (4.59) is stable under laboratory 
conditions. The synthesis of 4.59 has previously been reported in the literature and furthermore, 
4.59 has been shown to form a stable imine.43 We reasoned that following the formation of the 
Strecker product the halogen group may be reductively removed.43-45 The synthesis of 4.59 was 
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planned according to Scheme 4.16. 
 
Scheme 4.16 – Synthesis of 4-iodocubane-1-carbaldehyde (4.59). 
The initial step was based on the work of Moriarty et al., who demonstrated that the hypervalent 
iodine reagent (IBDA, 4.61) initiated an oxidative decarboxylative iodination in which a 
hypervalent system underwent carboxylate ligand exchange (Scheme 4.17).46,47 The reaction was 
performed under thermal or photochemical conditions to give the iodinated product (4.63) in high 
yield (~80%). 
 
Scheme 4.17 – Moriarty’s iodination of cubane. 
The synthesis through to the aldehyde proceeded in a similar manner to that previously reported and 
the aldehyde did prove stable under standard laboratory conditions. The reaction was performed 
under conditions identical to those reported by Pellicciari and produced the two diastereomers 
which could be separated by column chromatography (Scheme 4.18).31 
 
Scheme 4.18 – Synthesis of the iodinated Strecker product. 
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It must be noted that originally the synthesis used (R)-2-amino-2-phenylethanol (4.45) as a chiral 
auxiliary. However, in order to preferentially generate the desired (R)-2-cubylglycine (4.29α), (S)-
2-amino-2-phenylethanol (4.46) is required. The reason for this particular choice of chiral auxiliary 
was due to the fact that (R)-2-amino-2-phenylethanol (4.45) is more readily available and less 
expensive for trial syntheses. 
Nevertheless, the resultant Strecker products, when purified were observed as amorphous solids 
which were observed to decompose under standard laboratory conditions. The two isomers could be 
stored for a limited period of time below -4 ºC. These isomers were taken onward in the synthesis 
of the amino acid using the method of Pellicciari (Scheme 4.18).  
This point in the synthesis was determined to be most appropriate for dehalogenation (Scheme 
4.19). This was due to the known propensity for unwanted side reactions occurring in latter stages 
of the synthesis. For example, the subsequent imine or carboxylic acid group may be susceptible to 
any reagents used for dehalogenation. 
 
Scheme 4.19 – Dehalogenation of iodinated Strecker intermediate. 
Attempts at dehalogenation of the iodinated Strecker product were initially via hydrogenation. Our 
group had recently purchased a flow hydrogenation device, the ThalesNano H-Cube®, which 
provided a potentially rapid and straightforward method for dehalogenation of the cubane core. This 
method had recently been reported to work on aromatic systems.48 Our hope was to find conditions 
for reductive removal of iodine in preference to the know propensity for cubane to ring-open when 
exposed to hydrogenation conditions. 
 
Scheme 4.20 – H-Cube dehalogenation of 4.64. 
Although initially, it was difficult to determine whether any reaction was taking place, it was 
discovered that minimal transformation was indeed taking place as NMR of the crude reaction 
mixture indicated formation of a scant amount of the dehalogenated product (4.66). The formation 
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of the product was difficult to monitor as its retention factor was nearly identical to that of the 
starting material via thin layer chromatography, which also hindered purification. 
The method also produced a large amount of decomposition of the starting material over a variety 
of different temperatures, pressures, flow rates and catalyst cartridges (Table 4.1). It has been 
reported that hydrogenation of cubane can result in the loss of the cubane framework (Scheme 
1.11).49,50 
Table 4.1 – Catalytic dehalogenation conditions tested in H-Cube. 
Catalyst Solvent Temp. (ºC) Pres. (bar) Rate Cycles Yield Dec. 
Pd/C MeOH 20 0 1 (ml/min) 10 0 Yes 
Pd/C MeOH 25 0 1 (ml/min) 4 0 Yes 
Pd/C MeOH 50 0 1 (ml/min) 10 0 Yes 
Pd/C MeOH 25 20 1 (ml/min) 1 0 Yes 
PtO MeOH 25 0 1 (ml/min) 1 0 Yes 
Ra/Ni MeOH 25 0 1 (ml/min) 1 0 Yes 
This method was thus deemed inappropriate to provide sufficient material for use in later stages of 
the synthesis and subsequently for biological testing. As an alternative, tributyltin hydride mediated 
dehalogenation was explored.37 It was anticipated that the radical initiated process would generate a 
stable radical (4.68) on the cubane core, for which there is literature precedence (Scheme 4.21).40,51-
53 
 
Scheme 4.21 – Generation of the cubyl radical.51 
Della et al. found that hexamethylditin had not performed well in previous dehalogenation 
reactions.51 In these experiments it was reported that triethylsilane (Et3SiH) did perform the 
dehalogenation with the identification of various products, including the hydrogenated cubane and 
dimerisation as well as an intractable tar, which was assumed to be the product of cubane 
decomposition. It was also reported that trimethyltin was able to generate a radical on the cubane 
core but methods of product purification and yield were not described.53 
 80 | Chapter 4 
 
Scheme 4.22 – Proposed method for dehalogenation. 
We attempted to dehalogenate the cube using tin hydride (Scheme 4.22), with 1,1'-Azobis 
(Cyclohexane-1-Carbonitrile) (VAZO88, 4.69) as a radical initiator, under photochemical 
conditions. Tributyltin hydride (Bu3SnH) was included in the reaction medium to act as a hydride 
source. After 3 hours the solution was worked up using 10% K2CO3/Silica to remove the tin by-
products.54 Only meagre amounts (<2%) of dehalogenation product were observed in the 1H-NMR 
spectrum. 2,2′-Azobis(2-methylpropionitrile) (AIBN, 4.70) was then used to initiate radical 
formation. Once again no reaction was observed after 3 hours and following similar workup the 
yields were once again minimal (<2-3%) by 1H-NMR. Finally, triethylborane (Et3B, 4.71) was used 
as the radical initiator, similar workup conditions were employed and a small improvement in yield 
was observed (approx. 10%). These reactions were performed in both toluene and tetrahydrofuran 
but no significant improvement was observed to be gained by changing the solvent.  
 
Figure 4.7 – Selected radical initiators. 
Under all conditions yields were not significant enough to warrant continuation with this method of 
dehalogenation. Decomposition of either the starting material or product may also have been caused 
by the K2CO3/Silica workup conditions, however, removal of tin contaminants from the product 
remained incomplete even under these conditions, which may have influenced future biological 
testing results. 
Tris(trimethylsilyl)silane,55 aluminium chloride56 and even indium(III)chloride57 were considered as 
possible alternatives for dehalogenation, however, these dehalogenation methods were quite 
expensive and it was deemed prudent to exhaust alternative methods first. 
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Scheme 4.23 – Butyl lithium mediated dehalogenation. 
In an attempt to accomplish the dehalogenation a previously discarded theoretical option was 
reinvestigated. Originally, butyl lithium was disregarded as an option as it may react with the nitrile 
group present in 4.64. However, under anhydrous conditions, a molar equivalent of butyl lithium 
has been shown to selectively dehalogenate cubane in the presence of a carboxylic acid group.34 
Therefore, both n-butyl lithium and t-butyl lithium were used in a small scale test synthesis to 
determine their efficacy. Under anhydrous conditions low yields (16%) of the desired 
dehalogenated product were formed (Scheme 4.23). However, the yields were still too low to justify 
continuation with this line of synthesis. 
Although removal of iodine proved difficult we decided to proceed towards an iodinated cubyl 
analogue of Cefaclor. The continuation of this synthetic route would provide experience in later 
synthetic steps should a synthesis of the desired monosubstituted Strecker product be developed. 
 
Scheme 4.24 – Lead acetate mediated oxidative cleavage. 
The ensuing step in the synthetic route was reported as a lead tetraacetate mediated oxidative 
cleavage.31 This was according to the work of Chakraborty who incorporated the work of his own 
prior studies on the oxidation of amino alcohols.58 The reaction was performed at 0 ºC in a 50:50 
solution of methanol and methylene chloride. The reaction is quite rapid, coming to completion 
within 5 min. Best results were observed when the Strecker product, in a 50:50 solution of 
methylene chloride and methanol, was added to a stirred solution of lead tetraacetate in the same 
solvent mixture. When the reaction was deemed complete by thin layer chromatography, a solution 
of sodium bicarbonate was added and a precipitate formed. The product was easily isolated by 
extraction of the solution with methylene chloride which gave the pure Schiff base imine (4.72) in 
excellent yield (>80%). 
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Scheme 4.25 – Hydrolysis of the imine to the S-amino acid salt. 
This imine can be analysed by NMR spectroscopy which interestingly shows only a single 
enantiomer. However, this is unimportant as the subsequent acid hydrolysis to the amino acid 
cleaves the imine bond, both hydrolysing the nitrile to the carboxylic acid and forming 
benzaldehyde as a by-product.†† 
The resulting salt was analysed by LRESIMS to determine that complete conversion to the desired 
amino acid hydrochloride salt (4.73) was achieved; as the insolubility of the product in D2O caused 
significant difficulties with NMR analysis. 
In order to complete the synthesis of 4.74 as a free base the hydrochloride salt needed to be 
neutralised via ion exchange chromatography. Unfortunately, the solubility of the salt in water was 
incredibly low and hence it could not be passed through the ion exchange resin. Therefore, our 
success culminated in the formation of the ammonium chloride salt (4.73). 
 
Scheme 4.26 – Synthesis of the S-4-iodocubyl amino acid. 
We reasoned that it may be possible to proceed to the Dane salt using two molar equivalents of 
potassium hydroxide to facilitate the reaction. However, we were concerned that this would affect 
later reactions due to the presence of hygroscopic salt by-products which may affect reactions due 
to the presence of water. As such, we were reluctant to immediately proceed with this approach and 
sought to pursue other avenues of investigation.  
After having some success in a concurrent synthesis forming the Wittig product from a cubane 
carboxaldehyde (Chapter 5), an alternative attempt at forming the monosubstituted amino acid was 
undertaken. We discovered that a Ley oxidation technique may be employed in the formation of the 
                                                 
†† It is important to note that, whilst a fairly robust reaction, a gentle reflux with concentrated hydrochloric acid is 
required to prevent decomposition. Conversely, if dilute hydrochloric acid is used and not heated sufficiently the nitrile 
is not hydrolysed to the carboxylic acid. 
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cubane carboxaldehyde. 
 
Scheme 4.27 – Proposed method to yield the Dane salt. 
The cubylmethyl alcohol was subjected to a Ley oxidation and the tetrapropylammonium 
perruthenate (TPAP) subsequently removed using Celite and a minimal amount of silica. Without 
isolating the aldehyde product (4.27) it was reacted immediately with a phosphorous ylide in the 
subsequent Wittig reaction to give the desired adduct (5.50b) in good yield (Section 5.2). 
 
Scheme 4.28 – Formation of the aldehyde as reactive intermediate (Chapter 5). 
Therefore, it was envisioned that a similar method may be employed in the formation of the cubyl 
glycine amino acid. In this way the volatile and potentially unstable aldehyde can be formed and 
reacted immediately without excessive handling, to prevent the loss of the product. 
A solution of cubylmethyl alcohol (4.26) was prepared in anhydrous methylene chloride. The Ley 
oxidation was then performed under standard conditions to give the aldehyde in a solution of 
methylene chloride.59 To ensure that the subsequent Strecker synthesis would proceed as desired, 
the removal of the water produced in the imine formation was believed to be important. As such, 
powdered molecular sieves were added to the solution of the aldehyde and the synthesis proceeded 
as per the method of Pellicciari.  
During the course of the reaction analysis by thin layer chromatography showed evidence of new 
products forming. Following purification via column chromatography the new TLC spots were 
identified to be the desired diastereomers (S, R – 4.75β and R, R – 4.75α). The major diastereomer 
was formed in adequate yield (40%) for progression in the proposed synthetic pathway (Scheme 
4.8). The products readily decomposed at ambient temperatures but could be stored below -4 ºC. 
The synthesis of these compounds in their pure form allowed for verification of earlier 
dehalogenation reactions as the 1H-NMR spectrum were identical to those found in traces against 
the iodinated precursors. In this case the major diastereomer was carried through for further 
reaction. The pure minor diastereomer was recovered in low yields along with a small amount of 
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the diastereomeric mixture. The mixture could be separated consecutively, however, yields were 
lowered each time (presumably due to decomposition) and separation was not absolute. 
 
Scheme 4.29 – Synthesis of the monosubstituted Strecker products.‡‡ 
It was observed from the 1H and 13C-NMR spectrum of these products that the two diastereomers 
were indeed easily differentiated from each other. However, due to the difficult separation of the 
two compounds through column chromatography a small amount of the major diastereomer 4.75β 
may be observed in the spectrum of 4.75α. The 1H-NMR spectrum of 4.75β indicates a 5H 
multiplet typical of aromatic protons along with a 7H multiplet at 3.96 ppm which is indicative of 
the protons of the cubane core. A sharp singlet at 3.48 ppm was attributed to the proton of the 
methine carbon bound to cubane core and a multiplet at 4.09 ppm was assigned to the remaining 
methine proton. The two remaining multiplets at 3.79 and 3.58 ppm were assigned to the remaining 
two methylene protons. It must also be noted that the 1H-NMR spectrum contains residual solvent 
resonances which were difficult to remove given the tenuous stability of the product.  
In the case of the 13C-NMR spectrum signature cubyl carbon resonances were observed between 51 
ppm and 44 ppm. Similarly, resonances observed between 139 ppm and 127 ppm were indicative of 
the aromatic carbons present in the structure. Most notable is the resonance present at 118 ppm 
which was assigned to the newly formed nitrile carbon. In the case of the alternate diastereomer 
4.75α the resonances in the 13C-NMR are observed to have shifted marginally and are easily 
observed due to the presence of a minimal amount of 4.75β in the spectra of 4.75α. 
The formation of the Strecker products (4.75α and 4.75β) at this stage was very encouraging. 
Maintaining the aldehyde (4.27) in solution was deemed to be crucial to the procedure under 
standard laboratory conditions. The reduced yield from the alcohol (4.26) through to the Strecker 
product (4.75) is indicative of both the instability of the aldehyde as well as the difficulty in 
accurately determining the progress of the Ley oxidation.  
The method was then revised to incorporate the required chiral auxiliary (S)-α-phenylglycinol 
                                                 
‡‡α – The nitrile carbon is in the (R)–configuration. β – The nitrile carbon is in the (S)–configuration. 
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(4.46) in order to direct the diastereomer formation to give the (R)-configuration at the desired 
amino-nitrile carbon. The synthesis yielded the desired (R)-2-{[(S)-2-hydroxy-1-
phenylethyl]amino}-2-cubylacetonitrile (4.76α, Scheme 4.30) as the major diastereomer as well as 
the minor diastereomer 4.76β. The 1H and 13C-NMR spectrum of these two compounds were again 
quite similar to that of 4.75β with resonances being observed within expected regions of the NMR 
spectra. 
 
Scheme 4.30 – Synthesis of the desired Strecker diastereomer.§§ 
Following the previously explored reaction pathway in the iodine analogue the imine was formed in 
an identical, lead tetraacetate-mediated, oxidative cleavage. The resultant imine (4.77α) was once 
again isolated with excellent purity and yield (80%) following methylene chloride extraction of the 
precipitated lead oxide suspension (Scheme 4.31). The Schiff base imine intermediate (4.77α) was 
once again unstable but was not volatile and could be analysed spectroscopically, although it 
required low temperature storage if not reacted immediately via acid hydrolysis.  
The 1H and 13C-NMR spectra of the imine showing noticeable change when compared to the 
spectra of the precursor compound (4.76α). In the 1H-NMR spectrum the cubyl proton resonances 
have now diverged into two multiplets, the aromatic resonances are also observed to be two distinct 
2H and 3H multiplets separate from the single 5H multiplet observed in 4.76α. Finally, the methine 
proton of the imine is observed as a singlet at 8.48 ppm and the proton of the nitrile carbon is 
observed as a doublet at 4.85 ppm. In the 13C-NMR spectrum it is observed that the carbon of the 
nitrile remains at 116 ppm, however a new peak corresponding to the carbon of the imine is 
observed at 163 ppm. 
 
Scheme 4.31 – The monosubstituted Schiff-base imine. 
                                                 
§§α – The nitrile carbon is in the (R)–configuration. β – The nitrile carbon is in the (S)–configuration. 
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Upon reflux in hydrochloric acid, the nitrile was hydrolysed to the carboxylic acid and the 
benzylideneamine protecting group was removed.  
The resultant product, (R)-carboxy(cubanyl)methanaminium chloride (4.78) was indeed soluble in 
water and spectroscopic analysis indicated that a small number of organic side-products were also 
present. Most likely, these side-products are the result of decomposition during hydrolysis, 
however, they may also be the result of decomposition over time. These impurities were removed in 
the process of ion exchange chromatography and the result was the first synthesis of the 
enantioenriched R-2-cubylglycine. 
 
Scheme 4.32 – The hydrolysis of the Schiff base imine (4.77α). 
Pellicciari reported the enantiomeric excess (e.e.) of the para-substituted compound to be 47%.31 
 
Scheme 4.33 – Protection of the cubyl amino acid. 
To determine the e.e. we synthesised the Boc-protected amino acid ester (4.80α); forming both a 
methyl ester on the carboxylic group as well as protecting the free amine as a t-butyl carbamate. 
This allowed us to analyse the e.e. via chiral HPLC. It was necessary to fully protect the amino acid 
to lower the polarity of the compound as a reverse phase chiral column was unavailable for 
analysis.  
In order to effect the t-butyl carbamate protection a standard method was employed, whereby two 
equivalents of di-t-butyl dicarbonate (Boc2O) were added to a stirred solution of the amino acid 
(4.29α) in a mixture of tetrahydrofuran and water (2:1), NaOH was then added to facilitate the 
reaction.37 The reaction was stirred for 2 hours before the pH of the solution was adjusted (pH 2) to 
allow for sufficient extraction with ethyl acetate without effecting the removal of the protecting 
group. Following a complete workup the amine protected compound (4.79α) was dissolved in 
diethyl ether and cooled to 0 ºC, then diazomethane was used to give the methyl ester (4.80α) in 
good overall yield (85%).  
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The product was once again characterised by NMR and HRMS techniques, in addition to this the 
compound was found to give an optical rotation of -79.67º at 25 ºC. Chiral HPLC analysis of the 
product showed a single pure peak under a variety of solvent conditions leading us to believe the 
product to be enantiomerically pure. 
 
Figure 4.8 – The protected cubyl glycine stereoisomers. 
Following the synthesis of 4.29α the Dane salt (4.30α) synthesis was to be performed in order to 
proceed to the final product (Scheme 4.8). The synthesis of the Dane salt, as outlined earlier, 
protects the amine group. It was discerned from the literature that methanol is used as the solvent to 
couple ethyl acetoacetate (4.81) forming the Dane salt.  
The use of methanol as the solvent under basic, refluxing conditions may result in the 
transesterification of the protecting group leading to a mixture of the methyl and ethyl esters of the 
Dane salt (4.82 and 4.07 respectively). This would result in difficulties in calculating the correct 
weight of the material leading to discrepancies in molar calculations for subsequent reactions. 
 
Scheme 4.34 – Transesterification of the Dane Salt. 
Therefore, the synthesis of the cubyl amino acid Dane salt (4.30α) was performed in ethanol to 
prevent transesterification. The reaction proceeded well and, following recrystallisation in ethanol, a 
near quantitative yield of 4.30α was obtained (Scheme 4.35). The salt was dried under high vacuum 
at 40 ºC to ensure that no water was present. The compound was slightly brown in colour but was 
characterised well by NMR and HRMS analysis. 
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Scheme 4.35 – The Dane salt of R-2-cubyl glycine (4.30α).12,37 
The method of Kemperman was chosen as the most appropriate route for the next step due to the 
detailed procedure provided in the reported experimental data.23 As such 4.30α was dissolved in a 
solution of methylene chloride with a small amount of N,N-dimethylformamide to facilitate full 
dissolution of the salt for the mixed anhydride formation. Once dissolved, the solution was cooled 
to -25 ºC and pivaloyl chloride (4.86) was added. The solution was maintained at a lower 
temperature for 30 min. to ensure complete formation of the mixed anhydride (Scheme 4.36).  
 
Scheme 4.36 – Dane anhydride intermediate. 
During the formation of the anhydride the cephalosporin core, 7-amino-3-chloro cephalosporanic 
acid (7-ACCA, 4.89) was dissolved in methylene chloride and a slight excess of 
tetramethylguanidine (TMG, 4.88) was added. The solution was stirred at room temperature for 20 
min., before being cooled to -10 ºC. 
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Scheme 4.37 – 7-ACCA-TMG salt (4.90) formation. 
Once dissolved, the solution was slowly added to the Dane anhydride (4.87α) at -50 ºC. The 
solution was then stirred as the temperature rises slowly to -30 ºC. The reaction was then simply 
worked up after 5 hours.  
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Scheme 4.38 – Coupling of the two intermediates to form the amide bond. 
The workup required removal of the enamine protecting group as well as dissociation of the TMG 
salt. This was performed by addition of water and subsequent acidification of the solution to pH 
1effecting the removal of the enamine as well as the TMG salt, in addition to this the product was 
water soluble at this pH. Extraction of the solution with methylene chloride was used to remove any 
organic by-products. At this point Kemperman added pyridoxal hydrochloride to initiate the chiral 
resolution.23,24 This was not necessary in our method as we had an enantiomerically pure amino acid 
and we were interested in garnering any and all cephalosporin product and as such the pH was 
simply adjusted with 5% aqueous ammonia solution to approximately pH 7 at 0 ºC. At this pH the 
product should precipitate out, but unfortunately the precipitate did not contain product, merely the 
7-ACCA starting material. The solution, which had turned brown, was evaporated but no cubane 
material could be identified in the intractable tar. 
An alternative method was explored to synthesise the cephalosporin analogue. Woodward reported 
the use of BSA as an alternative solubilising reagent rather than TMG.15 When tested under these 
conditions, complete dissolution of the 7-ACCA was achieved, however, the subsequent coupling 
reaction once again did not yield the desired product. 
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The workup method used to synthesise cephalosporins uses pH balance to effect the removal of the 
amine protecting group as well as to precipitate the product. If the cubane had not coupled to the 
cephalosporin core, upon acid/base workup it may be that polymerisation of the amino acid 
occurred and this, along with the excess of unreacted cephalosporin core makes isolation of any 
unreacted amino acid difficult. Therefore, the final step in the reaction has serious repercussions if 
unsuccessful and as such must be perfected. 
In order to ensure that no further valuable material was lost due to unforseen complications in the 
ensuing synthesis a series of trial syntheses were undertaken on the original (R)-2-phenylgycine 
starting material. These tests did not give a good yield of Cefaclor under any of the reported 
conditions which caused a suspicion to be placed upon the purity and quality of the cephalosporin 
side-chain (7-ACCA). As such an alternative side-chain, 7-AminoDesacetoxyCephalosporanic Acid 
(7-ADCA, 4.92) was ordered from Sigma-Aldrich (Catalogue #A8398). 
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Figure 4.9 – Cephalexin (4.23), 7-ADCA (4.92) and the proposed cubyl analogue (4.93). 
Although this cephalosporin core deviated slightly from our initial target, the overall goal of the 
project may still be said to be the same. In this case a cubyl analogue (4.93) of the antibiotic 
Cephalexin (4.23) was to be formed. 
However, these syntheses were also unsuccessful and no cephalosporin products were recovered. 
Logistically, the continuation of this project became untenable and it was thus abandoned with 
much regret. As stated earlier, new methods for cephalosporin synthesis utilise penicillin G acylase 
(PGA) to effect the coupling of the phenylglycine side chain to the cephalosporin core (Scheme 
4.4).16 A future project utilising this method may be undertaken. This would be particularly 
interesting as it would show that a biological enzyme, used for phenylglycinol, could be applied to 
the cubyl analogue and also could provide an effective route to the desired novel cephalosporin 
analogue. 
4.3 Biological Studies 
Due to the unfortunate failure of the coupling reaction we were unable to test the comparative 
efficacy of the Cefaclor analogue. However, should we successfully couple the cubyl amino acid 
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the subsequent antibacterial tests will be performed by Prof. Peter Parsons of the Drug Discovery 
group at the Queensland Institute of Medical Research (QIMR), who has been a collaborator in a 
number of related cubane analogue drug tests. 
4.4 Experimental 
(S,R)-2-[(2-Hydroxy-1-phenylethyl)amino]-2-(4-iodocubanyl)acetonitrile (4.64) and (R,R)-2-
[(2-hydroxy-1-phenylethyl)amino]-2-(4-iodocubanyl)acetonitrile (4.65) 
NH
I
HO
N
NH
I
HO
N
 
To a stirred solution of 4.59 (0.46 g, 1.78 mmol) in methylene chloride and methanol (10ml: 10ml) 
at room temperature was added (S)-2-Amino-2-phenylethanol (4.46, 0.248 g, 1.80 mmol) as a solid. 
The solution was stirred for 30min. then cooled to 0 ºC. Trimethylsilyl cyanide (0.47ml, 3.56 mmol) 
was added and the solution is stirred for 2 h to ensure complete conversion. The solvent was 
removed by rotary evaporation and the crude product was purified via column chromatography 
(ethyl acetate 25%: petroleum spirit) to give 4.64 (0.525 g, 73%) and 4.65 (0.128 g, 18%) as white 
foams that are amorphous at room temperature.  
4.64:  
1H-NMR (300MHz, CDCl3) δ: 3.54-3.51 (m, 2H), 3.76 (m, 1H), 4.12 (m, 4H), 4.20 (m, 3H), 7.32 
(m, 5H); 13C-NMR (75MHz, CDCl3) δ: 138.07, 128.84, 128.32, 127.58, 117.55, 67.11, 62.89, 
57.54, 54.03, 49.73, 47.66, 36.97. 
4.65: 
1H-NMR (300MHz, CDCl3) δ: 3.60 (m, 1H), 3.75 (m, 1H), 3.92-4.38 (m, 10H), 7.33 (m, 5H); 13C-
NMR (75MHz, CDCl3) δ: 139.32, 128.88, 128.35, 127.35, 117.55, 66.58, 62.97, 58.08, 54.89, 
54.64, 53.92, 50.92, 50.31, 48.33, 47.96, 36.77, 29.67. 
 (S)-2-(Benzylideneamino)-2-(4-iodocubanyl)acetonitrile (4.72) 
N
I
N
 
4.64 (0.312 g, 0.77 mmol) was dissolved in methylene chloride (3 ml) and methanol (3 ml) and the 
 92 | Chapter 4 
solution was stirred at 0 ºC. Lead(IV) acetate (0.369 g, 0.832 mmol) was added as a solid at 0 ºC 
and the solution was stirred for 5 min. The reaction was monitored via TLC to ensure complete 
conversion before a solution of saturated NaHCO3(10 ml) was added. A precipitate in the aqueous 
phase was formed and the aqueous phase was extracted and washed with methylene chloride (2 x 10 
ml). The organic phase was combined, dried (MgSO4), filtered and the solvent removed to give a 
pale yellow liquid which, upon cooling gave a pale yellow solid of 4.72 (0.173 g, 80%) which was 
taken through immediately. 1H-NMR (300MHz, CDCl3) δ: 4.21 (m, 6H), 4.87 (d, 1H, JHz = 1.75), 
7.44 (m, 3H), 7.76 (m, 2H), 8.48 (s, 1H); 13C-NMR (75MHz, CDCl3) δ: 138.07, 128.84, 128.32, 
127.58, 117.55, 67.11, 62.89, 57.54, 54.03, 49.73, 47.66, 36.97. HRESIMS m/z calculated for 
(C17H14N2I + H): 373.0202; Found: 373.0199. 
 (R)-Carboxy(4-iodocubanyl)methanaminium chloride (4.73) 
HO
O
ClH3N
I
 
To a recently formed sample of 4.72 (0.823 g, 2.21 mmol) was added concentrated hydrochloric 
acid (5 ml) and the solution was stirred at 60 ºC for 2 h. The solvent was removed in vacuo 
(aspirator) and the product was washed with acetone and diethyl ether to give 4.73 (0.752 g, 90%) 
as a brown solid. The product was highly insoluble in all solvents and spectral analysis of the 
product was not achieved. 
(R)-2-(Cubanyl)-2-{[(S)-2-hydroxy-1-phenylethyl]amino}acetonitrile (4.76α)  
 (S)-2-(Cubanyl)-2-{[(S)-2-hydroxy-1-phenylethyl]amino}acetonitrile(4.76β) 
NH
N
OH
NH
N
OH
α β  
A solution of cubanylmethanol (4.26, 0.865 g, 6.45 mmol) and 4-methylmorpholine-N-oxide (0.832 
g, 7.10 mmol) in anhydrous methylene chloride (20 ml) was added tetrapropylammonium 
perruthenate (0.113 g, 0.32 mmol) and the solution was stirred at room temperature. The progress of 
the reaction was monitored by thin layer chromatography until the starting material was no longer 
observed. The resultant solution was filtered through Celite™ and eluted via the addition of a 
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further 20 ml of methylene chloride. The resultant cubane-1-carboxaldehyde (4.27) solution was 
identified by thin layer chromatography and methanol (40 ml), (S)-2-amino-1-phenylethanol (1.06 
g, 7.72 mmol) and 4 Å molecular sieves (0.20 g) were added. The solution was stirred and cooled to 
0 ºC and trimethylsilyl cyanide (0.97 ml, 0.77 g, 7.72 mmol) was added. The solution was then 
stirred for 2 h, allowing the solution to warm to room temperature. The solvent was subsequently 
removed and the resultant oil was purified via column chromatography using (ethyl acetate 30%: 
petroleum spirit). The resultant diastereomers were recovered as white foams; 4.76α (0.929 g, 
52%), 4.76β (0.189 g, 11%), mixed fractions (0.144 g, 8%). HRESIMS m/z calculated for 
(C18H18N2O + Na): 301.1317; Found: 301.1311 
4.76α 
1H-NMR (400MHz, CDCl3) δ: 3.48 (m, 1H), 3.58 (m, 1H), 3.79 (m, 1H), 3.98 (m, 7H) 4.09 (m, 
1H), 7.32 (m, 5H); 13C-NMR (100MHz, CDCl3) δ: 138.15, 128.88, 128.33, 127.74, 117.90, 67.26, 
62.99, 56.77, 50.21, 48.56, 46.85, 44.37. 
4.76β 
1H-NMR (400MHz, CDCl3) δ: 3.49 (s, 1H), 3.65 (m, 1H), 3.78 (m, 1H), 3.94 (m, 7H) 4.11 (m, 1H), 
7.34 (m, 5H); 13C-NMR (100MHz, CDCl3) δ: 139.59, 128.81, 128.20, 127.37, 118.14, 66.22, 62.87, 
57.32, 51.09, 48.59, 47.00, 44.25. 
(R)-2-(Benzylideneamino)-2-cubanylacetonitrile (4.77α) 
N
N
 
To a stirred solution of lead tetraacetate in methanol/methylene chloride (5 ml: 5 ml) chloride at 0 
°C was added a solution of (R)-2-(Cubanyl)-2-{[(S)-2-hydroxy-1-phenylethyl]amino}acetonitrile 
(4.76α , 0.054 g, 0.19 mmol). The reaction was monitored by TLC and was complete within 5 min. 
Upon complete disappearance of 4.76α, as shown by TLC, a saturated solution of NaHCO3 was 
added and a precipitate was immediately formed. The solution was extracted with methylene 
chloride (3 x 10 ml) and the organic layer was dried (MgSO4), filtered and the solvent removed to 
yield 4.77α (0.043 g, 90%) as a pale yellow liquid which formed a pale yellow solid upon cooling. 
1H-NMR (400 MHz, CDCl3) δ: 3.94 (m, 3H), 4.04 (m, 4H), 4.85 (d, J =1.6Hz, 1H), 7.44 (m, 3H), 
7.78 (m, 2H), 8.48 (d, 1H, J = 1.6 Hz); 13C-NMR (100MHz, CDCl3) δ: 44.39, 46.97, 48.75, 57.55, 
60.55, 115.87, 128.98, 129.72, 131.62, 135.06, 163.19; HRESIMS m/z calculated for (C17H14N2 
+Na): 269.1055; Found: 269.1049. 
 94 | Chapter 4 
(R)-Carboxy(cubanyl)methanaminium chloride (4.78α) 
HO
O
ClH3N
 
To a recently formed sample of (R)-2-(Benzylideneamino)-2-cubanylacetonitrile (4.77α , 0.043 g, 
0.18 mmol) was added concentrated hydrochloric acid (4ml) and the solution was stirred at 60 ºC 
for 2 h. The solvent was removed in vacuo (aspirator) and the product was washed with acetone and 
diethyl ether to give 4.78α (0.037 g, 99%) as an off-white solid. M.p. >250 ºC; 1H-NMR (D2O, 300 
MHz) δ: 3.85 (m, 3H), 3.93 (m, 4H), 4.07 (s, 1H); 13C-NMR (D2O, 75 MHz) δ: 54.91, 54.71, 48.12, 
46.96, 43.77; HRESIMS m/z calculated for (C10H12NO2Cl): 213.0577; Found: 213.0563. 
(R)-2-Amino-2-(cubanyl)acetic acid (4.29α) 
HO
O
H2N  
4.78α (0.037 g, 0.17 mmol)was dissolved in H2O (5 ml) and added to the top of a column of freshly 
prepared ion exchange resin (Amberlite IR-120H, hydrogen form cation exchange resin). The 
product was then eluted with 5% Ammonia solution to give 4.29α as an off white solid (0.030 g, 
98%). The solid 4.29α was used for subsequent reactions immediately after drying. HRESIMS m/z 
calculated for (C10H11NO2 +H): 178.0868; Found: 178.0868. 
 (R)-2-[(4-Methoxy-4-oxobut-2-en-2-yl)amino]-2-cubanylacetic acid (4.30α) 
ONa
O
HN
OEt
O
  
To a stirred solution of 4.29α (0.220 g, 1.24 mmol) in ethanol (5 ml) was added potassium 
hydroxide (0.07 g, 1.26 mmol) and the solution was heated at reflux for 10 min., ensuring the 
solution was clear. Ethyl acetoacetate (0.195 ml, 1.33 mmol) in ethanol (2.5 ml) was added to the 
refluxing solution and the solution was heated at reflux for 30 min. The solution was concentrated 
to approximately 1 ml then cooled. The product crystallised as an off-white solid which was filtered 
and washed with ice cold ethanol and dried in vacuo at 40 ºC to give 4.30α (0.390 g, 96%). 1H-
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NMR (300 MHz, D2O) δ: 1.08 (t, 3H, JHz = 7Hz), 1.15 (s, 3H), 3.82 (m, 6H), 3.97 (m, 3H), 4.05 (s, 
1H), 4.42 (s, 1H); HRESIMS m/z calculated for (C16H19NO4+ Na): 312.1212; Found: 312.1206. 
(R)-Methyl 2-[(t-butoxycarbonyl)amino]-2-cubanylacetate (4.80α) and (S)-methyl 2-[(t-
butoxycarbonyl)amino]-2-cubanylacetate (4.80β) 
NHBoc
OMeO
S
4.80β
NHBoc
OMeO
R
4.80α  
To a stirred solution of 4.29 (50 mg, 0.28 mmol) in tetrahydrofuran: water (1:1, 6 ml) was added di-
t-butyl dicarbonate (66 mg, 0.30 mmol) at room temperature. NaOH (24 mg, 0.60 mmol) was then 
added and the solution stirred at room temperature overnight. The tetrahydrofuran was then 
removed via rotary evaporation and the aqueous layer was washed with diethyl ether (2 x 5 ml). The 
aqueous phase was then acidified with 1N HCl to pH 3 and extracted with methylene chloride (3 x 5 
ml). The organic phases were then combined, dried (MgSO4) and the solvent removed under rotary 
evaporation to yield a white solid.  
The resultant solid was then dissolved in diethyl ether and cooled to 0 ºC. Diazomethane solution 
was added at 0 ºC until the solution was observed to retain a yellow colouration. The solution was 
then stirred for 5 minutes before a stream of nitrogen gas was blown over the solution to quench any 
unreacted diazomethane. The solution was observed to contain a single spot when analysed by thin 
layer chromatography and was thus passed through a small plug of silica gel to remove any baseline 
impurities. The resultant solution was then dried via rotary evaporation to yield 4.80 (69.5 mg, 
89%) as a white solid. M.p. (87-89 ºC); 1H-NMR (300 MHz, CDCl3) δ: 1.42 (s, 9H), 3.71 (s, 3H), 
3.88-3.97 (m, 7H), 4.48 (m, 1H), 4.96 (s, 1H); 13C-NMR (75 MHz, CDCl3) δ:  28.26, 47.10, 48.50, 
52.01, 55.00, 57.46, 79.90, 155.66, 171.23; HRESIMS m/z calculated for (C16H21NO4 + Na): 
314.1368; Found: 314.1363. [αᴅ] (4.80α, CHCl3, 0.240952 w/v%, 25.2 ºC): -79.6673 º. Optical 
rotation could not be gained for 4.80β as it was not deemed to be enantiomerically pure in the 
preceding synthesis. 
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Chapter 5 A Cytochrome P450 Oxidation Study 
5.1 Introduction 
In the previous chapters we have focussed primarily on the synthetic aspects of producing cubane 
analogues of pharmaceutical drugs. In an effort to better understand the potential for incorporation 
of cubane in pharmaceutical drugs further investigations into the biological compatibility of the 
unnatural cubane core must be performed. For instance, the body’s metabolism may bind or break 
down the cubane core in ways that are quite different to the benzene pathways.  
In Chapter 4 we briefly reviewed the study of Pellicciari et al. and his synthesis of a cubane amino 
acid analogue (4.44) in order to gauge its ability to bind to metabotropic glutamate receptors 
(mGluR) (Figure 5.1). It was determined that 4.44 selectively bound to mGluR1 and did not bind at 
all to mGluR5. Although less active than other known antagonists to these receptors such as (S)-4-
carboxyphenyglycine (5.01), these results indicated that it may become a tool capable of 
differentiating mGluR1 and mGluR5.1 
HO2C
NH2
CO2HS
NH2
O
OH
O
HO
S
4.445.01  
Figure 5.1 – S-4-CPG and Pellicciari’s mGluR1 receptor (S)-2-(4'-carboxycubyl)glycine. 
In order to better understand how a common enzyme interacts with the cubane core a trial study 
may be employed. An alternative study focussed upon the P450 oxidation of cubanyl compounds 
was perceived to significantly add to the current understanding of the potential for cubane based 
compounds to be bound in biological systems. The non-polar nature of cubane, as well as its highly 
strained structure, may also be explored in the metabolic sense. These factors may influence the 
binding of cubane as well as possibly indicating whether the cubane core remains stable while 
bound and upon enzymatic turnover. 
The metabolic processes of the human body are very complex. Any of these metabolic processes 
may alter the structure of the compound, which may have adverse effects that were not present in 
the original compound. We elected to use P450 enzymes to determine the potential for the unnatural 
cubane compounds to bind to the enzyme in comparison to their benzene analogues. Furthermore, 
we planned to determine the potential for, and location of, hydroxylation once bound. 
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Cytochrome P450 enzymes (CYP) are an excellent selection for an initial study on the biological 
fate of any potential drug molecule. They are vital in the oxidative metabolism of drugs in human 
biology, being the major class of enzymes involved in drug metabolism. As such, they have gained 
importance in the pharmaceutical industry and can be used to help determine the approval of new 
therapeutic agents. The efficacy of drugs and insecticides has also been linked to the activity of 
CYP enzymes. It is often observed that insects develop rapid resistance to insecticides via P450 
mutations that allow for improved metabolism of insecticidal compounds leading to their 
detoxification.2 Therefore, it is desirable that novel insecticides, as well as drug compounds, be 
designed to have a certain level of stability towards P450 metabolism to allow for the full efficacy 
of the drug to be achieved. The unnatural cubane core may limit the ability of CYP enzymes to 
purge the drug from the body and thus increase the time in which the active drug is able to reach 
and treat the target site of affliction. 
5.1.1 P450 Oxidation 
A large number of comprehensive reviews on Cytochrome P450 have been published delving into 
the complex biology of the enzyme.3-5 In 1958, Klingenberg et al. identified an active enzyme that 
characteristically absorbed light at 450nm under certain conditions.6 
 
Figure 5.2 – Oxidation of the haem-porphyrin reactive site within the enzyme. 
Further investigations over the years yielded greater insight into the enzyme revealing a plethora of 
individual cytochrome P450 enzymes, which were subsequently sorted into various classes 
depending on functional characteristics. The general nature of the enzyme was found to be a b-type 
haem protein (Figure 5.2) of which many crystal structures have now been determined (Figure 
5.3).7 
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Figure 5.3 – The crystal structure of the ternary complex formed between carbon monoxide (CO), camphor, and 
ferrous cytochrome P450cam.7 
The role of P450 is postulated to have initially become relevant over 2 billion years ago.8 As the 
levels of oxygen in the earth’s atmosphere increased, free oxygen species would also have become 
more prevalent. Furthermore, living organisms in this time would not have been accustomed to 
aerobic respiration. As such, it has been proposed that early mutations of P450 would have been 
required to detoxify oxygen and trap free oxygen species.8 From this point forward, mutations in 
P450 enzymes have been directed towards incorporating oxygen for various purposes: from 
metabolism of undesired compounds to the generation of beneficial substances (e.g. biotoxins and 
antibiotics).3 The most basic mode of cytochrome P450 metabolic action is best described in 
Scheme 5.1. 
 
Scheme 5.1 – NAD(P)H in the reaction of substrate catalysed by P450. 
A more descriptive analysis of the basic mode of action, represented by Scheme 5.2, beginning in 
the top left, is as follows: the substrate (SH) binds to the iron of the enzyme FeIII; NAD(P)H 
provides an electron, resulting in the reduction of the enzyme to FeII; molecular oxygen is bound to 
the P450 complex; a second reduction and protonation yields a vital Fe(III) complex; further 
protonation breaks the O-O bond heterolytically to form an iron-oxo intermediate (Fe=O) with the 
loss of water; oxygen is transferred to the bound substrate and the complex dissociates yielding the 
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hydroxylated product (SOH) and a renewed catalyst.9 It can be noted that some side reactions may 
occur to limit the efficacy of the enzyme. These generally result in oxygenated species such as 
peroxide and free radical oxygen being formed. 
 
Scheme 5.2 – Consensus catalytic cycle of cytochrome P450 enzyme. 
As stated earlier, P450 enzymes are vital for drug metabolism, but the production of P450 enzymes 
may also be affected by drugs. This can result in adverse effects under certain circumstances. For 
instance, the anti-cancer drug Cisplatin can alter the hormone production in the human body which 
ultimately leads to a lowered production of CYP. The lowered production of enzyme then impacts 
on the metabolism of other drugs administered and hence lowers their efficacy.3,10-12 
One particularly well investigated P450 enzyme is that of the bacteria Pseudomonas putida, which 
catalyses the hydroxylation of a number of substrates. In particular, it is known for the 
hydroxylation of camphor (5.04) to 5-exo-hydroxycamphor (5.05), and as such was named P450cam 
(CYP101) (Scheme 5.3).7 
 
Scheme 5.3 – P450cam selectively hydroxylates camphor. 
Studies into the P. putida P450 system lead to the discovery that the bacteria is able to rely solely 
upon camphor as a substrate for free oxygen species turnover. In realising that P450cam developed as 
a circumstantial mutation arising from a need to specifically metabolise camphor if required, it can 
be assumed that under certain conditions alternative mutations in the enzyme may occur. For 
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example, P450cin was isolated from a species of Citrobacter braakii after it was isolated from soil 
surrounding eucalypt trees. This P450 enzyme was correctly envisioned to be capable of 
hydroxylating cineol, a monoterpene found in high amounts in eucalypt essential oils. In this case 
P450cin hydroxylates cineol (5.06) to give 2-hydroxycineol (5.07, Scheme 5.4).13 
 
Scheme 5.4 – P450cin is capable of hydroxylating cineol. 
The science of P450 enzymes is extensive and extends far beyond the scope of this chapter. In 
relation to the intent of this project, one study in a particular must be noted. In 1998, Sibbesen et al. 
investigated the effects of substrate structure and its ability to stimulate coupled and uncoupled 
turnover of two mutated P450cam enzymes. It was discovered that substrate size had an impact on 
binding and also that substrate structure dictated the location of hydroxylation.14 The study focussed 
on alkylbenzenes; increasing the size of the alkyl substituent as well as the overall alkylbenzene. 
This is pertinent to our research and will be detailed in Section 5.1.3. 
5.1.2 Cubane in P450 Oxidation Studies 
Cubane has previously played a role in investigational studies on the mode of action of cytochrome 
P450. It was a widely held belief that, within the P450 oxidation process, protons from a 
hydrocarbon species are first abstracted by the enzyme, which resides in the high-valence iron-oxo 
species. This generates a radical intermediate, which is then trapped by the hydroxyl species that 
transfers from the enzyme (Figure 5.4). 
 
Figure 5.4 – Original proposed method of P450 hydroxylation. 
When methyl cubane (5.08) was treated with P450 (Scheme 5.5) the reaction gave all of the 
possible geometric isomer hydroxylated products (4.26, 5.09, 5.10, 5.11), although in limited yield. 
The major product was hydroxylation of the methyl group (4.26).15,16 This was interesting as it was 
thought that radicals formed on the methylcubane would lead to decomposition of the cubane 
framework. 
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Scheme 5.5 – P450camhydroxlation of methylcubane. 
According to Eaton’s research of cubylcarbinyl radicals this degradation would result in a number 
of products which can ultimately be identified.17 This was demonstrated first by the radical 
decomposition of a bromomethylcubane (4.49) which, following radical initiation by 
AIBN/Bu3SnH gave two diastereomeric trienes (5.16 and 5.17, Scheme 5.6). 
 
Scheme 5.6 – A radical degradation pathway of the cubane core. 
In a second demonstration, under Barton decarboxylation conditions and inclusion of phenyl thiol 
as a radical trapping source, two diene products (5.20 and 5.21) were observed (Scheme 5.7). None 
of these species were observed in the P450 catalysed reaction and because of this a radical based 
P450 oxidation mechanism was therefore questioned.15-17 
 
Scheme 5.7 – A second radical degradation pathway of the cubane core. 
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A cationic OH+ attack was discounted due to the fact that the hydroxymethyl product (4.26) formed 
under P450 catalysis. Due to the strain of the cubane core, should a cationic species attack the 
methyl group a Wagner-Meerwein 1,2-bond shift of the cubane system would have occurred as it 
had under imposed conditions (Scheme 5.8).17 This rearrangement was not observed and the methyl 
alcohol (4.26) was formed in significant amounts following P450 oxidation.15,16 
 
Scheme 5.8 – Cationic rearrangement of the cubane core. 
These findings lead to a review of the mode of action in the P450 system, and furthermore an 
alternative transition state (5.26) in the P450 cycle was proposed (Figure 5.5).4 
 
Figure 5.5 – Alternative transition state of the haem binding mechanism. 
However, the authors of this study also provided a counter-argument to their own rationale. Firstly, 
it was observed that 5.08 reacted slowly with P450 enzymes; and secondly, if radical products that 
are formed on the cubane core do lead to decomposition of the core they would become 
undetectable by the GCMS analysis methods used within the study.15,16 
The mode of action of P450 is generally now accepted as described previously (Scheme 5.2). 
However, some debate still continues and P450 studies are ongoing to fully elucidate the 
mechanisms of this important enzyme. 
5.1.3 Scope 
This chapter describes an investigation into the comparative efficacy of P450 to bind and 
hydroxylate larger cubane substrates in comparison to their phenyl analogues. A library of cubyl 
and phenyl derivatives were synthesised and then subjected to cytochrome P450 oxidation 
conditions. It has already been stated that earlier publications identified a number of benzyl 
substrates that were selectively hydroxylated by mutated cytochrome P450cam enzymes.14 These 
substrates, depicted as 1-unit carbon increments, are shown below in Figure 5.6. The phenyl 
derivatives are hydroxylated by P450cam to varying degrees at very specific regions. In some cases 
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certain alkyl groups are reported to not be hydroxylated seemingly due to their position on the 
phenyl ring. In some cases meta- and para-substituted phenyl groups are reported to be unreacted 
(3A-C) and yet not in others (4C). As such, the results are rather interesting regarding the structure 
and size of the substrate and its hydroxylation. 
 
Figure 5.6 – P450camsubstrates and their hydroxylation products.*** 
The substrate of particular interest is that of t-butyl benzene. Hydroxylation of t-butyl benzene is 
reported to occur both on the aromatic ring and on the methyl groups (3E, Figure 5.6). If a cubyl 
analogue of t-butyl benzene is synthesised, the efficacy of hydroxylation may be identified with 
comparatively more ease. Furthermore, if the cubane is hydroxylated in a similar manner to the 
benzyl group it will give credence to the hypothesis that cubane can interact in a similar way to 
benzene within a biological system.  
The proposed library of synthetic cubyl targets along with their benzyl analogues are presented 
below (Figure 5.7). These compounds contain a variety of functional groups as well as the purely 
hydrocarbon based t-butyl compounds (5.54). Of particular note are the ethyl cinnamate (5.50), 
butenone (5.51) and thioether (5.53) analogues. The two olefinic analogues (5.50 and 5.51) have 
been included due to their potential for epoxidation/oxidation under P450 catalysis.9 Similarly, the 
inclusion of the analogues of 5.53 is due to the potential for P450 catalysed sulphur oxidation to 
                                                 
*** N.B.: In this figure the substrates are the alkylbenzenes without hydroxyl groups. Image taken directly from 
Sibbesen’s paper.13 
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give the corresponding sulfoxide.3 
 
Figure 5.7 – Proposed synthetic targets for P450 analysis.††† 
5.2 Results and Discussion 
The synthesis of the first cubane analogue, methyl cubane carboxylate (5.46b), is achieved through 
Barton decarboxylation of the 4-(methoxycarbonyl)cubane-1-carboxylic acid (2.12).18 
 
Scheme 5.9– Synthesis of the cubanyl methyl ester. 
In previous synthetic routes this compound was immediately hydrolysed without isolation to yield 
the cubane carboxylic acid (2.19). The methyl ester is identified by a strong sweet scent, a 
pronounced methyl singlet and an indicative 3H, 4H multiplet splitting pattern around 4 ppm in the 
proton NMR spectrum. Under the modified Barton conditions reported by Ko et al. the compound 
was purified very easily under low polarity solvent conditions.19 The initial method described by 
Eaton and Cole, which uses t-butyl thiol as the proton donor, is hindered by the presence of t-butyl 
thiol which co-elutes with the methyl ester product.18 
                                                 
††† In order to facilitate reference between the various phenyl and cubyl derivatives within this chapter the investigated 
compounds are numbered as given in Figure 5.7 regardless of their numbering in other chapters. 
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Scheme 5.10 – Hydrolysis to the cubane carboxylic acid. 
Hydrolysis of the methyl ester to the carboxylic acid produced a precursor that was used in all 
subsequent reactions (Scheme 5.8). It is worth noting the fortuitous inclusion of carboxylic ester 
functionality on the cubane core. These side chains (which are a result of the key Favorskii 
rearrangement that yields the cubane core) provide a convenient functionality for further 
modification of the cubane core (Scheme 1.5). 
 
Scheme 5.11 – Formation of the ethyl ester under microwave conditions. 
From the carboxylic acid (2.19) the ethyl ester (5.47b) was prepared by acid catalysed 
esterification. The process can be enhanced under microwave irradiation conditions (Scheme 5.11). 
Simple addition of the carboxylic acid to a solution of ethanol with a catalytic amount of sulphuric 
acid resulted in a near quantitative yield under microwave conditions. The complete dissolution of 
the cubane carboxylic acid should be ensured before being subjected to microwave irradiation. 
Solid cubane carboxylic acid placed under microwave irradiation conditions can result in 
combustion of the compound due to the high energy nature of the cubane core. 
The ethyl ester (5.47b) was once again easily identified via the 1H-NMR spectrum which contained 
the indicative cubyl 3H, 4H multiplet splitting pattern around 4 ppm, however, the methylene 
quartet was situated between these two multiplets at 4.12 ppm. In addition, a 3H triplet at 1.24 ppm 
due to the ester methyl group was observed. The 13C-NMR spectrum and HRMS data were also 
consistent with the ethyl ester structure, 5.47b. 
The cubane carboxylic acid (2.19) was reduced using borane dimethylsulfide (BH3·SMe2) complex 
to yield the cubane carbinol (5.48b) quantitatively, as demonstrated earlier (Chapter 4).20 Carbinol 
5.48b is then oxidised via the Swern oxidation to yield the cubane carboxaldehyde (5.49b) as was 
reported previously by Eaton and others (Scheme 5.12).21 As previously mentioned this aldehyde 
(5.49b) is unstable and volatile and should be kept at low temperature to prevent loss. 
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Scheme 5.12 – Synthesis of cubane carbinol and cubane carboxaldehyde. 
These two compounds were used for P450 oxidation tests. In order to synthesise the ethyl 
cinnamate analogue (5.50b) it was envisioned that the aldehyde could be used in a Wittig-type 
reaction with the appropriate ylide. Unfortunately, as described in the previous chapter (Chapter 4), 
the aldehyde was difficult to isolate and manipulate when isolated from the Swern oxidation. The 
aldehyde needed to be immediately redissolved in a solvent that could be heated to a high enough 
temperature to effect formation of the Wittig product.  
 
Figure 5.8 – Possible degradation pathway of cubane carboxaldehyde. 
The synthesis of cubane carboxaldehyde (5.49b) using Swern oxidation methods has been reported, 
and its formation has been reportedly high yielding.21 However, following purification on silica the 
yield is significantly reduced.22 This may be explained as an analogous rearrangement to that 
observed when cubylmethyl bromide (4.49) was rearranged on silica gel to give the 1-homocubyl 
bromide (5.56, Figure 5.8, Scheme 5.13).17 
 
Scheme 5.13 – Rearrangement of cubylcarbinyl bromide. 
Therefore, in order to generate the aldehyde whilst avoiding the rearrangement, the Ley oxidation 
was employed. The mild oxidation method was performed in toluene, which was then filtered 
through Celite™ and eluted with an additional amount of toluene in order to remove the 
perruthenate and molecular sieves from the solution. To this filtered solution was then added the 
appropriate phosphorous ylide (5.57) and the solution was heated at reflux (Scheme 5.14).  
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Scheme 5.14 – Aldehyde formation with subsequent Wittig reaction. 
This method minimised decomposition of the aldehyde and produced the ethyl cinnamate analogue 
(5.50b) in good yield (60%). The yield may be improved in future reactions by ensuring complete 
conversion of the aldehyde via improved reaction monitoring methods. In this case the reaction was 
monitored by TLC to determine the amount of starting alcohol (5.48b) within the reaction. The 1H-
NMR spectrum of 5.50b contains a 1H doublet at 7.14 ppm as well as a coupled 1H doublet at 5.66 
ppm which was indicative of the E-isomer. Once again the indicative cubyl multiplets are present at 
4.00 ppm and the methylene quartet and methyl triplet further support the synthesis of 5.50b. The 
13C-NMR spectrum and HRMS data were also consistent with the product, 5.50b.  
 
Scheme 5.15 – Allylic addition via the Weinreb amide. 
The methyl cubane carboxylate (5.46b) formed earlier also provided the starting material in the 
synthesis of the cubanyl butenone (5.51b) via Grignard addition of allylmagnesium chloride (5.59) 
to the Weinreb amide (5.58, Scheme 5.15).23 
 
Scheme 5.16 – Mechanism of Weinreb ketone synthesis. 
The Weinreb amide (5.58) in this case prevents the over addition of the Grignard reagent (5.59) 
which would generally occur if a carboxylic ester were used instead.24 The Weinreb amide can be 
identified in the 1H-NMR spectrum by two distinct 3H methyl singlets at 3.16 and 3.68 ppm along 
with the two cubyl multiplets at 4.00 ppm. The 13C-NMR spectrum also contains these methyl 
resonances; however, the carbonyl resonance at 173 ppm was poorly resolved and required 
extensive accumulation in order to record the resonance. HRMS analysis was consistent with the 
Weinreb amide (5.58). 
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The allyl ketone (5.51b) was identified in the 1H-NMR spectrum by the notable 1H olefin multiplet 
at 5.92 ppm and the 2H multiplet at 5.10 ppm, the deshielded methylene triplet at 3.20 ppm and the 
standard 3H, 4H multiplet splitting pattern at 4.00 ppm typical of the cubane core. The 13C-NMR 
and HRMS analysis further supported the synthesis of this novel compound. 
 
Scheme 5.17 – Grignard addition to the methyl ester. 
As mentioned earlier, should the Weinreb amide not be used Grignard reagents would add to the 
ester in a less controlled manner resulting in double addition products as well as reduction of the 
ketone to the alcohol. This type of addition was utilised to effect the synthesis of the isopropyl 
alcohol cubane (5.52b) target. In this case methylmagnesium bromide was added in excess (2.2 
equivalents) to the methyl carboxylic ester (5.46b). It should be noted that a lowered yield (50%) of 
the desired 2-cubanylpropan-2-ol (5.52b) was obtained due to a spill during workup. Nevertheless, 
the spectroscopic data was well in accord with those reported in the literature for this compound.25 
 
Scheme 5.18 – Suzuki type coupling towards the ethyl sulfane. 
The aforementioned cubane analogues were obtained through relatively simple methods, however 
to generate the final two proposed targets (5.53b and 5.54b) novel methods were required. In the 
case of 5.53b we anticipated that a modified Mitsunobu reaction using ethane thiol with 
triphenylphosphine (PPh3, 5.65) and diethylazodicarboxylate (DEAD, 5.66) to couple to the cubane 
carbinol (5.48b) would lead to the desired product. However, under these conditions the product 
was not obtained, and unfortunately the starting material (5.48b) was also not retrieved. The loss of 
starting material indicated a reaction had taken place; however, the reaction did not result in 
conversion to the desired product.  
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Scheme 5.19 – Proposed mechanism of the Mitsunobu reaction. 
This failure to yield product may be explained in a number of ways. It has been reported that 
aliphatic thiols do not produce good yields and perhaps lack the acidity required to participate in the 
Mitsunobu reaction.26 As such the phosphoryl cubane intermediate would not undergo the 
subsequent elimination reaction. However, no attempts to isolate the intermediate from the reaction 
were made. An alternative explanation may be that the mechanism of the reaction causes an 
unstable cubane intermediate to be formed by creating a partial positive charge on the methylene 
group exocyclic to the cubane cage. 
However, the nature of this investigation allowed for some freedom in the targets synthesised and, 
as the study could be further investigated should positive results be achieved, it was decided that 
this target be abandoned for the present. Future investigation may benefit from modifications to the 
reaction methods. For instance, the reaction of alcohols with aliphatic thiols has been shown to be 
improved with the use of trimethylphosphine (Me3P), 1,1'-(azodicarbonyl)dipiperdine (ADDP) and 
imidazole.27 The use of ZrCl4 mixed in dry silica gel has also been shown to promote Mitsunobu 
type coupling.28 
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Scheme 5.20 – Eaton’s synthesis of t-butyl cubane and side reactions. 
It was important however, that the t-butyl cubane (5.54b) be synthesised for P450 oxidation studies. 
This compound, at the least, would provide a direct comparison to Sibbesen’s published data.14 
Furthermore, the synthesis of 5.54b has previously been achieved.29,30 In the literature the precise 
details of the synthesis were not reported, but the synthesis was summarised as a reaction between 
an excess of t-butyl lithium and a solution of 1,2-diiodocubane with subsequent quenching of the 
product with methanol.29,30 
In order to synthesise the 1,2-diiodocubane (5.73) a complex series of modifications to the cubane 
core was required (Scheme 5.21). Initially, the acyl chloride (5.81) was converted into the N,N-
diisopropylamide (5.82). This moiety functions as a directing group for the ortho-lithiation of 
cubane. In the presence of mercury(II)chloride the reaction is driven forward to give the ortho-
mercurated product (5.85). This could then be converted to the iodinated product (5.86) in good 
yield (72%) when stirred overnight at room temperature with iodine in methylene chloride.31 
Following this was a reduction of the amide to give the amine (5.87), which then subsequently 
undergoes oxidation to the carboxylic acid (5.88). 
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Scheme 5.21 – Eaton’s route to 1,2-diiodocubane. 
The final conversion to the o-diiodide (5.73) can be performed under various conditions. Initially, 
Eaton used a known method of t-butyl hypoiodite under photolysis conditions. This was then 
improved upon using a modified Barton decarboxylation method with 2-iodo-1,l,l-trifluoroethane as 
the iodide source.30,32 It may also be possible to use iodobenzene diacetate (IBDA, 4.61) with 
iodine, in a similar manner to that described by Moriarty et al.33 
The synthesis of the o-diiodide (5.73) is quite extensive and requires several steps to achieve the 
starting material for the subsequent synthesis of t-butyl cubane (5.54b, Scheme 5.20). There is 
evidence of the formation of 5.54b via an alternative method. The addition of t-butyl lithium to 1,4-
diiodocubane (5.90) has been shown to form a reactive species which, under the right conditions, 
may form t-butyl cubane.34 
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Scheme 5.22 – 1,4-diiodocubane undergoes lithiation and subsequent alkylation. 
An excess of t-butyl lithium dehalogenates 5.90 to give the monolithiated species (5.91). 
Dehydrohalogenation can then occur in a competitive reaction followed by addition of the t-butyl 
group and lithium across the double bond. This can be quenched by carbon dioxide to give the 
alkylated diacid (5.95; which is easily converted to the ester via diazomethane). Quenching the 
lithiated species (5.94) with methanol results in the formation of t-butyl cubane (5.54b, Scheme 
5.22).34 
 
Scheme 5.23 – Moriarty synthesis of 1,4-diiodocubane. 
This is particularly beneficial as the synthesis of 5.54b is thus achieved under far simpler methods 
using the methods of Moriarty et al.33 As mentioned earlier, the use of iodobenzene diacetate (4.61) 
under photolysis initiates a decarboxylative mechanism to give a species which can be trapped with 
iodine to give the iodinated product (Scheme 5.23). Therefore, it was this method that was used to 
achieve the synthesis of t-butyl cubane in this study. 
The conversion of 1,4-diiodocubane (5.90) to t-butyl cubane required a significant excess of t-butyl 
lithium to be used (10-20 equivalents). Addition of a solution of 5.90 in tetrahydrofuran at -78 ºC 
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gave 5.54b in very small yields (as observed by GCMS). The solution was stirred for a short time 
before being quenched with anhydrous methanol. This solution was then extracted with n-pentane 
and distilled carefully to remove excess solvent.  
 
Scheme 5.24 – Reaction of 1,4-diiodocubane with excess t-BuLi and resultant major products. 
A number of these reactions were performed and the crude solutions of 5.54b were combined for 
purification. Isolation and purification by preparatory gas chromatography (prep. GC) gave small 
yields of the product which were combined over consecutive runs. A significant amount of pure 
cubane (1.01) was also isolated as the first eluent from the prep. GC column. The desired product, t-
butyl cubane (5.54b), was trapped as a colourless solid at -78 ºC via prep. GC. It was noted to be a 
colourless liquid at room temperature. This physical property, a mass of 145 m/z (M - 15) with 
indicative cubyl resonances of 103 and 91m/z, along with quite poorly resolved 1H-NMR and 13C-
NMR spectra consistent with anecdotal data retrieved from the literature allowed for confirmation 
of the product.29 A mass of 205 m/z was attributed to cubyl cubane (5.78), however, this product 
was not isolated from the preparatory GC and was observed to crystallise from solution as the 
solvent evaporated. 
Whilst perhaps not being the most effective method of generating t-butyl cubane (5.54b) the 
method did yield the desired product. These synthesised compounds were submitted to catalytic 
turnover experiments via P450 oxidation using both P450cam and P450cin. 
5.3 P450 Studies 
As stated earlier, P450cam and P450cin were chosen for these catalytic turnover studies for a number 
of reasons. P450camhas been the primary model P450 enzyme studied for a number of years.3 
Furthermore, P450cin was also used in a number of previous catalytic turnover experiments 
conducted within the University of Queensland. 
The biological testing was performed by Dr. Jeanette Stok a member of the research group lead by 
Prof. De Voss at The University of Queensland, St. Lucia. Prof. De Voss’ group is responsible for 
the isolation and identification of the P450cin enzyme.9,13,35,36 
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5.3.1 Methods 
5.3.1.1 Analysis of cubane and phenyl compounds with P450cin and P450cam 
Both P450cin and P450cam were expressed and purified according to previously published 
protocols.13,36 The dissociation constant (Kd) and spin state change were determined using 
established procedures.13,14 Catalytic turnover of each compound with P450cin and P450cam was 
performed to determine if any products were formed. A solution of P450cin (0.5 µM), E. coli 
reductase (1 µM), cindoxin (4 µM), NADPH (3 mM) and a relevant substrate (5 mM) in 50 mM 
KPi and 100 mM KCl, pH 7.4 was incubated for approximately 40 min at room temperature. The 
reaction products and remaining substrate were recovered by employing a solid-phase extraction 
cartridge (SPE; Phenomenex, strata-X reverse phase absorbent, 30 mg/ml). The ethyl acetate extract 
was then analysed by GC-MS (Zebron ZB-5MS, Phenomenex; 50°C for 2 min, 50-250°C at 
16°C/min). Samples containing carboxylic acids were treated with a drop of diazomethane before 
GC-MS analysis. 
Reactions with P450cam were carried out in a similar fashion, with the following exceptions. A 
solution of P450cam (1 µM), putidaredoxin reductase (2 µM), putidaredoxin (8 µM), NADH (3 mM) 
and a relevant substrate (5 mM) in 50 mM KPi and 100 mM KCl, pH 7.4 was incubated for 
approximately 40 min at room temperature.  
To assess whether P450cam was being irreversibly inhibited by t-butyl cubane, parallel catalytic 
turnover reactions were run either with camphor or t-butyl cubane as the substrate as outlined in the 
previous paragraph. This was followed by overnight dialysis of the reactions against 50 mM Tris-
HCl pH 7.4 containing 100 mM KCl to remove the substrate. The next day putidaredoxin reductase 
(2 µM), putidaredoxin (8 µM), camphor (5 mM) and NADH (3 mM) were added to both reactions 
to initiate a second catalytic turnover. The reaction products were extracted and analysed as 
indicated previously. All high-spin state measurements performed at 5mM final concentration.  
5.3.2 Results and Discussion 
Initial comparison between the phenyl substituent and the cubane group focused on evaluating both 
the binding constants and the percentage of P450 that was converted from low (417 nm) to high 
spin Fe(III) (392 nm). In general, the cubane compounds appear to have better binding constants 
(Kd) for both P450cam and P450cin than for the corresponding phenyl compounds (Table 5.1). In 
addition, there is very little difference between P450cam and P450cin with the majority of the 
substrates tested.  
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Further analysis revealed that only the t-butyl benzene and t-butyl cubane were substrates for both 
P450cam and P450cin. The products observed from the t-butyl benzene (5.54a) catalytic turnover by 
P450cam were generally consistent with previous observations; with the hydroxylation reported to be 
occurring mainly on one of the three methyl groups (Figure 5.6).14,16 
 
Figure 5.9 – Potential structures of the hydroxylated t-butyl cubane. 
In contrast, P450cin targeted the ortho and meta positions mainly producing 2- and 3-t-butyl phenols 
(49% and 44% respectively). The catalytic turnover of t-butyl cubane (5.54b) with both P450cam 
gave a new product by GCMS analysis that had a molecular ion consistent with hydroxylation of 
the substrate (MW: 176). This product was observed to have a GCMS fragmentation pattern similar 
to other cubane compounds (Figure 5.9). It is most likely that the major product is 5.101 as it has 
been reported that compounds such as 5.102R, bearing a bridgehead alcohol, undergo rapid 
homoketonisation leading to decomposition.37 However, a hydroxylated cubane compound has 
previously been reported to be stable upon synthesis with methyl(trifluoromethyl)dioxirane (TFDO, 
5.104) as well as via the Baeyer-Villiger oxidation of a cubyl methyl ketone using 3-
Chlorooperoxybenzoic acid (mCPBA, 5.105) to give the acetylated hydroxycubane product (5.108, 
Scheme 5.25).16,38 
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Scheme 5.25 – Some reported syntheses of hydroxylated cubanes.16,38 
A large scale catalytic turnover, approximately twenty times a standard reaction size, was 
performed with P450cam and t-butyl cubane (5.54b). Curiously, turnover of 5.54b was limited 
(regardless of the reaction scale the maximum concentration of hydroxylated product could not be 
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exceeded) and as such the resultant product was not obtained in large amounts. Therefore, multiple 
small scale reactions were performed simultaneously in order to generate a greater amount of the 
desired product. 
Due to the scale of the turnover only a very minor amount of the turnover product was thus made 
available for acetylation. This was performed by first removing a large portion of the solvent (ethyl 
acetate) in which the theorised hydroxylated t-butyl cubane was extracted upon turnover. Solvent 
was removed by blowing a steady stream of nitrogen over the sample with gentle heating (~45 ºC). 
Once the sample had been reduced from 15 ml to 1 ml a few drops of acetic anhydride was added 
along with two drops of pyridine and the solution was stirred at room temperature for 2 hours. 
The solution was then extracted with water and 1M hydrochloric acid, dried (MgSO4), filtered and 
the excess solvent was once again removed under a stream of nitrogen with gentle heating to give 
~0.5 ml of solution. This solution was then purified via column chromatography to give several 
spots via TLC each of which was isolated and analysed via GCMS to identify the fraction with a 
mass corresponding to that of the acetylated t-butyl cubane (5.81, MW: 218). The GCMS trace also 
included a highly characteristic (M - 43)+ peak indicating a loss of acetate. 
 
Scheme 5.26 – Acetylation of the hydroxylated t-butyl cubane. 
NMR spectroscopy, whilst difficult on such a minute scale, was performed using a Shigemi 
(CDCl3) NMR tube. However, the spectroscopic data proved quite difficult to analyse as even the 
purified sample was contaminated with residual solvent resonances that overshadowed the minor 
product resonances and made analysis unreliable. However, considering the known data; that 
P450cam hydroxylated preferentially on the methyl groups in the analogous benzyl derivative; and 
that the cubane core is often reported to be unstable upon direct hydroxylation of the bridgehead 
carbons; we can reasonably infer that the most likely hydroxylated product is 5.101. 
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Scheme 5.27 – Proposed synthetic route to 5.101. 
An attempt to synthesise 5.101 was made via the proposed method outlined in Scheme 5.27.39 
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Following the synthesis of 5.110 via reported literature methods, the attempted synthesis did not 
yield the desired conjugate addition product 5.112 and 5.110 was retrieved following workup. The 
failure of the desired SRN1 reaction is most likely due to the large amount of steric hindrance of the 
cubane core preventing the nucleophilic free radical species attacking the halide.  
From Table 5.1 it can be seen that for a number of compounds, both benzyl and cubyl there is no 
binding to the enzyme. Furthermore, the majority of those compounds that do bind to the P450 
enzyme, as determined by the dissociation constant, are not oxidised. However, it can be seen that a 
large number of benzyl analogues are also not oxidised. 
Also of note is the fact that 5.54b was also observed to not irreversibly inhibit P450cam. This 
indicates that having cubanyl compounds incorporated in the P450 binding pocket does not 
permanently prevent the system from performing its biological role. It may be seen only to inhibit 
the action of the enzyme in much the same way as was desired in Chapter 2. 
 
Table 5.1 – Results of P450 catalysed turnover. 
 P450cam P450cin 
a b  
Kd (µM) % high spin Products Kd (µM) % high spin Products 
R
5.54  
a 639 ± 71 48 Yes14 542 ± 87 90 Yes 
b 6.1 ± 0.4 83 Yes 6.7 ± 0.9 81 Yes 
R
OH
5.52  
a NM 9 ND 1550 ± 250 8 ND 
b 41 ± 4 61 ND 60 ± 3 27 ND 
R
O
O
5.47  
a 1400 ± 200 33 ND NM 56 ND 
b 18 ± 3 61 ND 2310 ± 160 44 ND 
O
OR
5.50  
a 670 ± 120 23 ND NM 25 ND 
b - - ND - - ND 
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 P450cam P450cin 
a b  
Kd (µM) % high spin Products Kd (µM) % high spin Products 
R
O
5.51  
a - - - - - - 
b - - - - - - 
R
O
O
5.46  
a - - - - - - 
b - - - - - - 
R
OH
5.48
H
H
 
a - - - - - - 
b - - - - - - 
R
O
H
5.49  
a - - - - - - 
b - - - - - - 
Note: NM = Not Measured; ND = Not Discernible; – indicates that no measurable result was observed. 
It can therefore be stated that this experiment, while still providing a small turnover of one cubyl 
analogue may have been flawed due to the enzyme having poor affinity to any of the substrates. 
However, it could also be said that from these results the preliminary evidence suggests that the 
cubyl substrates were bound to the biological system, indicating that there is some affinity towards 
the unnatural substrate. This may indicate that cubyl derivative may still be bound to a different 
enzyme which could then effect an enzymatic transformation and hence instigate a metabolic 
transformation of the unnatural cubane core.  
This result therefore bodes well for cubane as a potential pharmacophore in future medicines and 
whilst not definitively proving its ability to act as a bioisostere for benzene, perhaps indicates that it 
can be accepted into biological systems that also accept a benzene ring. In addition to this the 
inability of CYP to hydroxylate the cubane core may allow for cubane based drug compounds to 
reside within biological systems for longer periods of time, thus increasing the efficacy of the drug. 
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5.4 Experimental 
Methyl cubanecarboxylate (5.46b) 
O
O
 
To a solution of 2.19 (0.148 g, 0.99 mmol) in methanol (1 ml) in a microwave reaction vessel was 
added 2 drops of sulphuric acid. The solution was then heated by microwave at 110 ºC for 15 min. 
The reaction was monitored by TLC and upon completion the solution was then added to a cool 
solution of saturated Na2CO3. Ethyl acetate (10 ml) was added and the solution was washed with 
water (2 x 10 ml) and brine (2 x 10 ml). The organic phase was then dried (MgSO4), filtered and 
evaporated to dryness to give 5.46b (0.158 g, 97%) as a white solid. M.p. 51-52 ºC (lit. 51.8 – 52.5 
ºC)40; 1H-NMR (300 MHz, CDCl3) δ: 4.21 (m, 3H), 4.00 (m, 4H), 3.67 (s, 3H); 13C-NMR (75 MHz, 
CDCl3) δ: 172.8, 55.7, 51.4, 49.5, 47.8, 45.2. 
Ethyl cubanecarboxylate (5.47b) 
O
O
 
To a solution of 2.19 (0.124 g, 0.84 mmol) in methanol (1 ml) in a microwave reaction vessel was 
added 2 drops of sulphuric acid. The solution was then heated by microwave at 110 ºC for 15 min. 
The reaction was monitored by TLC and upon completion the solution was then added to a cool 
solution of saturated Na2CO3. Ethyl acetate (10 ml) was added and the solution was washed with 
water (2 x 10 ml) and brine (2 x 10 ml). The organic phase was then dried with MgSO4, filtered and 
evaporated to dryness to give 5.47b (0.137 g, 92%) as a colourless liquid. 1H-NMR (400 MHz, 
CDCl3) δ: 4.21 (m, 3H), 4.12 (q, J = 7.1 Hz, 2H), 3.97 (m, 4H), 1.24 (t, J = 7.1Hz, 3H); 13C-NMR 
(101 MHz, CDCl3) δ: 172.73, 60.29, 55.99, 49.63, 48.02, 45.32, 14.51; HRESIMS m/z calculated 
for (C11H12O2 + Na): 199.0735; Found 199.0730. 
2-(Cubanyl)propan-2-ol (5.48b) 
OH
 
To a solution of 2.19 (0.165 g, 0.92 mmol) in anhydrous tetrahydrofuran (1 ml) was added methyl 
magnesium bromide (3M in diethyl ether, 3 ml, 2.2 eq.) at 0 ºC. The solution was stirred for 15 min. 
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then warmed to 45 ºC. The reaction was monitored by TLC and upon completion the solution was 
then added to a solution of NH4Cl at 0 ºC. Ethyl acetate (10 ml) was added and the solution was 
washed with water (2 x 10 ml) and brine (2 x 10 ml). The organic phase was then dried with 
MgSO4, filtered and evaporated to dryness to give 5.48b (0.09 g, 50%) as a white solid. M.p. 54-56 
ºC; 1H-NMR (400 MHz, CDCl3) δ: 4.04 (m, 1H), 3.91-3.86 (m, 6H), 1.16 (s, 6H); 13C-NMR (75 
MHz, CDCl3) δ: 70.38, 64.75, 48.77, 46.07, 43.16, 22.68; HRESIMS m/z calculated for (C11H14O + 
Na): 185.0942; Found: 185.0937. 
N-Methoxy-N-methylcubanecarboxamide (5.58) 
O
N
O
 
To a solution of 5.46b (0.192 g, 1.20 mmol) in tetrahydrofuran (5 ml) was added dry N,O-
dimethylhydroxylamine hydrochloride (0.170 g, 1.8 mmol). The solution was then cooled to -30 ºC 
and stirred for 10 min. i-PrMgBr (2M in tetrahydrofuran, 1.2 ml, 2.4 mmol) was added dropwise 
and the solution was maintained at -30 ºC for 20 min. The solution was poured over a saturated 
NH4Cl solution (5 ml) at 0 ºC, diluted with water (8 ml) and the aqueous layer extracted with 
diethyl ether (3 x 8 ml). The organic phase was dried with MgSO4, filtered and evaporated to 
dryness to give 5.58 (0.172g, 75%) as a white solid. M.p. 83-85 ºC; 1H-NMR (CDCl3, 300 MHz) δ: 
4.26 (m, 3H), 3.97 (m, 4H), 3.68 (s, 3H), 3.16 (s, 3H); 13C-NMR (CDCl3, 125 MHz) δ: 173.43, 
61.17, 57.04, 49.21, 46.95, 44.67, 32.25; HRESIMS m/z calculated for (C11H13NO2 + Na): 
191.0941; Found 191.0943. 
1-(Cubanyl)but-3-en-1-one (5.51b) 
O
 
A stirred solution of 5.58 (0.086 g, 0.45 mmol) in anhydrous tetrahydrofuran (5 ml) was cooled to   
-78 ºC and allowed to stir for 10 min. Allylmagnesium chloride (2.0M in tetrahydrofuran, 0.4 ml, 
0.81 mmol) was added dropwise over 10 min. via syringe pump. The solution was stirred at -78 ºC 
for a further 20 min. and the reaction monitored by TLC. The solution was then poured slowly onto 
a 0 ºC solution of sat. NH4Cl. Diethyl ether (10 ml) was added and the solution was washed with 
brine (2 x 20 ml) and water (2 x 20 ml). The organic phase was dried with MgSO4 and the solvent 
removed by rotary evaporator to give 0.073 g of a yellow liquid which was then purified by column 
chromatography (ethyl acetate 10%: petroleum spirit). Upon drying the resultant clear liquid gave 
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5.51b (0.067 g, 87%) as a yellow liquid. The compound was found to be mildly volatile under high-
vacuum and due caution should be applied. 1H-NMR (300 MHz, CDCl3) δ: 5.92 (m, 1H), 5.18-5.09 
(m, 2H), 4.28 (m, 3H), 3.98 (m, 4H), 3.20 (dt, 2H, J= 7 Hz, 1.5 Hz); 13C-NMR (75 MHz, CDCl3) δ: 
206.15, 130.39, 118.65, 63.41, 49.78, 47.90, 44.81, 43.34; HRESIMS m/z calculated for (C12H12O + 
Na): 195.0786; Found: 195.0781. 
(E)-Ethyl-3-(cubanyl)acrylate (5.50b) 
O
O
 
To a freshly prepared sample of 5.49b (~0.01 g, 0.074 mmol) in toluene (10 ml) was added ethyl 2-
(triphenylphosphoranylidene)acetate (0.051 g, 0.15 mmol, 2 mol%). The solution was heated at 
reflux and the reaction monitored by TLC. After complete conversion of starting material the 
solution was filtered through a plug of silica. The solvent was removed by rotary evaporator to give 
5.50b (0.009 g, 60%) as a colourless liquid. 1H-NMR (300 MHz, CDCl3) δ: 7.15 (d, J = 15.5 Hz, 
22H), 5.64 (d, J = 15.5 Hz, 2H), 4.17 (q, J = 7.1 Hz, 2H), 4.03 (m, 4H), 3.90 (m, 3H), 1.27 (t, J = 
7.1 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ: 167.09, 147.41, 118.09, 60.15, 58.44, 50.07, 48.50, 
44.35, 14.30; HRESIMS m/z calculated for (C13H14O2 + Na): 225.0891; Found: 225.0886. 
t-Butylcubane (5.54b) 
 
A solution of t-butyl lithium (1.2M solution in hexanes, 24 ml, 28 mmol) was added slowly to 
tetrahydrofuran stirred at -100 ºC (internal thermometer, Liq. N2/ethanol). To this was added 
dropwise a solution of 1,4-diiodocubane (5.90, 0.500 g, 1.41 mmol) in anhydrous tetrahydrofuran 
(40 ml) over a period of 15 min. The solution was allowed to stir for a further 30 min. before 
quenching with methanol (5 ml). The temperature was monitored at all times to ensure that the 
temperature did not rise above -90 ºC. The solution was then warmed to 0 ºC and water (20 ml) was 
added. The solution was then extracted with pentane (80 ml, 2 x 20 ml), dried with MgSO4, filtered 
and most of the solvent removed carefully by distillation using a 20 cm Vigreux column. The 
remaining solution was diluted with pentane (5 ml) filtered and then purified by preparatory gas 
chromatography (Inj.: 200 ºC; Col.: 165 ºC; r.t.: 5:00 min – 6:25.) to give 5.54b (10 mg, 2.8%) as a 
colourless liquid. 1H-NMR (300 MHz, MeOH-d4) δ: 0.75 (s, 9H, t-Bu), 3.76 (m, 6 H), 3.97 (m, 1 
H); 13C-NMR (75 MHz, MeOH-d4) δ: 22.68, 31.21, 44.09, 46.91, 49.89; GCMS trace m/z (C12H16) 
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at retention time 6.8 minutes: 145, 130, 115, 105, 91, 78, 57, 51; HRESIMS m/z calculated for 
(C12H16 + H): 161.1330; Found: 161.9904; calculated for (C12H16– CH3): 145.1023; Found: 
145.1012. 
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Chapter 6 Cubane Analogues of Benzyl Benzoate 
6.1 Introduction 
The synthesis of the pharmaceutical analogues to this point have been of complex and recently 
marketed or clinically approved compounds. However, in searching for novel targets for synthesis it 
became apparent that smaller, less complex compounds also have the potential to be pharmaceutical 
compounds. One prime example of this type of molecule is benzyl benzoate (Figure 6.1). Benzyl 
benzoate (6.01), a simple ester identified before the 1890s,has been used as a topical treatment for 
scabies since 1937.1 We were interested to determine if the bioactivity of a cubane analogue such as 
6.02, within yet another class of pharmaceutical compounds, the anti-parasitic or “acaricide” would 
be observed.2 
O
O
O
O
6.01 6.02  
Figure 6.1 – Benzyl benzoate (6.01) and its fully substituted cubane analogue (6.02). 
Furthermore, comparing the activity of 6.01 with 6.02 may provide insight into the mode of action 
of benzyl benzoate (6.01) in the treatment of scabies. 
6.1.1 A Brief Pharmaceutical History of Benzyl Benzoate 
Scabies infection remains a major problem throughout the world, affecting not only humans but 
also in animals (in which case it is called sarcoptic mange).3 The disease is caused by infestation of 
the epidermis by the acaricide mite Sarcoptes Scabiei. In developing world areas, due to the poorer 
standards of living, diagnosis of scabies infection is often delayed. Furthermore, it is often the case 
that patients are unable to maintain an adequate treatment regime. In addition to this, the density of 
populated areas results in a rapid transmission of the disease, which is difficult to control. These 
factors often result in rampant spread of the parasite and subsequent secondary infection. Infection 
can also result in morbidity as compromised immune systems become unable to cope with other 
infections acquired through poor standards of living.3 
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Figure 6.2 – The female scabies mite. 
Infected hosts suffer considerable discomfort as the female mite burrows beneath the surface of the 
skin to lay up to 2-4 eggs per day for up to 4-6 weeks. In this time male mites also travel across the 
skin in order to find viable sites for further infestation. The eggs hatch after 3 days and the larvae 
then burrow upwards to the surface of the skin to develop (over approximately 2 weeks) and repeat 
the infestation cycle.4 Interestingly, in a typical infestation fewer than twenty mites are present on 
the host body.5 
It is unfortunate to mention that in extreme cases, immune deficiency in patients can often result in 
a severe form of this disease. This severe case is known as crusted, or Norwegian scabies and is 
quite common in HIV sufferers in third world countries.6 However, it is also known to occur in 
patients that are undergoing medical immunosuppression.7 In this form of the disease millions of 
mites infest regions all over the body, causing crusted skin to form across the entire body. Suffice it 
to say, treatment under these circumstances results in excruciating discomfort and penetration of the 
crusted skin surface impairs topical treatment.6 
O
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Figure 6.3 – Common topical treatments of Scabies, Permethrin (6.03) and Lindane (6.04). 
Treatment of the scabies disease is often topical; the most common examples of acaricides used are 
benzyl benzoate (6.01), permethrin (6.03) and lindane (6.04). A large majority of cases, particularly 
in developing areas of the world, are treated with benzyl benzoate due to its availability, low cost 
and ease of application. Benzyl benzoate lotions or creams generally range from 10 to 25% and 
require repeated application over several days with a repeat application after 10 days to ensure any 
untreated larvae are killed. Unfortunately, the cream causes extreme discomfort in patients causing 
irritation and a burning sensation on the affected skin. This often results in patients being unable to 
maintain topical application of the cream. Further to this some central nervous system disorders 
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have been tentatively linked to the application of benzyl benzoate.8 
S
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Figure 6.4 – Thianthol (6.05) and eugenol (6.06). 
Several other treatments have proven effective including the sulphur powder Thianthol (6.05), 
which can cause dermatitis; permethrin (6.03) cream which also often causes dermatitis; oral 
Ivermectin (6.07) with a number of possible side effects. Recent investigations into eugenol (6.06) 
based compounds, such as the essential oil extracted from clove flower buds have shown similar 
activity against scabies mites with less severe side-effects although extensive long-term studies 
have not been fully performed.2 
 
Figure 6.5 – Ivermectin (6.07) a broad-spectrum antiparasitic. 
To date, benzyl benzoate remains the foremost treatment worldwide and, as such, developing a 
potential analogue which maintains similar activity with potentially less severe side effects would 
be highly beneficial. Cubane, having similar spatial properties to benzene may impart similar 
acaricidal properties to benzyl benzoate but analogues may limit the side effects seen within 
humans. The simple structure of benzyl benzoate and the presence of two different benzene rings in 
the structure should enable a number of analogues to be formed rapidly in the laboratory. 
Incorporation of various functional groups on the cubane ring may provide an adequate analogue 
with similar or enhanced acaricidal properties.9 
Benzyl benzoate is also a recognised treatment for horses suffering a hypersensitivity to the midge 
species, Culicoides. This allergic reaction is known as ‘Sweet Itch’, ‘Queensland Itch’ or more 
formally as ‘recurrent seasonal pruritis’ (Figure 6.6). The cause is generally believed to be due to an 
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increase in dietary sugar intake from grazing during the summer season which attracts the 
Culicoides midges. In treatment, a solution similar to that used to treat human infestations (25% 
solution) is applied to the affected area up to two times a day in severe cases, but less often as a 
preventative measure. It is generally applied to the sensitised area, however, it is reported to cause 
skin irritation in the areas to which it is applied.10 
 
Figure 6.6 – A severe case of pruritis on a horse’s ventral midline due to Culicoides hypersensitivity.10 
In this sense, it is unclear as to whether the solution is an insect repellent or as a treatment for the 
hypersensitivity. However, it more likely to have a repellent effect based upon its known use as an 
acaricide. Therefore, if analogues of benzyl benzoate may be synthesised then they may also be 
tested for repellent activity against Culicoides midges. 
6.1.2 The Synthesis of Benzyl Benzoate 
The synthesis of benzyl benzoate is quite straightforward. Although it was originally found as an 
active ingredient in a traditional treatment known as “balsam of Peru”, the simplicity of the 
structure allowed for straightforward synthesis of benzyl benzoate which was tested at various 
concentrations for acaricidal activity (i.e. drug potency for killing mites). 
 
Scheme 6.1 – First synthesis of benzyl benzoate. 
Unsurprisingly, the first chemical synthesis of benzyl benzoate was performed as far back as 1864, 
when it was identified as a product of sodium amalgam treatment of benzaldehyde (6.08) as a 
stream of carbon dioxide is passed over the solution (Scheme 6.1).11 
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Scheme 6.2 – The Cannizzaro reaction mechanism. 
It took almost 25 years for a more directed synthesis to be developed. In 1887, Claisen showed that, 
in a similar mechanism to the Cannizzaro reaction (Scheme 6.2), benzaldehyde in sodium 
methoxide undergoes a redox reaction yielding a white precipitate consisting of the sodium 
benzoate (6.09) and benzyl alcohol (6.11). This mixture can then be treated with acetic acid to yield 
also benzyl benzoate and methyl benzoate (6.12, Scheme 6.3).12-14 This method was shown to work 
best under anhydrous conditions with an excess of benzaldehyde (6.08) to maximise the formation 
of benzyl benzoate.13 This method was further improved by the Earl of Berkeley when he noted the 
importance of drying and purifying the aldehyde. The benzyl alcohol (6.11), which was formed 
previously was converted to the sodium salt (6.09) and the aldehyde (6.08) was then added.15 
 
Scheme 6.3 – Claisen’s synthesis of benzyl benzoate. 
The Claisen type reaction would be the stalwart method for another 19 years. Until in 1906, 
Tishchenko showed that aluminium ethoxide generated benzyl benzoate in a catalytic, controlled 
and clean manner. The most important step in this reaction mechanism is the 1,3-hydride shift in the 
hemiacetal (6.14) that is proposed to be formed (Scheme 6.4).16 
 
Scheme 6.4 – The Tishchenko reaction mechanism. 
The use of the Tishchenko reaction has been a mainstay procedure for industrial scale production. 
 138 | Chapter 6 
This is due to the fact that benzaldehyde is a readily available and cost effective starting material. 
 
Scheme 6.5 – Firouzabadi’s oxidation of dibenzyl ether. 
Other interesting methods to generate benzyl benzoate have been developed over the years. For 
example, in 1986 Firouzabadi used zinc dichromate trihydrate to oxidise dibenzyl ether (6.15) to 
benzyl benzoate.17 
 
Scheme 6.6 – Toda’s solid state synthesis of benzyl benzoate. 
In 1988 Toda et al. developed a high yielding Baeyer-Villiger reaction that employed m-
chloroperbenzoic acid (mCPBA) reacting with 1,2-diphenylethanone (6.16) in the solid state 
(Scheme 6.6). The two reagents were ground together in a mortar and pestle and allowed to react 
over 24 hours. The result was a 97% yield of the benzyl benzoate product, which could be purified 
by extraction from  aqueous NaHSO3 followed by column chromatography.18 
 
Scheme 6.7 – Shieh’s benzylation of benzoic acid to produce benzyl benzoate. 
In 2003, Shieh et al. discovered and utilised dibenzyl carbonate (6.17) as a benzyl source. Using 
DBU as a catalyst in N,N-dimethyl acetamide (DMA) under relatively high temperature conditions 
(135 ºC) they were able to react benzoic acid (6.12) to give benzyl benzoate in 86% yield (Scheme 
6.7). This was deemed an effective benzylating method particularly in compounds containing 
nitrogen and sulphur functional groups.19 
 Chapter 6 | 139 
 
Scheme 6.8 – Khan’s synthesis of benzyl benzoate from readily available starting materials. 
Where in the previous methods more expensive starting materials were required, Khan’s method in 
2003 produced benzyl benzoate from benzoic acid (6.12) and toluene (6.18). This was reportedly 
achieved via the use of an aqueous solution of NaBrO3/NaHSO3 which generated a bromine radical 
in the organic phase. This then produced α-bromotoluene which proceeded after 40 hours to form 
the ester in 95% yield (Scheme 6.8). Extension of the reaction time to 60 hours gave a 99% yield of 
benzyl benzoate, which could be purified by extraction and subsequent column chromatography.20 
 
Scheme 6.9 – Naik and Pasha’s synthesis of benzyl benzoate under aqueous conditions. 
In 2005 Naik and Pasha published a rapid method of converting benzoic acid and benzyl amine into 
benzyl benzoate via an in situ diazotisation esterification reaction. In this method an aqueous 
solution of sodium nitrite was added dropwise to a solution of the starting materials in acetonitrile. 
The reaction was complete within 25 min. with benzyl alcohol as a by-product. Once again 
extraction and column chromatography were used to purify the desired benzyl benzoate in 85% 
yield.21 
 
 
Scheme 6.10 – Werner and Barrett’s ester synthesis via an imidazolecarboxylate. 
A recent publication by Werner and Barrett in 2006 presented the use of carbonyl diimidazole 
(6.20) as an alternative method of producing benzyl benzoate from benzyl alcohol (6.11). The 
benzyl imidazolecarboxylate intermediate (6.21) was then reacted with a phenyl Grignard reagent at 
0 ºC to give the desired product in 94% yield (Scheme 6.10).22 This method is perhaps not the best 
method for the preparation of benzyl benzoate due to the need to prepare Grignard reagents and the 
fact that the reaction takes place over two steps. It does, however, provide an interesting method for 
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the production of a reactive centre that ultimately results in a high yielding C1-carbon chain 
extension. 
Clearly benzyl benzoate can be formed under numerous conditions. This ease of synthesis, coupled 
with the well-established efficacy in treating Scabies disease, makes it an affordable and easily 
accessible treatment and thus it is the primary prescription for treatment in third world countries. 
6.1.3 A Cubane Analogue of Benzyl Benzoate 
As mentioned earlier, the primary method of synthesis of benzyl benzoate is via a Cannizzaro type 
reaction which makes use of benzaldehyde (6.03) as a readily available, cost effective and stable 
starting material. However, in previous chapters (Chapter 4 and Chapter 5) the cubane 
carboxaldehyde (4.27) is not readily available, cost effective nor stable. Therefore, neither the 
Claisen method (Scheme 6.3) nor the industry standard method of Tishchenko (Scheme 6.4), are 
suitable for an analogous cubane synthesis (Figure 6.7).  
 
Figure 6.7 – The Claisen and Tishchenko methods were deemed unsuitable. 
Upon review of the other methods presented in the earlier section it is clear that a number are not 
suitable for the cubane. For example, Firouzabadi’s method requires first the dibenzyl ether (6.10), 
which would be more technically demanding to form from a cubane analogue. Similarly, Toda’s 
method using mCPBA would first require the synthesis of 1,2-dicubylethanone (6.22), which has 
not previously been reported.18 
O
6.22  
Figure 6.8 – 1,2-dicubylethanone (6.22) has previously not been synthesised. 
Fortunately, the cubane carboxylic acid (2.16) and the cubane carbinol (4.26) have been synthesised 
previously.23 Furthermore, the coupling reaction to give (6.02) would appear to be straightforward 
and require only standard laboratory conditions to proceed.  
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Scheme 6.11 – Proposed synthesis of (cubanyl)methyl cubanecarboxylate. 
Therefore, we anticipated the synthesis of a cubane analogue of benzyl benzoate can be achieved by 
the coupling of cubane carboxylic acid [2.16, which may be activated by a leaving group (6.23)] to 
cubane carbinol (4.26) to form the ester (6.02, Scheme 6.11). This method, although perhaps not 
performed under such desirable conditions as seen in the Tishchenko reaction, is determined to be 
the best option. In this way the product is formed in the fewest steps from the readily available 
cubane dicarboxylate starting material (1.13). 
6.2 Results and Discussion 
Cubane carboxylic acid was prepared as previously described in the literature as well as earlier 
chapters, using the recently published method developed within our research group.24 This method 
has eliminated the need for the toxic and pungent t-butyl thiol by using chloroform as both the 
solvent and the hydrogen atom source and has maintained identical yields of the decarboxylated 
product. 
 
Scheme 6.12 – Barton decarboxylation and hydrolysis. 
Hydrolysis of the ester (2.15), as described in 0 and Chapter 4, gave the cubane carboxylic acid 
(2.16) in good yields. Half of this material was then reduced using borane dimethyl sulphide 
according to the method mentioned in Chapter 4 (Scheme 4.11), to give the cubylcarbinol (4.26) in 
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80% yield. 
 
Scheme 6.13 – Borane reduction to the cubylcarbinol. 
In the process of the Barton decarboxylation reaction, a stable and reactive acid chloride is formed 
and the Barton ester is easily formed with 2-mercaptopyridine N-oxide and a catalytic amount of 4-
N,N-dimethylaminopyridine. If the monosubstituted acid chloride could be formed in a non 
nucleophilic solvent, the addition of cubane carbinol should subsequently form the desired ester 
with a small amount of catalytic base.  
 
Scheme 6.14 – Synthesis of (cubanyl)methyl cubanecarboxylate via the acid chloride. 
As such, the synthesis of a novel benzyl benzoate analogue (6.02) was achieved rapidly using 
simple Schotten-Baumann type reaction conditions (Scheme 6.14). After attaining a number of 
viable cubane building blocks throughout the course of our investigations we identified the potential 
for a small library of analogues. The appropriate carboxylic acid was converted to the acyl chloride 
(6.25) using oxalyl chloride and catalytic N,N-dimethylformamide. The dropwise addition of a 
solution of the corresponding alcohol (6.26) and catalytic base (4-N,N-dimethylaminopyridine) is 
added followed by stirring at room temperature gave the crude product (6.27). 
 
Scheme 6.15 –Synthesis of benzyl benzoate analogues. 
Following this method, five analogues (Table 6.1) were produced and purified by column 
chromatography in good yields (60-80%). 
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Table 6.1 – Cubane based analogues of benzyl benzoate. 
R1 R2 Product Yield 
  
O
O
6.02  
85% 
  
O
O
6.28  
87% 
  
O
O
6.24  
86% 
 I  
O
O
I
6.30  
82% 
 I  
O
O
I
6.31  
69% 
As can be seen from the table, analogues of 4-iodocubanes (6.30 and 6.31) were also synthesised. 
These were prepared opportunistically as the iodinated starting materials were made earlier as 
described in Chapter 4. They provided additional analogues that could be tested for acaricidal 
activity. Furthermore, if results lead to positive acaricidal activity the iodo analogues may be used 
in radiolabelling experiments to further elucidate the biological mode of action. 
Interestingly, the physical properties of the different analogues were quite varied. Iodinated 
analogues 6.30, 6.31 were found to be solid at room temperature with higher melting points. The 
completely cubanyl analogue (6.02) was a low melting crystalline solid. The two cubyl/benzyl 
esters (6.28 and 6.29) were liquid at room temperature. This further exemplifies the altered stacking 
patterns that cubane derivatives experience. Since cubane is a pure hydrocarbon based structure, 
however, its stacking pattern causes cubane based materials to often yield quite solid compounds. 
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In terms of spectroscopic analysis the compounds were able to be easily identified by the 
characteristic cubanyl proton resonances at and around 4.0 ppm. Furthermore, the methylene 
protons were observed at ~3.5 ppm and the results were as expected for each compound and were 
further verified by HRMS. 
6.3 Biological Studies 
The biological studies for this project were highly important to gauge the comparative efficacy of 
the analogues against benzyl benzoate. Fortunately, a number of studies have previously been 
performed by Prof. James McCarthy and Dr. Cielo Pasay, at the Queensland Institute of Medical 
Research (QIMR) and the Australian Centre for International and Tropical Health (ACITH), 
University of Queensland, Brisbane, Queensland, Australia.  
6.3.1 Methods 
The methods presented below are those performed and previously reported by Dr. Cielo Pasay.2,25 
6.3.1.1 Scabies Mites 
S. scabiei mites were collected from scabies infected pigs maintained at the Centre for Advanced 
Animal Science (CAAS), University of Queensland, Gatton Campus, Australia. To establish the 
colony, mites had been collected from naturally infected farm pigs in southeast Queensland with no 
known previous exposure to acaricide.  
6.3.1.2 Contact Bioassays 
Mite bioassays were conducted following a method previously described, with some 
modifications.25 Briefly, 35 µl of test compound diluted in mineral oil was spread evenly across the 
surface of a 30 mm x 15 mm plastic petri dish (Proscitech, Qld, Australia) using a microtip. Live 
mites were placed directly into the petri dishes in direct contact with the test compounds and 
controls. Benzyl benzoate was used as the positive control acaricide while mineral oil alone was 
used as negative control. Mites were incubated in a 28 °C humidified incubator and observed 
microscopically within the first 15–30 mins, hourly thereafter up to 4 hours, and again at the 
completion of the assay (48 hrs.). Mortality was recorded by microscopic verification of absence of 
leg movement and gut peristalsis when touched with a probe.  
6.3.2 Results and Discussion 
All esters were dissolved in mineral oil with the assistance of heating at 60 ºC. Esters 6.28 and 6.29 
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remained as clear solutions after cooling to room temperature, 6.31 gave a cloudy suspension in 
mineral oil and 6.30 was observed to precipitate upon cooling. When observed under magnification 
6.31 was seen to also be crystalline. Despite the aforementioned solubility issues all samples were 
subjected to biological screening. 
Solutions were prepared at concentrations of 50 mM and 100 mM at 50 mM, all compounds were 
observed to have no effect on scabies mites after four hours of exposure. Mites were thus exposed 
overnight after which time it was observed that, once again, no acaricidal effects were apparent. 
As a positive control assay for acaricidal activity, scabies mites were exposed to a 25 mM solution 
of benzyl benzoate. When exposed at this concentration all mites perished within 5 min. of 
exposure. A negative control assay consisting of mites exposed to pure mineral oil showed all mites 
remained alive for up to 48 hours of exposure.  
Unfortunately, these results are quite easily interpreted to indicate that cubanyl analogues of benzyl 
benzoate do not act in an analogous biological manner. Furthermore, the inability of the cubane 
core to dissolve to give a homogeneous mineral oil solution demonstrates the intrinsic differences in 
polarity and molecular interactions which ultimately results in variations in biological uptake and 
subsequent biological activity. 
6.4 Experimental 
General method 
To a stirred solution of carboxylic acid (R1, 1.00 mmol) in anhydrous methylene chloride (2 ml) 
under an atmosphere of argon was added oxalyl chloride (0.152 g, 0.105 ml, 1.20 mmol.) and a 
drop of N,N-dimethylformamide. The solution was stirred at room temperature for 30 min. to ensure 
complete conversion to the acid chloride. Upon completion the solvent was removed in vacuo (via 
the use of a water aspirator) and then purged with argon. Following this, anhydrous methylene 
chloride (2 ml) was added and the solution stirred at room temperature. To the stirred solution was 
then added a solution of alcohol (R2, 1.00 mmol) and 4-N,N-dimethylaminopyridine (1.1 mmol) in 
anhydrous methylene chloride (2 ml). The solution was stirred at room temperature for 1 hour 
before the addition of 10%. NaHCO3(aq). The solution was then extracted with methylene chloride 
(3 x 5 ml), the organic layer dried with MgSO4, filtered and the solvent removed to yield the crude 
ester. The ester was then purified via column chromatography (ethyl acetate15%: petroleum spirit) 
to give the pure ester. Yields and spectroscopic data are given in detail below. 
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(Cubanyl)methyl cubanecarboxylate (6.02) 
O
O
 
Yield: (0.225 g, 85%) White solid; M.p.: 98-99 ºC; 1H-NMR (300 MHz, CDCl3) δ: 3.88 (m, 6H), 
3.99 (m, 5H), 4.21 (m, 3H), 4.24 (s,2H); 13C-NMR (75 MHz, CDCl3) δ: 44.55, 45.18, 47.40, 47.82, 
48.56, 49.56, 55.88, 56.00, 64.57, 172.73; HRESIMS m/z calculated for (C18H16O2 + Na): 
287.1048; Found: 287.1043. 
(Cubanyl)methyl benzoate (6.28) 
O
O
 
Yield: (0.207 g, 87%) colourless oil; 1H-NMR (300 MHz, CDCl3) δ: 3.95 (m, 6H), 4.03 (m, 1H), 
4.46 (s, 2H), 7.45 (m,2H), 7.57 (m, 1H), 8.05 (m, 2H); 13C-NMR (75 MHz, CDCl3) δ: 44.64, 47.43, 
48.64, 55.90, 65.53, 128.31, 129.59, 130.54, 132.79, 166.87; HRESIMS m/z calculated for 
(C16H14O2 + Na):261.0891; Found: 261.0886.  
Benzyl cubanecarboxylate (6.29) 
O
O
 
Yield: (0.205 g, 86%) colourless oil; 1H-NMR (300 MHz, CDCl3) δ: 3.99 (m, 4H), 4.25 (m, 3H), 
5.13 (s, 2H), 7.32 (m, 5H); 13C-NMR (75 MHz, CDCl3) δ: 45.12, 47.81, 49.47, 55.69, 65.78, 
128.04, 128.06, 128.49, 136.33, 172.20; HRESIMS m/z calculated for (C16H14O2 + Na): 261.0891; 
Found: 261.0886. 
(4-Iodocubanyl)methyl 4-iodocubane-1-carboxylate (6.30) 
O
O
I  
Yield: (0.319 g, 82%) White solid; M.p. 125-126 ºC; 1H-NMR (300 MHz, CDCl3) δ: 4.00 (m, 7H), 
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4.20 (m, 6H), 4.26 (s, 2H); 13C-NMR (75 MHz, CDCl3) δ: 38.50, 45.19, 47.81, 48.38, 49.54, 54.73, 
55.70, 56.72, 63.78, 172.54; HRESIMS m/z calculated for (C18H15O2I + Na): 413.0014; Found: 
413.0009.  
(4-Iodocubanyl)methyl benzoate (6.31) 
O
O
I  
Yield: (0.096 g, 69%) White solid; M.p. 133-134 ºC; 1H-NMR (300 MHz, CDCl3) δ: 4.12 (m, 3H), 
4.24 (m, 3H), 4.49 (s, 2H), 7.43 (m, 2H), 7.55 (m, 1H), 8.00 (m, 2H); 13C-NMR (75 MHz, CDCl3) 
δ: 38.36, 48.42, 54.76, 56.68, 64.71, 128.39, 129.60, 130.17, 133.01, 166.66; HRESIMS m/z 
calculated for (C16H13O2I + Na): 386.9858; Found: 386.9872. 
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Chapter 7 A Cubane Analogue of p-Dichlorobenzene 
7.1 Introduction 
Of further interest to our research is the comparison of more simple analogues to help determine if 
cubane is a bioactive functional group or merely a non-essential addition to the active moiety of the 
drug. In the case of p-dichlorobenzene (7.01, PDB, Figure 7.1) the simple structure of the molecule 
is capable of imparting an antifungal and moth repellent effect.1 Used primarily as a disinfectant 
and space deodorant in restrooms, in terms of pharmacological application PDB inhibits the growth 
of fungal moulds and mildews as well as being a repellent to moths, tree-boring insects, and ants 
with some additional antibacterial properties.2,3 p-Dichlorobenzene’s physical properties are such 
that, with a melting point of ~53 ºC, PDB sublimes at room temperature thus giving the desirable 
effect of being both a deodoriser and sanitiser for a larger space.4 Some evidence exists for harmful 
toxicology in humans, particularly those who are in prolonged exposure to areas in which PDB is 
used.3-7 
 
Cl
Cl
Cl
Cl
7.01 7.02  
Figure 7.1 – p-dichlorobenzene and its cubane analogue. 
 
In the case of the cubane analogue (7.02, Figure 7.1), no research into the physiological effects has 
been reported. In fact, p-dichlorocubane has previously been solely the focus of computational and 
physical chemistry investigations.8,9 A simple study into its ability to inhibit fungal growth would 
allow us to determine whether cubyl analogues can provide a suitable analogue in these 
circumstances and allow us to infer that the mode of action in the target biological system is similar.  
7.1.1 A Brief History of p-Dichlorobenzene 
Historically, p-dichlorobenzene has not been used as a pharmaceutical compound, but rather as a 
disinfectant and fungal inhibitor. Some of the earliest documentation is of its use as a control for 
blue mould disease in tobacco being reported as early as the late 1930s.2 The application of PDB 
was relatively confined to being the primary constituent in urinal sanitary blocks. Recent studies 
have shown adverse effects among those who have prolonged exposure; in particular, those within 
the sanitation industry. As such the workplace safety of PDB has recently come into question and 
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the Environmental Protection Agency (EPA) of the USA anticipated PDB to be a human 
carcinogen.4 Since this time further studies into the toxic effects of PDB were made as both humans 
and mice were shown to develop leukoencephalopathy upon prolonged exposure to PDB.3 More 
recent investigation into these adverse effects has shown that PDB can alter reproductive systems 
with highly negative effects.6 
7.1.2 The Synthesis of p-Dichlorobenzene 
Among the earliest reported synthesis of PDB is that of Kekulé and Jungfleisch in the mid-1860s to 
1870s.10-12 Jungfleisch’s synthesis involved addition of iodine and chlorine to a solution of benzene 
which then formed p-dichlorobenzene along with o-dichlorobenzene (Scheme 7.1).13 
 
Scheme 7.1 – Synthesis of p-dichlorobenzene. 
Kekulé transformed 4-hydroxybenzenesulfonic acid using phosphorous pentachloride to give 
greater selectivity of the para- formation (Scheme 7.2).11 
 
Scheme 7.2 – Kekulé’s synthesis of p-dichlorobenzene. 
Following these early procedures a number of alternative reaction conditions were used with varied 
success. In particular, several authors utilised the Sandmeyer process to convert p-
phenylenediamine to p-dichlorobenzene. Using this method p-phenylenediamine was converted first 
to the diazonium salt, which is then added to a solution of copper chloride in concentrated 
hydrochloric acid, effecting the release of nitrogen gas and formation of the dichloro product 
(Scheme 7.3).14,15 
In 1952, a patent was published claiming a catalytic method for producing p-dichlorobenzene from 
benzene using iron(III) chloride.16 However, this method requires high pressures and the generation 
of liquid chlorine, a volatile corrosive and highly dangerous liquid. Further catalytic methods 
requiring rather extreme conditions of either high pressure or high temperature were also reported.17  
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Scheme 7.3 – Synthesis of p-dichlorobenzene via the Sandmeyer process. 
Table 7.1 – Influence of catalysts on the ratio 1,4-:1,2-dichlorobenzene18 
Catalyst Proportion of p-dichlorobenzene (%) 
in the dichlorobenzene fraction 
Ratio para- : ortho-
dichlorobenzene 
MnCl2+H2O ca. 50 1.03 
SbCl5  1.5 
FeCl3 or Fe ca. 59 1.49 – 1.55 
Metallosilicon organic 
compounds 
61-74 1.56 – 2.8 
AlCl3-SnCl4  2.21 
AlCl3-TiCl4  2.25 
Fe-S-PbO ca. 70  
FeCl3 – diethyl ether  2.38 
Aluminium silicate – 
hexamethylenediamine 
 2.7 
FeCl3 – S2Cl2 ca. 76  
FeCl3 – divalent organic 
sulphur compounds 
 3.3 
L-type zeolite ca. 77 8.0 
TiCl4 (FeCl3 as chlorinating 
agent) 
ca. 88 20 – 30 
Interestingly, in the early 1990s a method described zeolite (in particular zeolite L, structure type 
LTL) as a particularly good catalyst for chlorinating benzene. Further to this, more catalytic 
methods have been discovered. More recently, antimony based catalysts have been investigated 
with good results.19 The results of these various conditions are summarised in Table 7.1. From these 
results it can be seen that the optimum conditions for p-dichlorobenzene synthesis, from benzene 
and gaseous chlorine at atmospheric pressure, is with the use of a cocatalyst at lower temperatures 
between 20–80 ºC.18 FeCl3 is the most commonly used catalyst for industrial scale production of 
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PDB with quantities of over 23,000 tons being produced each year.18 
7.1.3 A Cubane analogue of p-Dichlorobenzene 
As an analogue to p-dichlorobenzene, 1,4-dichlorocubane should provide a strong structural 
similarity. As stated earlier the distance across the cubane core diagonally (2.72 Å) is almost 
equivalent to the distance across the benzene ring (2.79 Å). The comparative testing of the cubane 
analogue should provide at least some minor insight as to the pharmacological effects of a 
minimally substituted core. Interestingly, as stated earlier, it has also been noted that the cubane 
core is relatively non-toxic, whilst benzene is a known carcinogen with mutagenic side effects. 
Our previously described studies into the application of cubane as a pharmaceutical analogue have 
retained the key pharmacophores which, in some cases, most likely provide the pharmacological 
effects of the drug. In this chapter, it is hoped that screening the cubyl analogue against a variety of 
bacteria and fungi will show similar activity and potentially less toxicity than PDB. 
Fortunately, the synthesis of 1,4-dichlorocubane has been previously documented in a number of 
papers.8,9,20,21 Of these only three have documented a practiced synthetic approach to the desired 
compound.8,9,21 
 
Scheme 7.4 – Honegger's synthesis of 1,4-dichlorocubane. 
 
Following the work of Eaton and Cole as well as that of Chapman, Key and Toyne; Honegger was 
able to generate the cubane dicarboxylic acid (1.02, Scheme 7.4).22,23 Following this Honegger 
utilised the work of Della and Patney to convert the diacid to the 1,4-substituted dibromocubane 
(7.07).24 Della’s method employed the Cristol-Firth-Hunsdiecker reaction first forming the mercuric 
oxide salt of the cubane diacid (7.08) in methylene bromide with subsequent bromine addition then 
refluxing to give the desired product, 7.07 (Scheme 7.5).25 Although employing the use of highly 
toxic mercuric oxide, the reaction may be performed without anhydrous conditions, making it a 
relatively straightforward approach to halogenation of the cubane core.9,25 
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Scheme 7.5 – Cristol-Firth type Hunsdiecker Mechanism. 
Honegger then proceeded to utilise the work of McKinley et al. to perform a combined bridgehead 
halogen exchange to give the desired 1,4-dichlorocubane (7.02, Scheme 7.4).26 This final step 
employed the in situ formation of AlBr3 from excess aluminium and bromine in chloroform. The 
aluminium halide catalyst then proceeds to react with the bridgehead halogen causing halogen 
exchange with the solvent and subsequent formation of the desired product in good yield (65%) 
following workup, sublimation and recrystallisation.9 McKinley was unable to postulate a suitable 
reaction mechanism to demonstrate the nature of the transformation, however, he did state that 
“within the generation there may be the possible formation of partial carbonium ion character on the 
bridgehead”. 
 
Scheme 7.6 – Irngartinger's synthesis of 1,4-dichlorocubane. 
Irngartinger’s route (Scheme 7.6) makes use of a similar mechanistic approach, proceeding once 
again from the dicarboxylic acid (1.02). Although not explicitly reported, Irngartinger states that the 
synthesis of 1,4-dichlorocubane proceeded via an oxidative halodecarboxylation mediated by lead 
tetraacetate addition to the diacid followed by addition of LiCl.8 In this way the reaction proceeds 
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once more via a Hunsdiecker-type reaction and follows closely the procedure first elaborated by 
Kochi and reported to some extent on the cubane core by Moriarty et al.27-29 Although Moriarty’s 
work focussed on arylation of the cubane core rather than halogenation, it showed that the necessary 
radical formation induced by lead tetraacetate addition to the carboxylic acid is possible under these 
conditions. The currently accepted mechanism of the reaction was proposed by Sheldon and Kochi 
and is shown below for cubane (Scheme 7.7).29 
 
Scheme 7.7 – Lead Tetraacetate mediated oxidative Halodecarboxylation.29 
It can be seen that upon formation of the desired product PbIII(OAc)3 once again reacts with free 
carboxylic acid to further propagate the reaction. The reaction is terminated upon formation of the 
desired alkyl halide product. 
 
Scheme 7.8 – Fokin's Phase-Transfer Catalysed Synthesis of 1,4-dichlorocubane.21 
Finally, Fokin reported a phase transfer catalysed method in which cubane was heated at reflux in a 
mixture of carbon tetrachloride, aqueous NaOH and TBAB over a 5 day period (Scheme 7.8). The 
result was the monosubstituted chlorocubane. This was then subjected to the same conditions for a 
 Chapter 7 | 159 
further 10 days resulting in the formation of 1,2-, 1,3-, and 1,4-dichlorocubane (7.15, 7.16 and 7.02) 
being formed in a combined yield of 55%. This is not attractive in a preparative sense as the author 
reports that the resultant products could not be separately isolated and the formation of the initial 
cubane starting material is quite labour intensive.30 
7.2 Results and Discussion 
A simple and straightforward carbon-halogen bond formation may also be achieved via a modified 
Barton decarboxylation reaction.31 The use of carbon tetrachloride as the reaction solvent provides 
the halogen source and the reaction proceeds under photolysis and/or thermolysis conditions. 
Decarboxylative chlorination has also been demonstrated to be possible under less harsh conditions; 
sonication has been shown to be capable of generating radicals from the decomposition of carbon 
tetrachloride.32 In this way 7.02 can be synthesised quite readily via the diacyl chloride (7.17).  
Thus our reaction proceeded from the 1,4-dicarboxylic acid (1.02) and its subsequent 
transformation to the diacyl chloride using oxalyl chloride and catalytic N,N-dimethylformamide to 
give the Vilsmeier-Haack reagent. Dropwise addition of pyrithione gave the reactive Barton ester, 
which upon formation, was heated at reflux with concurrent photolysis to give 7.02, which was then 
purified by column chromatography.  
 
Scheme 7.9 – Synthesis of 1,4-dichlorocubane via Barton decarboxylation halogenation. 
In terms of physical properties 7.01 and 7.02 are colourless when pure and are crystalline solids at 
room temperature. 1,4-Dichlorocubane has a significantly higher melting point (157-158 ºC) than 
that of 1,4-dichlorobenzene (52-54 ºC).4,6,9 Sublimation of 1,4-dichlorocubane has also been shown 
to occur at 60 ºC under 15mmHg which indicates that its utility as an analogous space deodorant is 
unlikely.8,9 Furthermore, from limited exposure to the olfactory sense it does not impart a similar 
scent to its benzene analogue. 
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7.3 Biological Studies 
Biological studies were performed by Prof. Peter Parsons of the Drug Discovery group at the 
Queensland Institute of Medical Research (QIMR). 
7.3.1 Methods 
In order to compare the antibacterial activity of the two analogues both samples were diluted in 
DMSO at a concentration of 50 mg/ml. 1,4-Dichlorocubane (7.02) was found to be soluble upon 
warming in DMSO, but upon cooling, the sample would precipitate to a minor extent. Spot samples 
of the solution were then tested at various dilutions against Escherichia Coli and Streptococcus 
Salivarius grown on agar plates 
A sample of Aspergillus sp. was also isolated and grown with various dilutions of the two analogues 
in RPMI1640 medium and inspected for the presence of colonies via observation of the growth 
media. 
7.3.2 Results and Discussion 
Only very modest antibacterial activity was observed from both 7.01 and 7.02 at a concentration of 
1 mg/ml however, at 0.1 mg/ml both drugs were seen to be ineffective antibacterial agents. 
 In the case of antifungal activity it was observed that Aspergillus growth was blocked by both 
drugs at 0.25 mg/ml but not at 0.05 mg/ml. 
It is difficult to draw firm conclusions from the results. p-Dichlorobenzene (7.01) has been reported 
as only a modest antibacterial and antifungal, little substantive data exists to support this conjecture. 
Nevertheless, the cubyl analogue 7.02 has a similar spectrum of activity based upon the limited 
evidence observed. It was also observed that neither compound was soluble and as such 
antibacterial investigations may have been compromised.  
From the limited results, we can conclude that a cubyl analogue of dichlorobenzene has a similar 
activity in solution. However, it is less soluble and less volatile when compared to dichlorobenzene. 
Since dichlorobenzene is generally utilised for its ability to sublimate at room temperature it may 
also be stated that the cubyl analogue (7.02), which does not appear to sublime to the same extent, 
would not provide a direct analogue for dichlorobenzene in application. However, in terms of 
biological effect the cubyl analogue can be seen to be acting in a similar manner to that of the 
original compound (7.01). Its human toxicity profile, however, could be better. 
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As dichlorobenzene’s mode of application is via sublimation it follows that a test in which fungal 
growth inhibition is measured in a dry environment would be more applicable. It will require more 
experimentation to determine whether the cubyl analogue has a similar pesticidal and anti-fungal 
activity and its ability to sublime at room temperature in order to act as a space deodoriser. Should 
the cubyl analogue be applied as a direct replacement for PDB in this manner then the deleterious 
side effects may be lessened as the biological uptake may be quite different. 
7.4 Experimental 
1,4-Dichlorocubane (7.02) 
Cl
Cl  
To a stirred solution of 1,4-cubanedicarboxylic (1.02, 0.510 g, 2.65mmol) in methylene chloride (10 
ml) was added oxalyl chloride (0.50 ml, 0.75 g, 5.80 mmol) and a drop of N,N-dimethylformamide. 
The solution was stirred at room temperature for 30 min. before the solvent was removed in vacuo. 
The resulting acid chloride was dissolved in anhydrous carbon tetrachloride (5 ml) and added to a 
stirred solution of 2-mercaptopyridine N-oxide sodium salt (0.870 g, 5.80 mmol) and catalytic 4-
N,N-dimethylaminopyridine (0.02 g, 0.16 mmol) in anhydrous carbon tetrachloride (10 ml). The 
solution was stirred with irradiation from a 500 W Tungsten lamp for 1 hour. The solvent was 
removed and the resultant residue was purified via column chromatography to give the desired 
product (7.02, 0.261 g, 57%) as a pale yellow solid. M.p. 156-158 ºC (Lit. 157-158 ºC)9; 1H-NMR 
(500 MHz, CDCl3) δ: 4.12 (s, 6H); 13C-NMR (125 MHz, CDCl3) δ: 52.4, 72.9. 
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Chapter 8 Conclusion 
The research performed herein has provided illumination as to the potential for cubane based 
analogues to perform as substitutes for phenyl groups. The results were quite comparable to those 
seen in the phenyl drug analogues. Furthermore, additional functional group modification to the 
cubane core may provide a solution to the lowered activity. The evolution and mutation of bacteria, 
viruses, parasites and other genetic illnesses continuously requires novel drug treatments and as 
such, cubane may still hold an answer to this problem. 
In the case of Vorinostat, Leteprinim and Cefaclor the functionality of the molecule is not entirely 
imparted from the phenyl group of course, but rather from pharmacophores bound to the functional 
group. In stating this, however, it is important to note that while the phenyl group may not impart 
activity in the molecule, it is by no means to be disregarded as an integral part of the molecule in 
terms of biological uptake, metabolism or reactivity. The same may also be said for the cubane 
moiety. Cubane may not currently be shown to provide drugs which are suitably active or 
biologically available; however, cubane may eventually provide the key for a drug which may be 
designed for a specific target. The benefit of cubane in this instance is that it provides a unique 
building block capable of forming poly-substituted molecules whose unique binding angles may be 
found to be necessary for particular binding sites. However, little is known of the biological activity 
across a spectrum of pharmaceutical drug targets.  
Indeed, cubane based drugs may provide a novel core from which many innovative pharmaceuticals 
can be founded. From the results reported within, the basic activity of the drug has not been 
inhibited per se. This may be attributed to the fact that the cubane structure does not replace the 
active moiety of the drug (Chapter 2, Chapter 3). Although, as expected, variations to the biological 
uptake, metabolism and lifetime of the drug is altered quite substantially (Chapter 5) the desired 
effect was still observed to some extent. 
The results reported in Chapter 2, Chapter 3 and Chapter 5 highlight that the cubane moiety is 
certainly capable of being incorporated in biological systems. P450 enzymes displayed a strong 
binding to cubyl derivatives in vitro (Chapter 5). It was also observed that the cubane analogues 
were not hydroxylated to any extent except when alkylated, as was the case of t-butyl cubane 
(5.45b). Cubane may therefore provide a framework that imparts a longer biological lifetime for 
active molecules. As such, the overall activity of such drugs may be observed to be greater than 
other non-cubyl analogues. 
This study may also have great impact in the field of pesticidal compounds which are often reported 
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to show diminishing activity as the target pest develops a biological response (usually enzymatic) 
which is capable of purging the pesticide. Interestingly, results seen in both Chapter 6 and Chapter 7 
indicate that the inherently nontoxic nature of cubane makes pesticidal derivatives less deleterious 
to the target pest. Cubyl analogues of benzyl benzoate (Chapter 6) showed that the activity of the 
drug appears to be imparted by the presence of both of the two phenyl groups. This was 
demonstrated by substitution of various cubyl derivatives that showed significant decrease in the 
activity of the molecule against scabies mites. This result, in itself, is important and warrants further 
investigation to determine the biological mechanism of benzyl benzoate toxicity towards scabies 
mites. However, further studies into a wider array of pesticidal derivatives remain an intriguing 
avenue of investigation and studies towards the metabolism of the cubane core in biological systems 
also remains necessary in order to develop a more directed approach to synthesis. 
It is unfortunate to report that despite great efforts to complete the synthesis of a cubyl analogue in 
the cephalosporin family we were unable to develop a satisfactory method of coupling the newly 
derived cubyl amino acid to the cephalosporin core (Chapter 4). However, we have developed a 
good method for the synthesis of an enantioenriched unsubstituted cubyl amino acid (4.29) which 
may be used in future novel drug analogues. Additionally, a number of methods suitable for the 
often fragile cubane framework have also been developed: the formation of novel cubyl amides 
(e.g. 2.20); Michael addition reactions using a cubyl acrylamide (3.27) as the Michael acceptor have 
been demonstrated; and the direct transformation of the cubane carboxaldehyde (4.27), formed via a 
Ley oxidation, is capable of generating both Wittig (e.g. 5.50b) and Strecker (e.g. 4.76) reaction 
products, avoiding excessive loss of the labile aldehyde intermediate (4.27) hence, improving the 
yield. These methods may thus be utilised to good effect in later syntheses of cubane derivatives. 
Although cubane chemistry can occasionally become quite fickle, the robust nature of the cubane 
core does allow for a number of transformations to be performed. The use of synthetic techniques, 
both old and new to generate novel functionality on the cubane core is exciting and provides an 
excellent avenue of exploration in the scientific community as substituents can be placed in further 
spatial directions that are unavailable to the benzene core. Although a large variety of syntheses 
have been reported there remains a large number of synthetic routes that remain to be discovered. 
Research into other transformations will hopefully provide stronger foundations for future 
transformations on the cubane core. 
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Scheme 8.1 – Bridgehead alkynylation using Silver(I) acetylides.1 
For instance, investigations into carbon bond extension at the bridgehead of bicyclic cages 
(8.01→8.02) have already been undertaken in our laboratory (Scheme 8.1).1 In future cytochrome 
P450 research a cubyl alkyne may be tested for ketene formation as previously reported for aryl 
alkynes. It has been reported that aryl alkynes, upon oxidation to a reactive ketene intermediate 
such as 8.04, are capable of inactivating human P450s via a covalent adduction to the apoprotein 
(Scheme 8.2).2  
 
Scheme 8.2 – A cubyl alkyne may potentially be oxidised via P450 oxidation. 
Although it has previously been noted that cubyl Grignard reagents and cubyl lithium species have 
been synthesised in the past, little has been demonstrated in the way of carbon-carbon bond 
formation and the application of these methods in forming novel compounds.3 In fact, the majority 
of cubyl compounds reported in the literature are derived from the carboxylic acid functional group 
present from the initial generation of the cubane core. Therefore, further investigation into carbon-
carbon bond forming reactions would provide further synthetic potential for cubane compounds. 
N
N
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N
N
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N
N
O
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8.05 8.06 8.07  
Figure 8.1 – 4-anilidopiperidines, powerful clinical analgesics. 
Given the results of LogP studies given in Chapter 2 it is possible that cubyl derivatives may have a 
greater penetration of the central nervous system. As such, drugs targeted towards CNS activity 
hold great potential for future application. Analgesics are a particularly important synthetic target 
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within the scientific community, not only in order to further understand the nature of opioid 
receptors but also to develop a less toxic pain relief for the clinical treatment of pain.4  
Currently, the 4-anilidopiperidines (8.05) such as fentanyl (8.06) and its analogues are known as the 
most potent of analgesics with some such as ohmefentanyl (8.07) having reported activity thousands 
of times more potent than morphine.5 However, whilst highly active and displaying a rapid onset of 
analgesia they have only a short duration of action.6 
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Figure 8.2 – Potential cubyl analogues of some 4-anilidopiperidines. 
From the results of Chapter 2and Chapter 5 we may be able to synthesise a cubyl analogue that is 
capable of greater CNS penetration or perhaps an extended duration of action as they may not be 
enzymatically modified in a similar mode of action. Furthermore, they may provide yet another 
method from which greater knowledge of the structure-activity relationship of these drugs and their 
target receptors may be obtained. 
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Scheme 8.3 – Proposed synthesis of a cubyl analogue of fentanyl (8.06). 
Their synthesis may be achieved as detailed in Scheme 8.3, which demonstrates one of only a few 
carbon-carbon bond formations reported for the cubane core.7 Initially, ethylene oxide (8.11) is 
reacted with a cubyl lithium species in order to generate the 2-cubanyl ethanol (8.12) which may 
then be further converted to the bromo derivative (8.13) in order to couple to the required, ketal 
protected, piperidone core (8.14). Upon forming 8.15, synthesis is proposed to follow the standard 
fentanyl synthesis to give the final analogue (8.09). 
NH2
OHO
4.80  
Figure 8.3 – The cubyl amino acid, 2-amino-2-(cubanyl)acetic acid (4.80). 
As has been stated earlier, further research into the development of drugs based around the cubyl 
amino acid (4.80) may provide an excellent building block for a large variety of cubane 
pharmaceuticals. In particular, the completion of the cephalosporin analogues may yet be achieved 
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through the use of Penicillin G acylase (PGA) as proposed in Section 4.2 (Scheme 8.4). 
 
Scheme 8.4 – The use of PGA in the synthesis of cubyl cephalosporin analogues. 
The cubane moiety has great potential in pharmaceutical chemistry and may indeed be acting as a 
bioisostere for the phenyl ring in some instances, although imparting quite different biological 
uptake properties compared to the phenyl analogues. Ultimately, the compounds studied in this 
thesis are only a small sample of the many hundreds of potential targets. As such, major conclusions 
regarding the use of cubane as a bioisostere for benzene cannot be drawn until more systems are 
investigate. It may be found that cubane derived drugs become targeted towards areas of the body 
that are inaccessible to the analogous phenyl derivative. In addition to this, modifications of the 
cubane framework may make the drug more accessible to the original target area thus providing a 
potentially less toxic and more biologically persistent analogue. The possibilities for future work 
with cubane are great and, whilst limited in some ways, cubane is an interesting, exciting and 
chemically unique molecule that has provided and will continue to provide a fantastic focus for 
investigation. 
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Appendices 
Appendix 1 Publications 
During the course of this study a publication was produced that was related to the overall theme of 
the study. The experimentation was performed during the research period and should be viewed as 
further work undertaken throughout the course of postgraduate research. As such the publication is 
supplied as an appendix and may pique interest of the reader. 
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Appendix 2 Crystallographic Data 
The following is the compiled crystallographic data pertaining to Chapter 2. 
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Figure A2.1 – Crystal structure of 2.02. 
 
 
Figure A2.2 – Crystal lattice formation of 2.02. 
 
Table 1 - Crystal data and structure refinement for 2.02. 
______________________________________________________________________________ 
Identification code  2.02 
Empirical formula  C16H22N2O3 
Formula weight  290.36 
Temperature  293(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 5.2841(17) Å α = 99.06(4)°. 
 b = 7.616(3) Å β = 97.15(3)°. 
 c = 17.736(7) Å  γ = 90.22(3)°. 
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Volume 699.2(5) Å3 
Z 2 
Density (calculated) 1.379 Mg/m3 
Absorption coefficient 0.096 mm-1 
F(000) 312 
Crystal size 0.4 x 0.05 x 0.05 mm3 
Theta range for data collection 3.12 to 25.00°. 
Index ranges -6<=h<=6, -9<=k<=9, -21<=l<=21 
Reflections collected 2916 
Independent reflections 2916 [R(int) = 0.0000] 
Completeness to theta = 25.00° 99.8%  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1 and 0.59575 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2916 / 0 / 192 
Goodness-of-fit on F2 0.961 
Final R indices [I>2sigma(I)] R1 = 0.0855, wR2 = 0.1922 
R indices (all data) R1 = 0.1492, wR2 = 0.2171 
Extinction coefficient 0.010(5) 
Largest diff. peak and hole 0.382 and -0.297 e.Å-3 
______________________________________________________________________________ 
 
Table 2 - Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 
103)for 2.02.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
______________________________________________________________________________ 
 x y z U(eq) 
______________________________________________________________________________ 
C(1) -5697(9) 11822(7) 3381(3) 29(1) 
C(2) -5753(9) 13659(7) 3871(3) 36(2) 
C(3) -8507(10) 13261(9) 4021(3) 40(2) 
C(4) -8424(9) 11400(8) 3522(3) 33(2) 
C(5) -7449(10) 12471(8) 4735(3) 42(2) 
C(6) -7413(10) 10620(8) 4232(3) 39(2) 
C(7) -4655(10) 10988(7) 4095(3) 33(2) 
C(8) -4710(11) 12879(8) 4592(3) 41(2) 
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C(9) -4545(9) 9911(8) 2255(3) 28(1) 
C(10) -3141(10) 9827(8) 1571(3) 44(2) 
C(11) -3862(9) 8274(7) 953(3) 31(1) 
C(12) -2302(10) 8228(7) 295(3) 37(1) 
C(13) -2847(10) 6688(7) -343(3) 34(1) 
C(14) -1172(9) 6638(7) -961(3) 32(1) 
C(15) -1588(10) 5043(7) -1571(3) 38(2) 
C(16) 279(10) 4845(8) -2130(3) 33(1) 
N(1) -4760(7) 11522(6) 2658(2) 29(1) 
N(2) -105(8) 3433(7) -2670(3) 41(1) 
O(1) -5400(6) 8605(5) 2473(2) 39(1) 
O(2) 1441(7) 3089(5) -3235(2) 49(1) 
O(3) 2121(7) 5846(5) -2083(2) 49(1) 
______________________________________________________________________________ 
 
Table 3 - Bond lengths [Å] and angles [°] for 2.02. 
_____________________________________________________ 
C(1)-N(1)  1.416(6) 
C(1)-C(2)  1.529(7) 
C(1)-C(4)  1.535(7) 
C(1)-C(7)  1.547(7) 
C(2)-C(8)  1.535(8) 
C(2)-C(3)  1.549(7) 
C(3)-C(5)  1.530(9) 
C(3)-C(4)  1.552(8) 
C(4)-C(6)  1.515(9) 
C(5)-C(8)  1.539(7) 
C(5)-C(6)  1.546(7) 
C(6)-C(7)  1.539(7) 
C(7)-C(8)  1.568(7) 
C(9)-O(1)  1.226(6) 
C(9)-N(1)  1.332(6) 
C(9)-C(10)  1.492(7) 
C(10)-C(11)  1.493(7) 
C(11)-C(12)  1.507(7) 
C(12)-C(13)  1.496(7) 
C(13)-C(14)  1.487(6) 
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C(14)-C(15)  1.490(7) 
C(15)-C(16)  1.475(7) 
C(16)-O(3)  1.220(6) 
C(16)-N(2)  1.319(7) 
N(2)-O(2)  1.365(5) 
N(1)-C(1)-C(2) 123.5(5) 
N(1)-C(1)-C(4) 125.5(5) 
C(2)-C(1)-C(4) 90.9(4) 
N(1)-C(1)-C(7) 125.6(5) 
C(2)-C(1)-C(7) 91.3(4) 
C(4)-C(1)-C(7) 89.4(4) 
C(1)-C(2)-C(8) 90.2(4) 
C(1)-C(2)-C(3) 90.0(4) 
C(8)-C(2)-C(3) 89.6(5) 
C(5)-C(3)-C(2) 90.0(4) 
C(5)-C(3)-C(4) 89.7(5) 
C(2)-C(3)-C(4) 89.5(4) 
C(6)-C(4)-C(1) 90.8(4) 
C(6)-C(4)-C(3) 90.1(5) 
C(1)-C(4)-C(3) 89.7(4) 
C(3)-C(5)-C(8) 90.2(5) 
C(3)-C(5)-C(6) 89.8(5) 
C(8)-C(5)-C(6) 90.7(4) 
C(4)-C(6)-C(7) 90.4(5) 
C(4)-C(6)-C(5) 90.5(5) 
C(7)-C(6)-C(5) 90.1(4) 
C(6)-C(7)-C(1) 89.4(4) 
C(6)-C(7)-C(8) 89.9(4) 
C(1)-C(7)-C(8) 88.3(4) 
C(2)-C(8)-C(5) 90.2(4) 
C(2)-C(8)-C(7) 90.3(4) 
C(5)-C(8)-C(7) 89.3(4) 
O(1)-C(9)-N(1) 119.6(5) 
O(1)-C(9)-C(10) 124.2(5) 
N(1)-C(9)-C(10) 116.1(5) 
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C(9)-C(10)-C(11) 114.7(4) 
C(10)-C(11)-C(12) 112.0(4) 
C(13)-C(12)-C(11) 115.8(4) 
C(14)-C(13)-C(12) 114.1(4) 
C(13)-C(14)-C(15) 114.4(4) 
C(16)-C(15)-C(14) 115.2(4) 
O(3)-C(16)-N(2) 121.7(5) 
O(3)-C(16)-C(15) 123.4(5) 
N(2)-C(16)-C(15) 114.8(5) 
C(9)-N(1)-C(1) 123.6(5) 
C(16)-N(2)-O(2) 121.5(4) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
 
Table 4 - Anisotropic displacement parameters (Å2x 103)for 2.02.  The anisotropic displacement 
factor exponent takes the form: -2π2[ h2a*2U11 + ... + 2 h k a*b*U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 34(3)  28(4) 28(3)  7(3) 13(3)  4(3) 
C(2) 48(3)  18(3) 44(4)  4(3) 21(3)  2(3) 
C(3) 41(3)  45(4) 37(4)  5(3) 15(3)  13(3) 
C(4) 31(3)  31(4) 31(3)  -7(3) -1(3)  -8(3) 
C(5) 54(4)  40(4) 33(4)  -1(3) 24(3)  6(3) 
C(6) 55(4)  37(4) 27(3)  2(3) 15(3)  -8(3) 
C(7) 41(3)  29(4) 30(3)  3(3) 7(3)  10(3) 
C(8) 49(4)  39(4) 31(4)  -8(3) 7(3)  3(3) 
C(9) 27(3)  33(4) 22(3)  -2(3) -1(3)  -7(3) 
C(10) 57(4)  31(4) 45(4)  -5(3) 21(3)  -18(3) 
C(11) 31(3)  29(4) 33(3)  2(3) 5(3)  -5(3) 
C(12) 46(3)  31(4) 32(3)  4(3) 8(3)  -7(3) 
C(13) 40(3)  35(4) 27(3)  5(3) 5(3)  -2(3) 
C(14) 38(3)  21(3) 35(3)  -1(3) 6(3)  -1(3) 
C(15) 45(3)  28(4) 38(4)  -2(3) 11(3)  -6(3) 
C(16) 38(3)  28(4) 34(4)  5(3) 11(3)  -5(3) 
N(1) 43(3)  19(3) 26(3)  4(2) 4(2)  -7(2) 
 Appendix 2 | 187 
N(2) 49(3)  39(3) 36(3)  -11(3) 29(3)  -11(2) 
O(1) 56(2)  24(2) 42(3)  7(2) 20(2)  -15(2) 
O(2) 64(3)  42(3) 41(3)  -2(2) 21(2)  -3(2) 
O(3) 57(3)  28(3) 62(3)  -7(2) 26(2)  -21(2) 
______________________________________________________________________________ 
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Appendix 3 Biological results pertaining to Chapter 3 
Biological studies for the cubyl analogue of Leteprinim were performed by Dr. Cathrin Nourse, a 
postdoctoral researcher in Prof. Helen Cooper’s Neuronal Migration Laboratory at the Queensland 
Brain Institute at The University of Queensland, St. Lucia.  
Captured images of the neuronal outgrowth (as pertaining to Section 3.3) are supplied within this 
appendix. 
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Appendix 4 Nuclear Magnetic Resonance Spectrum 
All novel NMR spectrum gathered throughout the course of the study are supplied in this Appendix. 
Spectra are arranged by chapter in order of synthesis. 
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4
Aminocubane hydrochloride (2.21) 
NH3Cl
 
1H, 300 MHz, D2O 
  
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
43
.4
0
48
.9
1
50
.5
8
64
.9
5
Aminocubane hydrochloride (2.21) 
NH3Cl
 
13C, 100 MHz, D2O (Dioxane Reference) 
  
  
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5 ppm
1.
23
1.
34
1.
62
2.
27
2.
33
4.
10
3.
00
0
4.
05
7
4.
44
9
4.
50
6
2.
02
1
8-Ethoxy-8-oxooctanoic acid (2.22) 
O
O
O
HO
 
1H, 300 MHz, CDCl3 
  
 
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
14
.2
3
24
.4
4
24
.7
1
28
.6
4
28
.6
9
33
.8
0
34
.2
4
60
.2
2
17
3.
77
17
9.
22
8-Ethoxy-8-oxooctanoic acid (2.22) 
O
O
O
HO
 
13C, 100 MHz, CDCl3 
  
 
10 9 8 7 6 5 4 3 2 1 0 ppm
1.
23
1.
32
1.
60
2.
15
2.
26
3.
91
4.
10
5.
93
3.
43
0
4.
32
5
4.
48
1
2.
06
7
2.
22
5
4.
00
0
5.
41
5
0.
93
9
Ethyl 8-(cubanylamino)-8-oxooctanoate (2.20) 
H
N
O
O
O
 
1H, 400 MHz, CDCl3 
  
  
102030405060708090100110120130140150160170180190200 ppm
14
.2
4
24
.7
5
25
.2
4
28
.7
8
28
.8
2
34
.2
5
36
.1
8
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.9
2
47
.8
1
52
.5
8
60
.1
9
66
.6
1
17
2.
28
17
3.
79
Ethyl 8-(cubanylamino)-8-oxooctanoate (2.20) 
H
N
O
O
O
 
13C, 100 MHz, CDCl3 
  
  
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm
1.
22
1.
45
1.
91
2.
05
3.
84
3.
88
4.
00
8.
40
8.
63
10
.3
0
4.
21
9
4.
15
6
1.
59
9
1.
95
8
4.
00
0
2.
95
8
0.
95
0
0.
77
5
0.
76
0
N1-(Cubanyl)-N8-hydroxyoctanediamide (2.02) 
H
N
O
N
H
O
OH
 
1H, 400 MHz, DMSO-d6 
  
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
24
.8
6
28
.2
3
32
.1
3
34
.9
6
41
.8
8
46
.6
9
51
.8
2
65
.9
2
16
8.
97
17
1.
38
N1-(Cubanyl)-N8-hydroxyoctanediamide (2.02) 
H
N
O
N
H
O
OH
 
13C DEPT-135, 100 MHz, DMSO-d6 
13C, 100 MHz, DMSO-d6 
  
Chapter 3
  
  
1-Methyl-4-(t-butoxycarbonylamino)cubane carboxylate (3.29) 
H
N
O
O
O
O
 
1H, 300 MHz, CDCl3 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
1.
43
3.
68
4.
07
9.
16
6
3.
43
2
6.
53
5
  
  
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
28
.4
4
44
.6
9
50
.2
8
51
.6
3
56
.0
8
66
.4
2
17
2.
85
1-Methyl-4-(t-butoxycarbonylamino)cubane carboxylate(3.29) 
H
N
O
O
O
O
 13C DEPT-135, 100MHz, CDCl3 
13C, 100 MHz, CDCl3 
  
  
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
2.
13
3.
64
4.
14
0.
56
2
3.
07
3
6.
00
0
4-(Methoxycarbonyl)cubane ammonium hydrochloride (3.30) 
O
O
NH3Cl
 
1H, 300 MHz, D2O 
  
  
220 200 180 160 140 120 100 80 60 40 20 0 ppm
44
.9
3
47
.7
4
52
.2
8
56
.1
3
64
.1
7
17
4.
96
4-(Methoxycarbonyl)cubane ammonium hydrochloride (3.30) 
O
O
NH3Cl
 
13C, 75 MHz, D2O 
  
  
Methyl 4-acrylamidocubane carboxylate (3.27) 
O
O
H
N
O
 
1H, 300 MHz, CDCl3 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
3.
69
4.
16
5.
64
5.
66
6.
08
6.
26
6.
30
3.
00
0
5.
94
7
0.
94
7
1.
76
3
0.
97
6
  
  
Methyl 4-acrylamidocubane carboxylate (3.27) 
O
O
H
N
O
 13C DEPT-135, 75 MHz, CDCl3 
13C, 75 MHz, CDCl3 
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
45
.0
9
50
.2
3
51
.5
2
55
.7
6
66
.6
0
12
7.
00
13
0.
01
16
4.
74
17
2.
65
  
  
Methyl 4-[3-(6-amino-9H-purin-9-yl)propanamido]cubane carboxylate (3.25) 
O
O
N
H
ON N
H2N
N
N  
1H, 400 MHz, DMSO-d6 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
2.
68
3.
61
3.
95
3.
96
4.
00
4.
01
4.
34
7.
96
8.
04
8.
31
8.
73
2.
25
3
3.
19
1
6.
00
0
2.
31
1
0.
98
4
1.
11
3
1.
40
3
1.
06
3
  
  
Methyl 4-[3-(6-amino-9H-purin-9-yl)propanamido]cubane carboxylate (3.25) 
O
O
N
H
ON N
H2N
N
N  
13C, 100 MHz, DMSO-d6 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
35
.1
0
44
.1
8
49
.4
4
51
.2
0
54
.9
7
65
.9
2
79
.1
8
12
3.
91
14
5.
51
14
8.
27
15
6.
69
16
8.
83
17
1.
71
  
  
Methyl 4-{3-[6-oxo-1H-purin-9(6H)-yl]propanamido}cubane carboxylate (3.24) 
O
O
N
H
OHN N
O
N
N  
1H, 400 MHz, MeOD-d4 
14 13 12 11 10 9 8 7 6 5 4 3 2 1 ppm
2.
67
3.
60
3.
94
4.
00
4.
33
7.
95
8.
03
8.
71
12
.2
6
2.
06
7
3.
00
0
5.
93
6
2.
00
0
0.
94
8
1.
03
3
0.
98
4
0.
79
0
  
  
Methyl 4-{3-[6-oxo-1H-purin-9(6H)-yl]propanamido}cubane carboxylate (3.24) 
O
O
N
H
OHN N
O
N
N  
13C DEPT-135, 100 MHz, MeOD-d4 
13C, 100 MHz, MeOD-d4 
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
35
.0
7
44
.1
5
49
.4
1
51
.1
6
54
.9
5
65
.9
0
12
3.
88
14
0.
34
14
5.
43
14
8.
23
15
6.
62
16
8.
79
17
1.
67
17
2.
10
  
  
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
2.
61
3.
67
3.
74
4.
22
7.
63
7.
88
8.
65
2.
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48
1
3.
35
5
2.
18
6
0.
95
4
0.
87
8
1.
00
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4-{3-[6-Oxo-1H-purin-9(6H)-yl]propanamido}cubane carboxylic acid (3.02) 
OH
O
N
H
OHN N
O
N
N  
1H, 400 MHz, MeOD-d4 
  
  
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
35
.3
5
44
.4
5
48
.5
7
59
.4
5
65
.9
6
12
4.
15
13
7.
41
14
9.
21
15
1.
42
16
4.
44
16
8.
80
17
5.
33
4-{3-[6-Oxo-1H-purin-9(6H)-yl]propanamido}cubane carboxylic acid (3.02) 
OH
O
N
H
OHN N
O
N
N  
13C DEPT-135, 100 MHz, DMSO-d6 
13C, 100 MHz, DMSO-d6 
 
  
  
Methyl 4-(3-methoxypropanamido)cubane carboxylate (3.32) 
H
N
O
O
O
O
 
1H, 500 MHz, CDCl3 
10 9 8 7 6 5 4 3 2 1 0 ppm
1.
65
2.
44
3.
36
3.
61
3.
68
4.
11
6.
76
1.
36
7
1.
94
2
2.
92
3
1.
95
3
3.
00
0
6.
06
4
0.
94
8
  
Methyl 4-(3-methoxypropanamido)cubane carboxylate (3.32) 
H
N
O
O
O
O
 13C DEPT-135, 75 MHz, CDCl3 
13C, 75 MHz, CDCl3 
  
Chapter 4
  
  
4-Iodocubanecarboxylic acid (4.57) 
I
HO
O  
1H, 300 MHz, CDCl3 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
4.
29
4.
41
3.
00
0
3.
04
3
  
  
10 9 8 7 6 5 4 3 2 1 0 ppm
1.
42
3.
78
4.
06
4.
22
1.
19
3
2.
01
2
2.
71
2
2.
68
7
(4-Iodocubanyl)methanol (4.58) 
I
OH
 
1H, 300 MHz, CDCl3 
  
  
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
38
.8
0
47
.8
1
54
.6
7
59
.0
1
63
.1
4
(4-Iodocubanyl)methanol (4.58) 
I
OH
 13C DEPT-135, 75 MHz, CDCl3 
 
 
13C, 75 MHz, CDCl3 
  
4-Iodocubanecarbaldehyde (4.59) 
I
O
H
 
1H, 300 MHz, CDCl3 
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
4.
28
4.
51
9.
73
3.
00
6
3.
00
0
0.
92
0
  
  
4-Iodocubanecarbaldehyde (4.59) 
I
O
H
 
13C, 75 MHz, CDCl3 
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
35
.6
0
49
.0
0
54
.8
3
62
.7
7
19
7.
12
  
  
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
3.
51
3.
54
3.
76
4.
06
4.
12
4.
20
7.
32
1.
96
8
0.
99
1
7.
20
3
5.
00
0
(S)-2-{[(R)-2-Hydroxy-1-phenylethyl]amino}-2-(4-iodocubanyl)acetonitrile (4.64) 
N
H
CN
OH
RS
I  
1H, 300 MHz, CDCl3 
  
  
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
36
.9
7
47
.6
6
49
.7
3
54
.0
3
57
.5
4
62
.8
9
67
.1
1
11
7.
55
12
7.
58
12
8.
32
12
8.
84
13
8.
07
(S)-2-{[(R)-2-Hydroxy-1-phenylethyl]amino}-2-(4-iodocubanyl)acetonitrile (4.64) 
N
H
CN
OH
RS
I  13C DEPT-135, 75 MHz, CDCl3 
13C, 75 MHz, CDCl3 
  
  
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
3.
60
3.
75
3.
92
4.
38
7.
33
1.
00
3
1.
03
5
10
.7
74
5.
00
0
(R)-2-{[(S)-2-Hydroxy-1-phenylethyl]amino}-2-(4-iodocubanyl)acetonitrile (4.65) 
N
H
CN
OH
SR
I  
1H, 300MHz, CDCl3 
  
  
(R)-2-{[(S)-2-Hydroxy-1-phenylethyl]amino}-2-(4-iodocubanyl)acetonitrile (4.65) 
N
H
CN
OH
SR
I  
13C, 75 MHz, CDCl3 
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
29
.6
7
36
.7
7
47
.9
6
48
.3
3
50
.3
1
50
.9
2
53
.9
2
54
.6
4
54
.8
9
58
.0
8
62
.9
7
66
.5
8
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7.
35
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8.
35
12
8.
88
13
9.
32
  
  
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
4.
21
4.
87
7.
44
7.
76
8.
48
7.
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2
1.
00
0
3.
48
6
2.
14
0
1.
07
4
(S)-2-(Benzylideneamino)-2-(4-iodocubanyl)acetonitrile (4.72) 
N
CN
I  
1H, 300 MHz, CDCl3 
  
  
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
47
.8
0
54
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9
58
.2
1
59
.9
8
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1.
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4.
67
16
3.
88
(S)-2-(Benzylideneamino)-2-(4-iodocubanyl)acetonitrile (4.72) 
N
CN
I  13C DEPT-135, 75 MHz, CDCl3 
13C, 75 MHz, CDCl3 
  
  
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
1.
43
3.
73
3.
89
4.
01
1.
31
8
2.
00
0
6.
04
5
1.
05
8
Cubanylmethanol (4.26) 
OH
 
1H, 300 MHz, MeOD-d4 
  
  
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
44
.4
0
46
.7
5
48
.6
3
58
.3
6
63
.8
6
Cubanylmethanol (4.26) 
OH
 
1H, 300 MHz, MeOD-d4 
  
  
Cubanecarbaldehyde (4.27) 
O
H
 
1H, 300 MHz, MeOD-d4 
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
4.
01
4.
37
9.
70
4.
00
0
2.
90
0
0.
70
4
  
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
3.
48
3.
58
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79
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4.
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33
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1.
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1
1.
03
7
7.
09
6
1.
29
4
5.
00
0
(S)-2-(Cubanyl)-2-{[(R)-2-hydroxy-1-phenylethyl]amino}acetonitrile (4.75β) 
N
H
CN
OH
RS
 
1H, 300 MHz, CDCl3 
  
.   
(S)-2-(Cubanyl)-2-{[(R)-2-hydroxy-1-phenylethyl]amino}acetonitrile (4.75β) 
N
H
CN
OH
RS
 
13C, 75 MHz, CDCl3 
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
44
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8
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.5
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9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
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1
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9
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0
(R)-2-(Cubanyl)-2-{[(R)-2-hydroxy-1-phenylethyl]amino}acetonitrile (4.75α) 
N
H
CN
OH
RR
 
1H, 300 MHz, CDCl3 
  
 
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
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(R)-2-(Cubanyl)-2-{[(R)-2-hydroxy-1-phenylethyl]amino}acetonitrile (4.75α) 
1H, 300 MHz, CDCl3 
 
 
 
 
N
H
CN
OH
RR
 
 
  
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
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(S)-2-(Cubanyl)-2-{[(S)-2-hydroxy-1-phenylethyl]amino}acetonitrile (4.76β) 
N
H
CN
OH
SS
 
1H, 100 MHz, CDCl3 
  
 
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
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(S)-2-(Cubanyl)-2-{[(S)-2-hydroxy-1-phenylethyl]amino}acetonitrile (4.76β) 
 
N
H
CN
OH
SS
 
13C, 100 MHz, CDCl3 
  
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
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(R)-2-(Cubanyl)-2-{[(S)-2-hydroxy-1-phenylethyl]amino}acetonitrile (4.76α) 
N
H
CN
OH
SR
 
1H, 400 MHz, CDCl3 
  
 
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
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(R)-2-(Cubanyl)-2-{[(S)-2-hydroxy-1-phenylethyl]amino}acetonitrile (4.76α) 
N
H
CN
OH
SR
 
13C, 100 MHz, CDCl3 
  
  
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
3.
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7
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1
2-(Benzylideneamino)-2-cubylacetonitrile (4.77) 
N
CN
 
1H, 400 MHz, CDCl3 
  
 
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
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2-(Benzylideneamino)-2-cubylacetonitrile (4.77) 
N
CN
 13C DEPT-135, 100 MHz, CDCl3 
13C, 100 MHz, CDCl3 
 
  
  
10 9 8 7 6 5 4 3 2 1 0 ppm
3.
85
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2.
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6
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00
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0.
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0
3.803.853.903.954.004.05 ppm
3.
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(R)-Carboxy(cubanyl)methanaminium chloride (4.78α) 
CO2H
NH3ClR
 
1H, 400 MHz, D2O 
  
  
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
43
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7
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1
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1
(R)-Carboxy(cubanyl)methanaminium chloride (4.78α) 
CO2H
NH3ClR
 
1H, 400 MHz, D2O 
  
  
10 9 8 7 6 5 4 3 2 1 0 ppm
1.
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1.
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9
(R)-Carboxy(cubanyl)methanaminium chloride (4.78α) 
NH
OKO
O
OR
 
1H, 400 MHz, D2O 
  
  
(R)-Methyl 2-[(t-butoxycarbonyl)amino]-2-cubylacetate (4.80α) 
CO2Me
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1H, 400 MHz, CDCl3 
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(R)-Methyl 2-[(t-butoxycarbonyl)amino]-2-cubylacetate (4.80α) 
CO2Me
NHBocR
 
13C, 100 MHz, CDCl3 
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Methyl cubanecarboxylate (5.46b) 
O
O
 
1H, 300 MHz, CDCl3 
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Methyl cubanecarboxylate (5.46b) 
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13C DEPT-135, 100MHz, CDCl3 
13C, 100 MHz, CDCl3 
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Ethyl cubanecarboxylate (5.47b) 
O
O
 
1H, 400 MHz, CDCl3 
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Ethyl cubanecarboxylate (5.47b) 
O
O
 13C DEPT-135, 100MHz, CDCl3 
13C, 100 MHz, CDCl3 
  
  
2-(Cubanyl)propan-2-ol (5.48b) 
OH
 
1H, 300 MHz, CDCl3 
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2-(Cubanyl)propan-2-ol (5.48b) 
OH
 13C DEPT-135, 75MHz, CDCl3 
13C, 75 MHz, CDCl3 
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(E)-Ethyl 3-(cubanyl)acrylate (5.50b) 
O
O
 
1H, 400 MHz, CDCl3 
  
  
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
14
.2
9
44
.3
5
48
.4
9
50
.0
7
58
.4
4
60
.1
5
11
8.
08
14
7.
40
16
7.
09
(E)-Ethyl 3-(cubanyl)acrylate (5.50b) 
O
O
 
13C, 400 MHz, CDCl3 
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N-Methoxy-N-methylcubanecarboxamide (5.58) 
N O
O
 
1H, 300 MHz, CDCl3 
  
  
N-Methoxy-N-methylcubanecarboxamide (5.58) 
N O
O
 13C DEPT-135, 125MHz, CDCl3 
13C, 125 MHz, CDCl3 
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1-(Cubanyl)but-3-en-1-one (5.51b) 
O
 
1H, 300 MHz, CDCl3 
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1-(Cubanyl)but-3-en-1-one (5.51b) 
O
 
13C, 75 MHz, CDCl3 
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1-(t-butyl)cubane (5.54b) 
 
1H, 400 MHz, MeOD-d4 
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1-(t-butyl)cubane (5.54b) 
 
13C, 100 MHz, MeOD-d4 
  
Chapter 6
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(Cubanyl)methylcubanecarboxylate (6.02) 
O
O
 
1H, 300 MHz, CDCl3 
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(Cubanyl)methylcubanecarboxylate (6.02) 
O
O
 
13C, 75 MHz, CDCl3 
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(Cubanyl)methyl benzoate (6.28) 
O
O
 
1H, 300 MHz, CDCl3 
  
  
(Cubanyl)methyl benzoate (6.28) 
O
O
 
13C, 75 MHz, CDCl3 
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Benzyl cubanecarboxylate (6.29) 
O
O
 
1H, 300 MHz, CDCl3 
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Benzyl cubanecarboxylate (6.29) 
O
O
 
13C, 75 MHz, CDCl3 
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(4-Iodocubanyl)methyl 4-iodocubane-1-carboxylate (6.30)
O
O
I  
1H, 300 MHz, CDCl3 
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(4-Iodocubanyl)methyl 4-iodocubane-1-carboxylate (6.30)
O
O
I  13C DEPT-135, 75 MHz, CDCl3 
13C, 75 MHz, CDCl3 
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(4-Iodocubanyl)methyl benzoate (6.31) 
O
O
I  
1H, 300 MHz, CDCl3 
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(4-Iodocubanyl)methyl benzoate (6.31) 
O
O
I  
13C, 75 MHz, CDCl3 
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1,4-Dichlorocubane (7.02) 
Cl
Cl  
1H 500 MHz, CDCl3 
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1,4-Dichlorocubane (7.02) 
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Cl  
13C, 125 MHz, CDCl3 
  
 
 
  
  
  
  
 
